[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 327
1. Stoner J, Martin G, O'Mara K, Ehlers J, Tomlanovich M: Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model. Acad Emerg Med; 2003 Mar;10(3):187-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model.
  • Despite mixed experimental data, some authors view bretylium as the drug of choice in hypothermic VF.
  • OBJECTIVES: To compare defibrillation rates from hypothermic VF after drug therapy with amiodarone, bretylium, and placebo.
  • Thirty anesthetized dogs were mechanically ventilated and instrumented to monitor coronary perfusion pressure (CPP), rectal core temperature, and electrocardiogram (ECG).
  • Ventricular fibrillation was induced as needed with a transthoracic AC current.
  • Return of spontaneous circulation (ROSC) was defined as a sustainable ECG rhythm generating a corresponding arterial pressure tracing lasting a minimum of 15 minutes.
  • RESULTS: CPR was adequate based on CPP > 15 mm Hg in all animals.
  • Mean (+/-SD) CPP was 35.3 +/- 18.8 mm Hg with an overall lower trend in the amiodarone group (p = 0.06).
  • [MeSH-major] Amiodarone / therapeutic use. Anti-Arrhythmia Agents / therapeutic use. Bretylium Compounds / therapeutic use. Ventricular Fibrillation / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Dogs. Hypothermia, Induced. Random Allocation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12615580.001).
  • [ISSN] 1069-6563
  • [Journal-full-title] Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
  • [ISO-abbreviation] Acad Emerg Med
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Bretylium Compounds; N3RQ532IUT / Amiodarone; RZR75EQ2KJ / bretylium
  •  go-up   go-down


2. Takahashi M, Yamamoto J, Aoyama Y, Soejima Y, Akiba D, Nishizawa S: Efficacy of multi-staged surgery and adjuvant chemotherapy for successful treatment of atypical choroid plexus papilloma in an infant: case report. Neurol Med Chir (Tokyo); 2009 Oct;49(10):484-7
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of multi-staged surgery and adjuvant chemotherapy for successful treatment of atypical choroid plexus papilloma in an infant: case report.
  • A 12-month-old girl presented with a rare atypical choroid plexus papilloma manifesting as conscious disturbance and vomiting.
  • Only partial removal of the tumor was performed because of excessive intraoperative hemorrhage at the first surgery.
  • The histological diagnosis was atypical choroid plexus papilloma.
  • To control the intraoperative hemorrhage, embolization of the feeding artery was performed before the second surgery, and the tumor was macroscopically totally removed.
  • MR imaging disclosed a small residual tumor which showed relatively rapid growth.
  • Two months later, MR imaging showed a cystic lesion with a small nodule adjacent to the midbrain, indicating dissemination of the tumor.
  • The lesion was successfully treated with chemotherapy.
  • Atypical choroid plexus papilloma was recently defined in the classification of the World Health Organization, so clinical data based on these criteria are lacking to establish the therapeutic strategy.
  • Total resection of atypical choroid plexus papilloma is the most reliable treatment at present.
  • However, postoperative chemotherapy should be considered for recurrence or dissemination.
  • [MeSH-major] Brain / surgery. Lateral Ventricles / surgery. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebral Arteries / pathology. Cerebral Arteries / physiopathology. Craniotomy. Embolization, Therapeutic. Female. Humans. Infant. Intraoperative Complications / etiology. Intraoperative Complications / physiopathology. Intraoperative Complications / therapy. Lethargy / etiology. Magnetic Resonance Imaging. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neurosurgical Procedures. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / physiopathology. Postoperative Hemorrhage / therapy. Reoperation. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy. Vomiting / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855149.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Meltzer-Brody SE, Zolnoun D, Steege JF, Rinaldi KL, Leserman J: Open-label trial of lamotrigine focusing on efficacy in vulvodynia. J Reprod Med; 2009 Mar;54(3):171-8
Hazardous Substances Data Bank. LAMOTRIGINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Chronic pelvic pain (CPP) affects 15% of women and has a high rate of psychiatric comorbidity.
  • Vulvodynia, a vulvar pain syndrome that includes vulvar vestibulitis, is the most common subtype of CPP.
  • This study examined the efficacy of lamotrigine for the treatment of CPP using an open-label design.
  • STUDY DESIGN: Forty-three women with CPP were recruited from a specialty pelvic pain clinic.
  • Of these, 31 completed 8 weeks of active treatment.
  • In particular, women with vulvodynia-type CPP (N = 17) had robust reductions in pain and mood symptoms.
  • CONCLUSION: CPP is a heterogeneous disorder, with psychiatric comorbidity and poor treatment response.
  • This open-label study suggests that treatment with lamotrigine in women with the vulvodynia subtype of CPP may be helpful in addressing both the pain and mood symptoms associated with this disorder.
  • [MeSH-major] Analgesics / therapeutic use. Pelvic Pain / drug therapy. Pelvic Pain / psychology. Triazines / therapeutic use. Vulvar Diseases / drug therapy. Vulvar Diseases / psychology
  • [MeSH-minor] Adult. Aged. Anxiety / drug therapy. Anxiety / epidemiology. Comorbidity. Depression / drug therapy. Depression / epidemiology. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Pain Measurement / drug effects. Pain Measurement / psychology. Psychiatric Status Rating Scales. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370903.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K23 HD053631
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Triazines; U3H27498KS / lamotrigine
  • [Other-IDs] NLM/ NIHMS580758; NLM/ PMC4676413
  •  go-up   go-down


Advertisement
4. Ortega-Martínez M, Cabezudo-Artero JM, Fernández-Portales I, Pimentel JJ, Gómez de Tejada R: Diffuse leptomeningeal seeding from benign choroid plexus papilloma. Acta Neurochir (Wien); 2007 Dec;149(12):1229-36; discussion 1236-7
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse leptomeningeal seeding from benign choroid plexus papilloma.
  • Choroid plexus papillomas (CPP) are rare intracranial tumours with a favourable long-term outcome after surgical excision.
  • Although they are histologically benign, local recurrences may occasionally occur, but leptomeningeal dissemination is exceptional.
  • We report an unusual example of a fourth ventricle choroid plexus papilloma with diffuse leptomeningeal seeding.
  • Treatment with systemic and intrathecal chemotherapy was ineffective in this patient.
  • We review the literature concerning leptomeningeal dissemination of benign choroid plexus papillomas.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Fourth Ventricle / surgery. Meningeal Neoplasms / secondary. Neoplasm Seeding. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Ki-67 Antigen / analysis. Laminectomy. Magnetic Resonance Imaging. Meninges / pathology. Reoperation. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924056.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


5. Braun K, Ehemann V, Wiessler M, Pipkorn R, Didinger B, Mueller G, Waldeck W: High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment. Int J Med Sci; 2009;6(6):338-47
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.
  • If metastatic prostate cancer gets resistant to antiandrogen therapy, there are few treatment options, because prostate cancer is not very sensitive to cytostatic agents.
  • Temozolomide (TMZ) as an orally applicable chemotherapeutic substance has been proven to be effective and well tolerated with occasional moderate toxicity especially for brain tumors and an application to prostate cancer cells seemed to be promising.
  • Unfortunately, TMZ was inefficient in the treatment of symptomatic progressive hormone-refractory prostate cancer (HRPC).
  • The reasons could be a low sensitivity against TMZ the short plasma half-life of TMZ, non-adapted application regimens and additionally, the aneuploid DNA content of prostate cancer cells suggesting different sensitivity against therapeutical interventions e.g. radiation therapy or chemotherapy.
  • The modular-composed carrier consists of a transmembrane transporter (CPP), connected to a nuclear localization sequence (NLS) cleavably-bound, which in turn was coupled with TMZ.
  • The NLS-sequence allows an active delivery of the TMZ into the cell nucleus after transmembrane passage of the TMZ-BioShuttle and intra-cytoplasm enzymatic cleavage and separation from the CPP.
  • This TMZ-BioShuttle could contribute to improve therapeutic options exemplified by the hormone refractory prostate cancer.
  • The high-resolution flow cytometric analysis showed to be an appropriate system for a better detection and distinction of several cell populations dependent on their different DNA-indices as well as changes in proliferation of cell populations after chemotherapeutical treatment.
  • [MeSH-major] Aneuploidy. Antineoplastic Agents, Alkylating / administration & dosage. Dacarbazine / analogs & derivatives. Drug Monitoring / methods. Drug Resistance, Neoplasm. Flow Cytometry / methods. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. DNA, Neoplasm / analysis. Drug Delivery Systems. Humans. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(6):509-12 [10854140.001]
  • [Cites] Med Res Rev. 2010 Jan;30(1):23-66 [19536866.001]
  • [Cites] Nature. 2001 May 17;411(6835):366-74 [11357144.001]
  • [Cites] J Mol Biol. 2002 Apr 26;318(2):237-43 [12051833.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35 [12243818.001]
  • [Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):952-8 [12440953.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):4147-50 [12553046.001]
  • [Cites] Urol Int. 2003;70(1):1-14 [12566808.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):125-31 [12706866.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):46-50 [14657665.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 [15234026.001]
  • [Cites] Chembiochem. 2004 Oct 4;5(10):1432-47 [15457527.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Biochem Pharmacol. 1987 Feb 15;36(4):457-62 [3470008.001]
  • [Cites] Adv Cancer Res. 1991;57:1-46 [1950701.001]
  • [Cites] Biochem Int. 1992 Aug;27(4):567-77 [1417893.001]
  • [Cites] J Histochem Cytochem. 1994 Jun;42(6):697-704 [8189032.001]
  • [Cites] Curr Opin Immunol. 1994 Apr;6(2):279-89 [8011211.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1816 [7933240.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1837-42 [7523731.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Dec;39(12):2620-4 [8592990.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1617-25 [8622080.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):524-31 [9012485.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):698-704 [9178829.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2272-9 [9626231.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500 [9635694.001]
  • [Cites] Semin Nephrol. 1998 Sep;18(5):505-18 [9754603.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Cancer Lett. 1999 Apr 26;138(1-2):101-6 [10378780.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1574-80 [10491435.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1613-21 [15520061.001]
  • [Cites] Radiother Oncol. 2004 Dec;73 Suppl 2:S119-22 [15971325.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] In Vivo. 2006 Jan-Feb;20(1):17-23 [16433023.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):952-6 [16565212.001]
  • [Cites] Hinyokika Kiyo. 2006 Jul;52(7):515-21 [16910582.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005247 [17054249.001]
  • [Cites] J Mol Histol. 2006 Sep;37(5-7):253-60 [16841236.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Urology. 2007 Feb;69(2):347-51 [17320676.001]
  • [Cites] BJU Int. 2007 Mar;99(3):497-501 [17092283.001]
  • [Cites] Amino Acids. 2007;32(3):373-9 [17077962.001]
  • [Cites] Drug Resist Updat. 2007 Feb-Apr;10(1-2):51-8 [17387035.001]
  • [Cites] Clin Genitourin Cancer. 2007 Mar;5(4):278-83 [17553208.001]
  • [Cites] Pathol Oncol Res. 2007;13(2):84-90 [17607368.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3965-70 [17761981.001]
  • [Cites] Cancer Treat Rev. 2007 Oct;33(6):521-7 [17658220.001]
  • [Cites] Hepatology. 2007 Sep;46(3):759-68 [17663418.001]
  • [Cites] Int J Oncol. 2008 Feb;32(2):341-7 [18202756.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1779(1):3-16 [18078840.001]
  • [Cites] Biostatistics. 2008 Apr;9(2):333-54 [17873151.001]
  • [Cites] Int J Med Sci. 2008;5(5):273-84 [18797509.001]
  • [Cites] J Pept Sci. 2009 Mar;15(3):235-41 [19177421.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):900-10 [19238631.001]
  • [Cites] Biomaterials. 2009 Jul;30(20):3466-75 [19304320.001]
  • [Cites] Oncol Rep. 2009 Aug;22(2):345-8 [19578775.001]
  • [Cites] BMC Cancer. 2009;9:210 [19563641.001]
  • [Cites] DNA Repair (Amst). 2009 Sep 2;8(9):1153-65 [19501553.001]
  • [Cites] Int J Cancer. 2009 Dec 15;125(12):2978-90 [19422046.001]
  • [Cites] Nature. 2001 May 17;411(6835):342-8 [11357141.001]
  • (PMID = 19946604.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA, Neoplasm; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2781174
  • [Keywords] NOTNLM ; Flow Cytometry / Prostate Cancer Cells / TMZ-BioShuttle
  •  go-up   go-down


6. Vercellini P, Viganò P, Somigliana E, Abbiati A, Barbara G, Fedele L: Medical, surgical and alternative treatments for chronic pelvic pain in women: a descriptive review. Gynecol Endocrinol; 2009 Apr;25(4):208-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical, surgical and alternative treatments for chronic pelvic pain in women: a descriptive review.
  • Several causes of chronic pelvic pain (CPP) are recognised, but in many women a definite diagnosis cannot be made.
  • Few randomised controlled trials on treatment of CPP have been conducted.
  • The aim of this descriptive review is to describe the management of CPP, which can focus on treating the pain itself, the underlying cause, or both.
  • Combination drug therapy with medications with different mechanisms of action may improve therapeutic results.
  • Several alternative non-invasive treatments have been proposed including exercise programmes, cognitive and behavioural medicine, physical therapy, dietary modification, massage and acupuncture.
  • Treatment of CPP, generally, requires acceptance of the concept of managing rather than curing symptoms.
  • [MeSH-major] Complementary Therapies. Pelvic Pain / drug therapy. Pelvic Pain / surgery
  • [MeSH-minor] Chronic Disease. Female. Humans

  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296329.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 98
  •  go-up   go-down


7. Bertelloni S, Mul D: Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl; 2008 Jul;10(4):525-34
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.
  • In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years.
  • In the last years, relevant improvements in the treatment of CPP have been achieved.
  • Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety.
  • In the present paper, recent advances of CPP management with GnRH analogs in men are summarized.
  • End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men.
  • The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.
  • [MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Puberty, Precocious / drug therapy
  • [MeSH-minor] Adolescent. Adult. Body Height / drug effects. Body Height / physiology. Child. Dose-Response Relationship, Drug. Humans. Male. Sex Characteristics. Treatment Outcome


8. Serrano-Fabiá A, Albert-Marí A, Almenar-Cubells D, Jiménez-Torres NV: Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy. J Oncol Pharm Pract; 2010 Jun;16(2):105-12
MedlinePlus Health Information. consumer health - Medication Errors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy.
  • OBJECTIVE: To analyze medication errors (MEs) in a multidisciplinary system with a Computerized Pharmacotherapy Process (CPP) in cancer patients.
  • DESIGN: A longitudinal, prospective 2-year (January 2003 -to December 2004) cohort study was made in adult patients administered antineoplastic treatment in Services of Oncology and Haematology.
  • MEs were identified by double cross-validation of each stage of the pharmacotherapeutic process (prescription, preparation, dispensing, administration, and follow-up) carried out by the multidisciplinary team (physician, pharmacist, nurse) with CPP assistance.
  • VARIABLES: Number of MEs per 1000 patient-days, percentage according to the stage of the pharmacotherapeutic process and the severity of intercepted ME (scored from 1 = no damage to the patient, to 5 = patient death).
  • RESULTS: A total of 1311 patients were receiving treatment, and MEs were identified in 225.
  • Out of a total of 13,158 patient-days, 276 MEs were detected, equivalent to 20.9 MEs per 1000 patient-days; of these, 16.8 MEs per 1000 patient-days (80%) were intercepted and did not affect any patient.
  • The detected ME distribution according to pharmacotherapeutic stage was: prescription 75.7%, preparation 21.0%, dispensing 1.8%, administration 1.1%, and follow-up 0.4%.
  • The system intercepted 98.9% of all MEs with severity >or=3 (MEs with a potential for causing patient damage).
  • CONCLUSIONS: The multidisciplinary system with a well-established CPP detects 20.9 MEs per 1000 patient-days and intercepts 98.8% of all MEs with a potential for causing patient damage.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hospitals, University / standards. Interprofessional Relations. Medication Errors / prevention & control. Medication Systems, Hospital / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617304.001).
  • [ISSN] 1477-092X
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Huang SJ, Hong WC, Han YY, Chen YS, Wen CS, Tsai YS, Tu YK: Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies. J Clin Neurosci; 2006 Oct;13(8):818-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies.
  • In the past 5 years, cerebral perfusion pressure (CPP) management has become the standard in the treatment of severe head injuries.
  • Guidelines published in 2000 suggest that CPP should be at least 70 mmHg; however, there is still debate about the optimal CPP.
  • The purpose of the present study was to evaluate the effectiveness of these three widely used therapies: (i) intracranial pressure (ICP) targeted;.
  • (ii) CPP-targeted with CPP >70 mmHg; and (iii) modified CPP-targeted (mCPP) therapy with CPP >60 mmHg.
  • Data, including patient age, sex, initial Glasgow Coma Scale, ICP, CPP, fluid status, amount of mannitol and vasopressor used, daily fluid intake and output, complications and clinical results, were collected from 213 patients with severe head injuries over a 12-year period.
  • Patients were categorized into three groups (ICP, CPP, mCPP) according to the treatment protocol used.
  • The mortality rate was 28.6%, 14.3% and 13.5% in the ICP, CPP, and mCPP groups, respectively.
  • Highest intake/output ratio, amount of vasopressor used and pulmonary complications were seen in the CPP patients.
  • Although CPP-targeted therapy is the most recommended therapeutic protocol, our data show that patients treated with modified CPP-target therapy with CPP >60 mmHg have better clinical outcomes and fewer complications.
  • [MeSH-major] Brain / blood supply. Cerebrovascular Circulation. Craniocerebral Trauma / therapy. Intracranial Hypertension / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Barbiturates / therapeutic use. Female. Humans. Hyperventilation. Intracranial Pressure / drug effects. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head Injuries.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908157.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Barbiturates; WQ92Y2793G / barbituric acid
  •  go-up   go-down


10. Wrede B, Liu P, Wolff JE: Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol; 2007 Dec;85(3):345-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors.
  • BACKGROUND: Choroid plexus carcinomas (CPC) are rare brain tumors with a dismal prognosis.
  • Although the role of surgery has been well established, the question of whether chemotherapy improves the prognosis is still under discussion.
  • METHODS: We created a database of all cases of choroid plexus tumors (CPT) reported in the literature up to the year 2004 to determine prognostic factors and different therapeutic modalities.
  • RESULTS: Of 857 documented cases of CPT (median patient age at diagnosis, 3 years), 347 were CPC, 15 atypical choroid plexus papilloma (APP), and 495 choroid plexus papilloma (CPP).
  • The 104 CPC patients who received chemotherapy had a statistically better survival than those without chemotherapy (P = .0004).
  • When subgroups were defined by radiation treatment, chemotherapy remained beneficial in the subgroup of nonirradiated tumors (P = .0001).
  • The benefit of chemotherapy was also significant when the analysis was restricted to the subgroup of patients with less than completely resected CPC (2-year overall survival (OS) 54.8 +/- 7% (standard deviation (SD) vs. 24.4 +/- 7%, P < .0001) and when this subgroup was further divided into smaller subgroups.
  • Likewise, in a multivariate analysis, chemotherapy was highly significantly linked to better prognosis (P = .0001).
  • CONCLUSION: Patients with less than completely resected CPC should receive chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Choroid Plexus Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Combined Modality Therapy. Databases, Bibliographic. Databases, Factual. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2002 Apr;57(2):123-6 [12125972.001]
  • [Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] Eur J Pediatr. 1983 Mar;140(1):51-6 [6873113.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):249-54 [10760416.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):409-14 [12946029.001]
  • [Cites] Am J Hum Genet. 1999 Nov;65(5):1342-8 [10521299.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):274-8 [8107660.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]
  • [Cites] Histopathology. 1995 Feb;26(2):137-43 [7737660.001]
  • [Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):369-83 [6886750.001]
  • [Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(6):557-63 [9755322.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]
  • [Cites] Neuropediatrics. 1996 Jun;27(3):143-8 [8837074.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] Acta Oncol. 1990;29(2):241-3 [2185805.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] Neoplasma. 2004;51(4):306-12 [15254663.001]
  • [Cites] Childs Brain. 1975;1(2-3):81-115 [1081032.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):571-7 [10550588.001]
  • [Cites] Neurosurgery. 1980 Apr;6(4):380-4 [7393420.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Mar;36(3):179-84 [8869156.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]
  • (PMID = 17576522.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Ratanalert S, Phuenpathom N, Saeheng S, Oearsakul T, Sripairojkul B, Hirunpat S: ICP threshold in CPP management of severe head injury patients. Surg Neurol; 2004 May;61(5):429-34; discussion 434-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ICP threshold in CPP management of severe head injury patients.
  • BACKGROUND: Elevated intracranial pressure (ICP) is significantly associated with high mortality rate in severe head injury (SHI) patients.
  • METHODS: Treatment protocol in this study consisted of therapeutic maneuvers designed to maximize cerebral profusion pressure (CPP) and control ICP.
  • Twenty-seven patients with severe head injury and intracranial hypertension (ICP >or=20 mm Hg) were enrolled and fourteen cases were allocated to the group of ICP threshold >or=25 mm Hg.
  • Logistic regression identified the presence of basal cisterns on the initial computed tomography (CT) scan as a significant predictor of good outcome.
  • [MeSH-major] Brain / blood supply. Craniocerebral Trauma / complications. Intracranial Hypertension / etiology. Intracranial Hypertension / therapy
  • [MeSH-minor] Adult. Algorithms. Cerebral Hemorrhage, Traumatic / diagnosis. Cerebral Hemorrhage, Traumatic / drug therapy. Cerebral Hemorrhage, Traumatic / etiology. Combined Modality Therapy. Diuretics, Osmotic / therapeutic use. Glasgow Coma Scale. Humans. Mannitol / therapeutic use. Oxygen / therapeutic use. Prospective Studies

  • MedlinePlus Health Information. consumer health - Head Injuries.
  • Hazardous Substances Data Bank. D-MANNITOL .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15120212.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics, Osmotic; 3OWL53L36A / Mannitol; S88TT14065 / Oxygen
  •  go-up   go-down


12. Celik T, Kayir H, Ceyhan M, Demirtaş S, Coşar A, Uzbay IT: CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo. Brain Res Bull; 2004 Sep 30;64(3):243-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo.
  • Effects of N-methyl-D-aspartate (NMDA) receptor and Ca2+ channel antagonists on extracellular acetylcholine and choline release in the hippocampus of ethanol-withdrawn rats were investigated by in vivo microdialysis.
  • Either an NMDA receptor antagonist (+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) or a calcium channel antagonist amlodipine was administered, and 15 min later, an audiogenic stimulus (100 dB, 1 min) was applied to rats.
  • CPP (15 mg/kg) and amlodipine (20 mg/kg) reversed the decrement in acetylcholine and increment in choline release in EW rats.
  • [MeSH-major] Acetylcholine / metabolism. Amlodipine / pharmacology. Ethanol / adverse effects. Hippocampus / drug effects. Piperazines / pharmacology. Substance Withdrawal Syndrome / metabolism
  • [MeSH-minor] Acoustic Stimulation / adverse effects. Alcohol-Induced Disorders, Nervous System / drug therapy. Alcohol-Induced Disorders, Nervous System / metabolism. Alcohol-Induced Disorders, Nervous System / physiopathology. Animals. Body Weight / drug effects. Calcium Channel Blockers / pharmacology. Choline / metabolism. Disease Models, Animal. Down-Regulation / drug effects. Down-Regulation / physiology. Drug Interactions / physiology. Epilepsy, Reflex / chemically induced. Epilepsy, Reflex / drug therapy. Epilepsy, Reflex / physiopathology. Excitatory Amino Acid Agonists / pharmacology. Glutamic Acid / metabolism. Male. Microdialysis. Neural Pathways / drug effects. Neural Pathways / metabolism. Neural Pathways / physiopathology. Rats. Rats, Wistar. Seizures / chemically induced. Seizures / drug therapy. Seizures / physiopathology. Synaptic Transmission / drug effects. Synaptic Transmission / physiology

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • Hazardous Substances Data Bank. AMLODIPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464861.001).
  • [ISSN] 0361-9230
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Excitatory Amino Acid Agonists; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 1J444QC288 / Amlodipine; 3K9958V90M / Ethanol; 3KX376GY7L / Glutamic Acid; N91BDP6H0X / Choline; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


13. Chen JH, Liang J, Wang GB, Han JS, Cui CL: Repeated 2 Hz peripheral electrical stimulations suppress morphine-induced CPP and improve spatial memory ability in rats. Exp Neurol; 2005 Aug;194(2):550-6
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated 2 Hz peripheral electrical stimulations suppress morphine-induced CPP and improve spatial memory ability in rats.
  • Our previous studies have shown that 2 Hz peripheral electrical stimulation (PES) can suppress morphine-induced conditioned place preference (CPP) in the rat, although the mechanisms remain unclear.
  • Since CPP involves the mechanism of learning and memory, it is rational to ask whether the suppressive effect of repeated 2 Hz PES on morphine-induced CPP is due to an impairment of the function of spatial learning and memory.
  • Rats were trained with 4 mg/kg morphine, i.p. for 4 days to establish the CPP.
  • Twenty-four hours after the CPP testing, they were given PES at 2 Hz once a day for 1, 3 or 5 days, followed by another CPP testing.
  • The results showed that (1) the morphine-induced CPP was significantly inhibited by 3 or 5 consecutive sessions, but not by single session of 2 Hz PES. (2) A test of spatial leaning and memory ability using the Morris water maze task revealed that 2 Hz PES per se exhibited a promoting, rather than a deteriorating effect on the ability of spatial memory. (3) 2 Hz PES by itself produced a moderate yet significant CPP.
  • The results imply that (a) a low frequency PES can produce a rewarding effect as revealed by the CPP testing, which may account, at least in part, for its suppressive effect on morphine induced CPP, (b) the suppressive effect of PES on morphine induced CPP is not due to a deteriorating effect on the ability of spatial memory.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Electroacupuncture. Maze Learning / drug effects. Memory Disorders / therapy. Morphine Dependence / therapy. Substance Withdrawal Syndrome / therapy
  • [MeSH-minor] Animals. Brain / drug effects. Brain / physiopathology. Disease Models, Animal. Male. Morphine / adverse effects. Narcotics / adverse effects. Rats. Rats, Sprague-Dawley. Recovery of Function / physiology. Reward. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890338.001).
  • [ISSN] 0014-4886
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Narcotics; 76I7G6D29C / Morphine
  •  go-up   go-down


14. Zheng PZ, Zhao CJ, Du YZ, Chen SJ, Chen Z, Zhang J, Zhang QH, Wang KK: [Establishment of CPP-SOM integrated cDNA microarray technology]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct;21(5):422-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of CPP-SOM integrated cDNA microarray technology].
  • OBJECTIVE: To get an insight into the molecular mechanisms of diseases development and targeted therapy at the transcriptome level and search for potential therapeutic targets.
  • METHODS: The present researchers established a cDNA microarray platform and applied component plane presentation integrated self-organizing map (CPP-SOM) to the microarray data obtained from a differentiation model, all trans retinoic acid-induced differentiation in NB4 cells.
  • By CPP-SOM, the researchers were able to not only well classify the regulated genes into functionally distinct categories but also depict transcriptional changes throughout the process of the development of diseases or drug treatment.
  • CONCLUSION: The platform has proven to be steady and reliable, and the CPP-SOM could serve as an important and good tool for analysis of microarray data.
  • [MeSH-minor] Cell Line, Tumor. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15476161.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


15. Valencak J, Dietrich W, Raderer M, Dieckmann K, Prayer D, Hainfellner JA, Marosi C: Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma. J Neurooncol; 2000 Sep;49(3):263-8
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma.
  • A pregnant 33-year old woman developed nystagmus and cerebellar ataxia.
  • A tumor in the roof of the fourth ventricle was diagnosed.
  • The tumor was subtotally removed using microneurosurgical techniques.
  • The histopathological diagnosis was choroid plexus papilloma (CPP).
  • Twenty-one months later, the tumor recurred and was reoperated.
  • Histologically the tumor displayed now increased mitotic activity and pleomorphism.
  • Radiation therapy of the neuroaxis was performed.
  • Within 59 months, the CPP recurred 3 more times with neuroradiological evidence of extensive spinal seeding.
  • After several palliative irradiations, including 2 gamma-knife boosts, the patient was referred to chemotherapy.
  • The course of disease in our patient provides evidence for therapeutic efficacy of CCNU in recurrent CPP.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Lomustine / therapeutic use. Papilloma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neoplasm Seeding. Pregnancy. Reoperation

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Cytol. 1980;65:117-91 [6248480.001]
  • [Cites] J Comput Assist Tomogr. 1979 Aug;3(4):530-2 [457968.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] J Neurosurg. 1982 May;56(5):722-7 [7069487.001]
  • [Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]
  • [Cites] Surg Neurol. 1984 Nov;22(5):472-6 [6495155.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):442-50 [894346.001]
  • [Cites] Klin Padiatr. 1995 Mar-Apr;207(2):52-8 [7752600.001]
  • [Cites] J Neurosurg. 1960 Nov;17:1002-27 [13768200.001]
  • [Cites] Brain. 1967 Mar;90(1):177-86 [6023072.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):470-5 [6821827.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Acta Cytol. 1985 Sep-Oct;29(5):846-9 [3863432.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Nov 30;100:136-42 [13818457.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]
  • (PMID = 11212906.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
  • [Number-of-references] 30
  •  go-up   go-down


16. Takamatsu Y, Yamamoto H, Ogai Y, Hagino Y, Markou A, Ikeda K: Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann N Y Acad Sci; 2006 Aug;1074:295-302
Hazardous Substances Data Bank. d-METHAMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice.
  • The monoamine transporters are the main targets of psychostimulant drugs, including methamphetamine (METH) and cocaine.
  • Interestingly, the rewarding effects of cocaine are retained in dopamine transporter (DAT) knockout (KO) mice, while serotonin transporter (SERT) and DAT double KO mice do not exhibit conditioned place preference (CPP) to cocaine.
  • ) CPP and locomotor sensitization to 1 mg/kg METH (i.p.) in C57BL/6J mice.
  • Fluoxetine treatment before both the conditioning and preference tests abolished METH CPP.
  • A two-way analysis of variance (ANOVA) revealed that METH CPP tended to be lower in mice pretreated with fluoxetine before the preference test than in control mice pretreated with saline before the preference test.
  • These results suggest that fluoxetine, a widely used medication for depression, may be also a useful tool for treating METH dependence.
  • [MeSH-major] Amphetamine-Related Disorders / drug therapy. Dopamine Agents / toxicity. Fluoxetine / therapeutic use. Methamphetamine / toxicity. Motor Activity / drug effects. Serotonin Uptake Inhibitors / therapeutic use

  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105925.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA11946
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agents; 0 / Serotonin Uptake Inhibitors; 01K63SUP8D / Fluoxetine; 44RAL3456C / Methamphetamine
  •  go-up   go-down


17. Karim A, Fowler M, McLaren B, Cardenas R, Patwardhan R, Nanda A: Concomitant choroid plexus papillomas involving the third and fourth ventricles: A case report and review of the literature. Clin Neurol Neurosurg; 2006 Sep;108(6):586-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant choroid plexus papillomas involving the third and fourth ventricles: A case report and review of the literature.
  • Choroid plexus papillomas (CPP) are histopathologically benign and rare central nervous system (CNS) neoplasms arising from the epithelium of the choroid plexus.
  • Third ventricular CPP are uncommon.
  • In this study, we present a case of a 66-year-old woman with complaints of progressive confusion, lethargy, and weakness who was found to have concomitant third and fourth ventricular masses on imaging studies.
  • Pathology from the biopsy and both resections was benign CPP.
  • Multifocal concomitant CPP is rare.
  • Concomitant CPPs may be secondary to mere coincidental tumor occurrence or to biologic seeding of cerebrospinal fluid (CSF) from a primary CPP despite otherwise benign histopathology.
  • The primary treatment for CPP is surgical resection.
  • Post-operative chemotherapy or radiation for CPP is of controversial benefit.
  • [MeSH-major] Fourth Ventricle. Papilloma, Choroid Plexus / pathology. Third Ventricle

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963638.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 21
  •  go-up   go-down


18. Zhao RJ, Woo RS, Jeong MS, Shin BS, Kim DG, Kim KW: Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport; 2003 Dec 19;14(18):2383-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Orphanin FQ/nociceptin (NOC) has been reported to regulate dopaminergic neurotransmission in rewarding pathway, and to suppress the development of conditioned place preference (CPP) induced by certain addictive drugs.
  • In this study, we investigated the effect of NOC on CPP induced by repeated administration of methamphetamine (MAP) in rats.
  • Repeated administration of MAP (1 mg/kg, i.p.) induced substantial CPP.
  • MAP-induced CPP was completely suppressed by NOC (10 nmol, i.c.v.).
  • ), an antagonist of the NOC receptor, antagonized the suppressive effect of NOC on MAP-induced CPP.
  • These results suggest that NOC blocks MAP-induced CPP by activation of the NOC receptor.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Methamphetamine / antagonists & inhibitors. Methamphetamine / pharmacology. Opioid Peptides / pharmacology
  • [MeSH-minor] Animals. Behavior, Addictive / drug therapy. Behavior, Addictive / psychology. Male. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • Hazardous Substances Data Bank. d-METHAMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14663196.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Opioid Peptides; 0 / nociceptin; 44RAL3456C / Methamphetamine
  •  go-up   go-down


19. Chiu WT, Lin TJ, Lin JW, Huang SJ, Chang CK, Chen HY: Multicenter evaluation of propofol for head-injured patients in Taiwan. Surg Neurol; 2006;66 Suppl 2:S37-42
Hazardous Substances Data Bank. PROPOFOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice of pharmacotherapy in head-injured patients.
  • Data on patients' demographics, laboratory data, GCS score, ICP, CPP, concurrent medications, and therapeutic outcomes were collected.
  • Mean CPP for the first 5 days in the ICU was 71.10 +/- 15.32 mm Hg in the propofol group and 43.20 +/- 29.92 mm Hg in the nonpropofol group (P<.001).
  • [MeSH-major] Brain Injuries / drug therapy. Brain Injuries / mortality. Hypnotics and Sedatives / therapeutic use. Propofol / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Glasgow Coma Scale. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071254.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; YI7VU623SF / Propofol
  •  go-up   go-down


20. Herzig V, Schmidt WJ: Repeated-testing of place preference expression for evaluation of anti-craving-drug effects. Amino Acids; 2005 May;28(3):309-17
Hazardous Substances Data Bank. ACAMPROSATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated-testing of place preference expression for evaluation of anti-craving-drug effects.
  • In addiction research, the conditioned place preference (CPP) paradigm is a widely used animal model of conditioned reward.
  • Usually, CPP development is studied, while only few studies examine CPP expression.
  • In the present study, the suitability of a schedule allowing repeated testing of CPP expression was evaluated.
  • This schedule consisted of four repeated applications of a sequence of drug- (i.e. cocaine or morphine), saline- and anti-craving-drug- (i.e. acamprosate, naloxone, their joint administration or saline as internal control) tests.
  • Methodologically, the repeated-testing-schedule produced stable CPP expression in both groups over 12 subsequent tests.
  • In conclusion, it is suggested as a useful method to study effects of anti-craving-drugs on CPP expression, thereby reducing the overall number of experimental animals.
  • The evaluation of the anti-craving-drug effects revealed that neither acamprosate and naloxone given separately nor their combined administration significantly reduced cocaine- or morphine-CPP expression.
  • Thus, we suggest that these anti-craving-drugs are unlikely to be effective for relapse prevention in cocaine- or morphine-addicts.
  • [MeSH-major] Behavior, Animal / drug effects. Conditioning (Psychology) / drug effects. Naloxone / administration & dosage. Narcotic Antagonists / administration & dosage. Opioid-Related Disorders / drug therapy
  • [MeSH-minor] Alcohol Deterrents. Analgesics, Opioid / administration & dosage. Analgesics, Opioid / adverse effects. Anesthetics, Local / administration & dosage. Anesthetics, Local / adverse effects. Animals. Cocaine / administration & dosage. Cocaine / adverse effects. Drug Evaluation, Preclinical. Male. Morphine / administration & dosage. Morphine / adverse effects. Rats. Rats, Sprague-Dawley. Taurine / analogs & derivatives

  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. NALOXONE .
  • Hazardous Substances Data Bank. COCAINE .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791393.001).
  • [ISSN] 0939-4451
  • [Journal-full-title] Amino acids
  • [ISO-abbreviation] Amino Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Alcohol Deterrents; 0 / Analgesics, Opioid; 0 / Anesthetics, Local; 0 / Narcotic Antagonists; 1EQV5MLY3D / Taurine; 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine; I5Y540LHVR / Cocaine; N4K14YGM3J / acamprosate
  •  go-up   go-down


21. Manoharan C, Singh J: Evaluation of polyanhydride microspheres for basal insulin delivery: Effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo absorption and bioactivity in diabetic rats. J Pharm Sci; 2009 Nov;98(11):4237-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The potential of poly 1,3-bis-(p-carboxyphenoxy) propane-co-sebacic acid (p(CPP:SA)) microspheres was investigated for controlled delivery of basal insulin.
  • CPP:SA copolymers with molar compositions of 20:80, 40:60, and 50:50 were synthesized, characterized, and used in the fabrication of microspheres by water-in-oil-in-water double emulsion solvent evaporation technique.
  • Insulin encapsulation efficiency (EE) and in vitro release kinetics were influenced by the molar ratios of CPP:SA copolymer.
  • Increasing CPP content and addition of zinc oxide increased EE, reduced burst release, and prolonged insulin in vitro release over a month.
  • Dimer aggregates were observed for insulin encapsulated in CPP:SA 50:50 microspheres and addition of zinc oxide prevented dimer formation.
  • Subcutaneous administration of CPP:SA 50:50 microspheres in diabetic rats controlled insulin release over a month, and the released insulin was bioactive as determined by lowering blood glucose levels.
  • The results indicate that CPP:SA microspheres controlled insulin release in vitro and in vivo over a month and the released insulin was conformationally and chemically stable, and bioactive.
  • [MeSH-minor] Absorption. Animals. Blood Glucose / metabolism. Chemistry, Pharmaceutical. Diabetes Mellitus, Experimental / drug therapy. Drug Carriers / chemistry. Drug Compounding. Drug Delivery Systems. Drug Stability. Insulin, Long-Acting. Kinetics. Male. Microscopy, Electron, Scanning. Molecular Structure. Molecular Weight. Particle Size. Polymers / chemical synthesis. Polymers / chemistry. Rats. Rats, Sprague-Dawley. Technology, Pharmaceutical / methods

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ZINC COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 19472196.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Drug Carriers; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin, Long-Acting; 0 / Polyanhydrides; 0 / Polymers; 0 / Zinc Compounds
  •  go-up   go-down


22. Yu LL, Wang XY, Zhao M, Liu Y, Li YQ, Li FQ, Wang X, Xue YX, Lu L: Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice. Psychopharmacology (Berl); 2009 Jun;204(2):203-11
Hazardous Substances Data Bank. d-METHAMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The purpose of this study was to examine whether rimonabant, a cannabinoid CB1 receptor antagonist, would disrupt the consolidation and reconsolidation of methamphetamine-related reward memory, using conditioned place preference paradigm (CPP).
  • MATERIALS AND METHODS: Separate groups of male Kunming mice were trained to acquire methamphetamine CPP.
  • Vehicle or rimonabant (1 mg/kg or 3 mg/kg, i.p.) was given at different time points: immediately after each CPP training session (consolidation), 30 min before the reactivation of CPP (retrieval), or immediately after the reactivation of CPP (reconsolidation).
  • Methamphetamine CPP was retested 24 h and 1 and 2 weeks after rimonabant administration.
  • RESULTS: Rimonabant at doses of 1 and 3 mg/kg significantly inhibited the consolidation of methamphetamine CPP.
  • Only high-dose rimonabant (3 mg/kg) disrupted the retrieval and reconsolidation of methamphetamine CPP.
  • Rimonabant had no effect on methamphetamine CPP in the absence of methamphetamine CPP reactivation.
  • CONCLUSIONS: Our findings suggest that cannabinoid CB1 receptors play a major role in methamphetamine reward memory, and cannabinoid CB1 receptor antagonists may be a potential pharmacotherapy to manage relapse associated with drug-reward-related memory.
  • [MeSH-major] Central Nervous System Stimulants / pharmacology. Memory / drug effects. Methamphetamine / pharmacology. Piperidines / pharmacology. Pyrazoles / pharmacology. Receptor, Cannabinoid, CB1 / antagonists & inhibitors
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Male. Mice. Reward

  • MedlinePlus Health Information. consumer health - Memory.
  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurobiol Learn Mem. 2008 Jul;90(1):1-9 [18342551.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):236-42 [18368604.001]
  • [Cites] Addiction. 1996 Jul;91(7):921-49; discussion 951-65 [8688822.001]
  • [Cites] Learn Mem. 2006 May-Jun;13(3):316-21 [16705137.001]
  • [Cites] Eur J Neurosci. 2007 Apr;25(7):2191-200 [17419755.001]
  • [Cites] Annu Rev Neurosci. 2007;30:123-52 [17417939.001]
  • [Cites] Neuropharmacology. 2002 Oct;43(5):857-67 [12384171.001]
  • [Cites] Eur J Neurosci. 2004 Oct;20(7):1849-57 [15380006.001]
  • [Cites] Acta Pharmacol Sin. 2007 Oct;28(10):1505-18 [17883935.001]
  • [Cites] Nat Med. 2001 Oct;7(10 ):1151-4 [11590440.001]
  • [Cites] J Neurosci. 2008 May 21;28(21):5602-10 [18495894.001]
  • [Cites] Nature. 1993 Sep 2;365(6441):61-5 [7689702.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):253-62 [18368606.001]
  • [Cites] Neuroscience. 1998 Mar;83(2):393-411 [9460749.001]
  • [Cites] Psychopharmacology (Berl). 2006 Mar;185(1):19-28 [16374599.001]
  • [Cites] Dialogues Clin Neurosci. 2007;9(4):389-97 [18286799.001]
  • [Cites] Science. 2002 Apr 26;296(5568):678-82 [11976437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2932-7 [16473939.001]
  • [Cites] Am J Addict. 2001 Summer;10(3):201-17 [11579619.001]
  • [Cites] J Neurosci. 2008 Dec 3;28(49):13248-57 [19052216.001]
  • [Cites] Brain Res. 2006 Feb 23;1075(1):60-7 [16464439.001]
  • [Cites] Trends Neurosci. 2003 Feb;26(2):65-72 [12536129.001]
  • [Cites] Ann N Y Acad Sci. 2004 Oct;1025:515-27 [15542757.001]
  • [Cites] Neurosci Lett. 2005 Jun 3;380(3):270-5 [15862900.001]
  • [Cites] J Psychopharmacol. 2002 Jun;16(2):139-43 [12095072.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):243-52 [18368605.001]
  • [Cites] Neuropsychopharmacology. 2004 Aug;29(8):1470-8 [15085091.001]
  • [Cites] Behav Brain Res. 2007 Mar 12;178(1):146-53 [17239969.001]
  • [Cites] Neurobiol Learn Mem. 2007 Jan;87(1):93-100 [16905344.001]
  • [Cites] Learn Mem. 2008 May 05;15(5):304-14 [18463174.001]
  • [Cites] J Neurochem. 2007 Dec;103(6):2505-17 [17953657.001]
  • [Cites] Nature. 2005 Sep 22;437(7058):556-9 [16100511.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):229-35 [18368603.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(2):223-31 [17211653.001]
  • [Cites] Neuroreport. 2007 Jul 16;18(11):1153-6 [17589317.001]
  • [Cites] Hippocampus. 2001;11(1):8-17 [11261775.001]
  • [Cites] Learn Mem. 2006 Jul-Aug;13(4):426-30 [16882859.001]
  • [Cites] Eur J Pharmacol. 2008 Jul 28;589(1-3):122-6 [18534572.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Dec;31(12):2001-5 [17949470.001]
  • [Cites] Am J Psychiatry. 2005 Aug;162(8):1414-22 [16055762.001]
  • [Cites] Drug Alcohol Rev. 2008 Mar;27(2):185-9 [18264880.001]
  • [Cites] Behav Pharmacol. 2005 Sep;16(5-6):395-404 [16148444.001]
  • [Cites] Eur J Pharmacol. 2003 Sep 23;477(3):213-7 [14522359.001]
  • [Cites] J Neurosci. 2001 Dec 1;21(23 ):9506-18 [11717385.001]
  • [Cites] Prog Neurobiol. 1999 Jul;58(4):315-48 [10368032.001]
  • [Cites] Neurobiol Learn Mem. 2005 Mar;83(2):119-24 [15721795.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):396-406 [15925401.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):875-83 [15525797.001]
  • [Cites] Alcohol Alcohol. 2005 Jan-Feb;40(1):46-53 [15582988.001]
  • [Cites] Neurosci Biobehav Rev. 2004 Jan;27(8):827-39 [15019432.001]
  • [Cites] Trends Pharmacol Sci. 1994 Oct;15(10):374-9 [7809953.001]
  • [Cites] Trends Pharmacol Sci. 2005 Aug;26(8):420-6 [15992935.001]
  • [Cites] Jpn J Pharmacol. 2000 Nov;84(3):229-36 [11138722.001]
  • [Cites] Neuron. 2005 Sep 15;47(6):873-84 [16157281.001]
  • [Cites] Nat Rev Neurosci. 2008 Mar;9(3):182-94 [18270514.001]
  • [Cites] J Neurosci. 1995 Mar;15(3 Pt 2):2301-11 [7891168.001]
  • [Cites] J Physiol Biochem. 2000 Mar;56(1):17-24 [10879677.001]
  • [Cites] Neuroreport. 2006 Sep 18;17(13):1443-7 [16932155.001]
  • [Cites] Nature. 1990 Aug 9;346(6284):561-4 [2165569.001]
  • [Cites] J Neurosci. 2006 Aug 16;26(33):8531-6 [16914679.001]
  • [Cites] Eur J Neurosci. 2007 Jun;25(11):3417-21 [17553010.001]
  • [Cites] Acta Pharmacol Sin. 2006 Feb;27(2):140-4 [16412261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11580-4 [17592122.001]
  • [Cites] Eur J Pharmacol. 2004 Sep 13;498(1-3):119-23 [15363985.001]
  • [Cites] Psychopharmacology (Berl). 2007 Dec;195(2):193-201 [17661018.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):387-95 [15935455.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:33-46 [15464124.001]
  • [Cites] Annu Rev Neurosci. 2006;29:565-98 [16776597.001]
  • [Cites] Neurocase. 2001;7(5):357-82 [11744778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8 [12538878.001]
  • [Cites] Neurobiol Learn Mem. 2008 Sep;90(2):374-81 [18524639.001]
  • [Cites] Trends Neurosci. 2006 Dec;29(12):695-703 [17084911.001]
  • [Cites] Trends Neurosci. 1990 Oct;13(10):420-3 [1700516.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):263-84 [15936806.001]
  • (PMID = 19148622.001).
  • [ISSN] 1432-2072
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 44RAL3456C / Methamphetamine; RML78EN3XE / rimonabant
  •  go-up   go-down


23. Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend; 2006 Sep 15;84(2):175-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the conditioned place preference (CPP) paradigm in rats, we demonstrated that co-administration of nalbuphine (1mg/kg, i.p.) with morphine (5mg/kg, i.p.) during conditioning could completely block the CPP induced by morphine.
  • All of these results suggest nalbuphine could have a great potential as a pharmacotherapy for opiate abuse.
  • [MeSH-major] Behavior, Animal / drug effects. Morphine / antagonists & inhibitors. Nalbuphine / pharmacology. Narcotic Antagonists / pharmacology. Reward
  • [MeSH-minor] 3,4-Dihydroxyphenylacetic Acid / metabolism. Animals. Chromatography, High Pressure Liquid. Conditioning (Psychology). Drug Tolerance. Homovanillic Acid / metabolism. Locomotion / drug effects. Male. Narcotics / administration & dosage. Narcotics / pharmacokinetics. Nucleus Accumbens / drug effects. Nucleus Accumbens / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517095.001).
  • [ISSN] 0376-8716
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Narcotic Antagonists; 0 / Narcotics; 102-32-9 / 3,4-Dihydroxyphenylacetic Acid; 76I7G6D29C / Morphine; L2T84IQI2K / Nalbuphine; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down


24. Biala G, Budzynska B, Staniak N: Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Behav Brain Res; 2009 Sep 14;202(2):260-5
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats.
  • Drug addiction is a chronic disorder characterized by a relatively high rate of relapse even after long period of abstinence.
  • In the present study, we used the conditioned place preference (CPP) paradigm to investigate the establishment, extinction, reinstatement and cross-reinstatement of nicotine-induced place conditioning in rats.
  • Nicotine produced a place preference to the initially less-preferred compartment paired with its injections during conditioning (0.5mg/kg, i.p., three drug sessions).
  • Once established, nicotine CPP was extinguished by repeated testing.
  • Following this extinction phase, the reinstatement of CPP was investigated.
  • These priming injections of both drugs induced a marked preference for the compartment previously paired with nicotine.
  • Furthermore, the objective of the present study was to evaluate the efficacy of CB1 cannabinoid receptor antagonist rimonabant (0.5, 1 and 2mg/kg, i.p.) in blocking the reinstatement of nicotine-induced CPP provoked by nicotine and morphine.
  • It was shown that rimonabant attenuated the reinstatement of nicotine-conditioned response induced by both drugs.
  • The outcome of our studies may suggest that CB1 receptor antagonists may become a promising target for effective pharmacotherapy of tobacco addiction and polydrug abuse.
  • [MeSH-major] Central Nervous System Agents / administration & dosage. Conditioning, Classical / drug effects. Morphine / administration & dosage. Nicotine / administration & dosage. Nicotinic Agonists / administration & dosage. Piperidines / administration & dosage. Pyrazoles / administration & dosage
  • [MeSH-minor] Analysis of Variance. Animals. Extinction, Psychological. Male. Random Allocation. Rats. Rats, Wistar. Receptor, Cannabinoid, CB1 / antagonists & inhibitors. Spatial Behavior / drug effects

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463710.001).
  • [ISSN] 1872-7549
  • [Journal-full-title] Behavioural brain research
  • [ISO-abbreviation] Behav. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Central Nervous System Agents; 0 / Nicotinic Agonists; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 158681-13-1 / rimonabant; 6M3C89ZY6R / Nicotine; 76I7G6D29C / Morphine
  •  go-up   go-down


25. Ramond A, Sartorius E, Mousseau M, Ribuot C, Joyeux-Faure M: Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts. Exp Biol Med (Maywood); 2008 Jan;233(1):76-83
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.
  • The use of chemotherapeutic agents, such as anthracycline or trastuzumab, in oncology is limited by their cardiac toxicity.
  • Doxorubicin exposure decreased left ventricular developed pressure (LVDP; approximately -40% of baseline) and increased end diastolic pressure (EDP; approximately +390% of baseline) and coronary perfusion pressure (CPP; approximately +70% of baseline).
  • Trastuzumab exposure increased CPP and EDP (approximately +70% of baseline for the both) without affecting LVDP.
  • Prior rhEPO treatment significantly prevented doxorubicin-induced deleterious effects on LVDP, EDP, and VT/VF incidence. rhEPO administration also prevented trastuzumab-induced deleterious effects on CPP and EDP.
  • [MeSH-major] Antibodies, Monoclonal / toxicity. Antineoplastic Agents / toxicity. Doxorubicin / toxicity. Erythropoietin / therapeutic use. Heart / drug effects
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Blood Pressure / drug effects. In Vitro Techniques. Protective Agents / therapeutic use. Rats. Recombinant Proteins. Trastuzumab. Ventricular Fibrillation / chemically induced. Ventricular Fibrillation / prevention & control

  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156309.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protective Agents; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 80168379AG / Doxorubicin; P188ANX8CK / Trastuzumab
  •  go-up   go-down


26. Levy ML, Goldfarb A, Hyder DJ, Gonzales-Gomez I, Nelson M, Gilles FH, McComb JG: Choroid plexus tumors in children: significance of stromal invasion. Neurosurgery; 2001 Feb;48(2):303-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors in children: significance of stromal invasion.
  • OBJECTIVE: A group of choroid plexus tumors fit the cellular criteria for choroid plexus papilloma (CPP) except for invasion into the adjacent parenchyma, with associated loss of the normal villus architecture at the site of invasion.
  • These tumors retain a benign cellular appearance.
  • In the existing literature, it is unclear whether these tumors are classified as choroid plexus carcinomas or as CPPs.
  • In our experience, although evidence of invasion is present, these tumors tend to exhibit benign behavior.
  • We suggest that stromal invasion of this type remains consistent with a benign clinical course, although surgical results may demonstrate higher morbidity rates, given the invasive nature of the tumors.
  • After gross total tumor removal, none of the eight children with CPPs received adjuvant therapy at our institution; all are alive without evidence of tumor recurrence after surgical excision (mean, 108 mo).
  • The one patient who underwent subtotal resection received chemotherapy at another facility.
  • CONCLUSION: It is recommended that CPPs with a benign cellular appearance but with evidence of local parenchymal invasion and loss of the normal villus architecture at the site of invasion be classified as CPPs.
  • Patients with these tumors respond to surgical therapy alone, without the need for adjuvant treatment.
  • [MeSH-major] Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / surgery. Papilloma / pathology. Papilloma / surgery
  • [MeSH-minor] Child. Child, Preschool. Humans. Infant. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11220372.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Groblewski PA, Lattal KM, Cunningham CL: Effects of D-cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice. Alcohol Clin Exp Res; 2009 May;33(5):772-82
Hazardous Substances Data Bank. CYCLOSERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of D-cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice.
  • BACKGROUND: D-cycloserine (DCS), a partial N-methyl-D-aspartate receptor agonist, has been shown to enhance the extinction of both cocaine and amphetamine-induced conditioned place preference (CPP).
  • Thus, the current experiments examined the effects of DCS on the extinction and subsequent reconditioning of ethanol-induced CPP in mice.
  • METHODS: Male DBA/2J mice received either 2 or 4 pairings of ethanol (2 g/kg) with a conditioned stimulus (CS+) floor cue (and an equal number of saline pairings with a CS- floor cue on alternate days) resulting in either a weak or strong ethanol CPP, respectively.
  • Following conditioning of a strong ethanol CPP mice received saline or 30 mg/kg DCS prior to each of the twelve 30-minute choice extinction trials administered at 48-hour intervals.
  • Mice that had received conditioning of a weak ethanol CPP received saline, 30 or 60 mg/kg DCS immediately before each of the six 30-minute choice extinction trials.
  • Following successful ethanol CPP extinction, mice received reconditioning trials similar to the initial conditioning trials.
  • A final experiment examined the effects 12 DCS pre-exposures (15, 30, and 60 mg/kg) on initial conditioning of ethanol CPP.
  • RESULTS: First, we showed that 2 doses of DCS (30 and 60 mg/kg) did not have aversive properties that could confound the effects on extinction of CPP (Experiment 1).
  • Second, we showed that DCS (30 and 60 mg/kg) had no effect on the rate of extinction of either strong (Experiment 2) or weak (Experiment 3) ethanol-induced CPP.
  • Interestingly, DCS administered during extinction interfered with reconditioning of ethanol-induced CPP--an effect specific to reconditioning, as DCS pre-exposure did not influence initial ethanol CPP conditioning (Experiment 4).
  • CONCLUSIONS: These experiments show that although DCS showed no effect on extinction behavior, when given during extinction it interfered with subsequent reconditioning of ethanol CPP.
  • The mechanisms of this effect were not, however, due to nonspecific interference with learning because repeated DCS pre-exposures did not impair initial conditioning of ethanol CPP.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Neurosci. 2006 Oct;120(5):1159-62 [17014266.001]
  • [Cites] Biol Psychiatry. 2006 Aug 15;60(4):369-75 [16919524.001]
  • [Cites] J Psychiatr Res. 2007 Sep;41(6):466-71 [16828803.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(2):195-202 [17216157.001]
  • [Cites] Neurobiol Learn Mem. 2007 May;87(4):476-82 [17275356.001]
  • [Cites] Neuroreport. 2007 May 28;18(8):777-80 [17471065.001]
  • [Cites] Nat Protoc. 2006;1(4):1662-70 [17487149.001]
  • [Cites] Neurosci Behav Physiol. 2007 Jun;37(5):509-15 [17505804.001]
  • [Cites] Int Clin Psychopharmacol. 2007 Jul;22(4):230-7 [17519647.001]
  • [Cites] Behav Neurosci. 2007 Jun;121(3):501-14 [17592941.001]
  • [Cites] Behav Pharmacol. 2007 Sep;18(5-6):497-506 [17762518.001]
  • [Cites] Biol Psychiatry. 2007 Oct 15;62(8):835-8 [17588545.001]
  • [Cites] Amino Acids. 2008 Apr;34(3):485-95 [17690951.001]
  • [Cites] Neurobiol Learn Mem. 2008 Oct;90(3):504-10 [18672079.001]
  • [Cites] Alcohol Alcohol. 2008 Nov-Dec;43(6):626-9 [18945754.001]
  • [Cites] Psychopharmacology (Berl). 2009 Jan;202(1-3):403-9 [18695929.001]
  • [Cites] Psychopharmacology (Berl). 2009 Jan;202(1-3):397-402 [18781295.001]
  • [Cites] Epilepsy Res. 2000 Jul;40(2-3):109-21 [10863138.001]
  • [Cites] J Neurosci. 2002 Mar 15;22(6):2343-51 [11896173.001]
  • [Cites] Psychopharmacology (Berl). 2002 Apr;160(4):414-24 [11919669.001]
  • [Cites] Behav Brain Res. 2003 Mar 18;140(1-2):1-47 [12644276.001]
  • [Cites] Psychopharmacology (Berl). 2003 Dec;170(4):409-22 [12955296.001]
  • [Cites] Behav Neurosci. 2004 Jun;118(3):505-13 [15174928.001]
  • [Cites] Behav Brain Res. 1986 Sep;21(3):189-94 [2876714.001]
  • [Cites] Nature. 1987 Feb 5-11;325(6104):529-31 [2433595.001]
  • [Cites] Eur J Pharmacol. 1992 Oct 20;221(2-3):249-54 [1330624.001]
  • [Cites] Eur J Pharmacol. 1994 May 12;257(1-2):7-12 [8082709.001]
  • [Cites] Mol Pharmacol. 1995 Oct;48(4):717-23 [7476899.001]
  • [Cites] Neurochem Int. 1996 Sep;29(3):255-61 [8885284.001]
  • [Cites] Alcohol Alcohol Suppl. 1994;2:199-204 [8974336.001]
  • [Cites] Pharmacol Biochem Behav. 1997 Dec;58(4):1059-64 [9408214.001]
  • [Cites] Arch Gen Psychiatry. 2004 Nov;61(11):1136-44 [15520361.001]
  • [Cites] Am Rev Tuberc. 1956 Nov;74(5):802-6 [13372966.001]
  • [Cites] Biol Psychiatry. 2005 Apr 15;57(8):841-7 [15820704.001]
  • [Cites] Neurobiol Learn Mem. 2005 May;83(3):224-31 [15820858.001]
  • [Cites] Arch Gen Psychiatry. 2006 Mar;63(3):298-304 [16520435.001]
  • [Cites] Behav Brain Res. 2006 Sep 15;172(1):173-8 [16769132.001]
  • [Cites] Neuroscience. 2006 Nov 3;142(4):979-90 [16934411.001]
  • (PMID = 19298331.001).
  • [ISSN] 1530-0277
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA007702-22; United States / NIAAA NIH HHS / AA / AA 007702; United States / NIDA NIH HHS / DA / R01 DA025922-02; United States / NIAAA NIH HHS / AA / T32 AA007468-20; United States / NIDA NIH HHS / DA / DA025922-02; United States / NIMH NIH HHS / MH / R01 MH077111-04; United States / NIAAA NIH HHS / AA / R01 AA007702-22; United States / NIDA NIH HHS / DA / DA 025922; United States / NIAAA NIH HHS / AA / T32 AA007468; United States / NIDA NIH HHS / DA / R01 DA025922; United States / NIAAA NIH HHS / AA / R37 AA007702; United States / NIMH NIH HHS / MH / R01 MH077111; United States / NIAAA NIH HHS / AA / AA007468-20; United States / NIAAA NIH HHS / AA / AA 007468; United States / NIMH NIH HHS / MH / MH 077111; United States / NIAAA NIH HHS / AA / R01 AA007702
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol; 95IK5KI84Z / Cycloserine
  • [Other-IDs] NLM/ NIHMS187094; NLM/ PMC2883465
  •  go-up   go-down


28. Martín Díaz MJ, Soriano Guillén L, Muñoz Calvo MT, Pozo Román J, Argente Oliver J: [Triptorelin therapy in girls with central precocious puberty increases body mass index]. An Pediatr (Barc); 2006 Nov;65(5):428-33
Genetic Alliance. consumer health - Central precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Triptorelin therapy in girls with central precocious puberty increases body mass index].
  • [Transliterated title] El tratamiento con triptorelina en las niñas con pubertad precoz central provoca incremento del índice de masa corporal.
  • INTRODUCTION: The most important complications of central precocious puberty (CPP) in girls are loss of height and multiple psychosocial problems.
  • OBJECTIVES: To study the effect of triptorelin therapy in a cohort of girls with CPP.
  • PATIENTS AND METHODS: Thirty-four girls diagnosed with organic or idiopathic CPP and treated with monthly triptorelin were studied.
  • Age, height in standard deviation (SD), bone age (Greulich and Pyle), height prediction (Bayle-Pinneau), body mass index (BMI) in SD, uterine size (pelvic ultrasound), target height, cranial magnetic resonance imaging, triptorelin dose, and treatment duration were studied.
  • RESULTS: Triptorelin produced a statistically significant reduction in growth velocity and an increase in BMI after 1 year of therapy and these changes were maintained after discontinuation of therapy.
  • Adult height in patients with organic CPP was significantly lower than that in patients with idiopathic CPP.
  • Triptorelin can increase BMI in girls with CPP.
  • 2. The presence of an organic cause in patients with CPP worsens the prognosis for adult height.
  • 3. The Bayley-Pinneau prediction method for "average" bone age is useful for establishing a prognosis of adult height in girls with CPP treated with triptorelin.
  • [MeSH-major] Body Mass Index. Growth / drug effects. Luteolytic Agents / pharmacology. Puberty, Precocious / drug therapy. Triptorelin Pamoate / pharmacology

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184602.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Luteolytic Agents; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


29. Lamvu G, Williams R, Zolnoun D, Wechter ME, Shortliffe A, Fulton G, Steege JF: Long-term outcomes after surgical and nonsurgical management of chronic pelvic pain: one year after evaluation in a pelvic pain specialty clinic. Am J Obstet Gynecol; 2006 Aug;195(2):591-8; discussion 598-600
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to describe long-term outcomes for women with chronic pelvic pain (CPP) after evaluation in a CPP specialty clinic.
  • STUDY DESIGN: This was a prospective observational cohort study of women treated for CPP at the UNC Pelvic Pain clinic between 1993 and 2000.
  • The primary outcome was improvement in pain and the main exposure was treatment group: primarily medical (pharmacotherapy, psychotherapy, physical therapy, or combinations of the 3) or surgical (hysterectomy, resection or ablative procedures, oophrectomy, diagnostic surgery, pain mapping, vulvar or vestibular repair).
  • Univariate, bivariate, and multivariable analyses were performed to look for relationships between background characteristics, treatment group, and improvement in pain.
  • RESULTS: Of 370 participants; 189 had surgical treatment and 181 had medical treatment.
  • Improvement in pain was similar in both treatment groups and odds of improvement were equal even after adjusting for background characteristics, psychosocial comorbidity, and previous treatments.
  • CONCLUSION: One year after evaluation in a CPP specialty clinic, women experienced modest improvements in pain and depression after recommended surgical or nonsurgical treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Comorbidity. Depression / etiology. Female. Follow-Up Studies. Humans. Logistic Models. Middle Aged. Multivariate Analysis. Pain Measurement. Prospective Studies. Sex Offenses. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729951.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Powers MS, Barrenha GD, Mlinac NS, Barker EL, Chester JA: Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. Psychopharmacology (Berl); 2010 Dec;212(4):571-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evidence suggests that the endocannabinoid system (ECS) is a promising therapeutic target for the treatment of individuals with anxiety and/or alcohol-use disorders.
  • OBJECTIVES: The present study assessed the effects of a novel endocannabinoid uptake inhibitor, LY2183240, on anxiety- and alcohol-seeking behaviors in a unique animal model that may represent increased genetic risk to develop co-morbid anxiety and alcohol-use disorders in humans.
  • We examined the effects of LY2183240 on the expression of FPS in HAP and LAP mice and on alcohol-induced conditioned place preference (CPP) and limited-access alcohol drinking behavior in HAP mice.
  • Both the 10 and 30 mg/kg doses of LY2183240 enhanced the expression of alcohol-induced CPP and this effect persisted in the absence of the drug.
  • LY2183240 may be an effective pharmacotherapy for individuals with anxiety disorders, such as post-traumatic stress disorder, but may not be appropriate for individuals with co-morbid anxiety and alcohol-use disorders.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. UREA .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacology (Berl). 2008 Jun;198(3):405-11 [18446325.001]
  • [Cites] Psychopharmacology (Berl). 2008 Jul;198(4):449-60 [18446329.001]
  • [Cites] Neurobiol Learn Mem. 2008 Jul;90(1):290-3 [18486502.001]
  • [Cites] Alcohol Clin Exp Res. 2008 Oct;32(10):1782-94 [18652593.001]
  • [Cites] Eur Neuropsychopharmacol. 2008 Dec;18(12):849-59 [18706790.001]
  • [Cites] Learn Mem. 2008 Nov;15(11):806-9 [18957525.001]
  • [Cites] Physiol Rev. 2009 Jan;89(1):309-80 [19126760.001]
  • [Cites] Psychopharmacology (Berl). 2009 Jun;204(2):203-11 [19148622.001]
  • [Cites] Cell Calcium. 2009 Jun;45(6):611-24 [19356798.001]
  • [Cites] Pharmacol Biochem Behav. 2009 Nov;94(1):154-62 [19698735.001]
  • [Cites] Pharmacol Biochem Behav. 2010 Apr;95(2):258-65 [20138906.001]
  • [Cites] J Neurosci Res. 2000 Apr 1;60(1):122-8 [10723075.001]
  • [Cites] J Clin Psychiatry. 2000;61 Suppl 7:22-32 [10795606.001]
  • [Cites] Alcohol Res Health. 2000;24(2):85-92 [11199282.001]
  • [Cites] Psychopharmacology (Berl). 2002 Jan;159(2):181-7 [11862347.001]
  • [Cites] Nature. 2002 Aug 1;418(6897):530-4 [12152079.001]
  • [Cites] Psychopharmacology (Berl). 2002 Nov;164(3):318-28 [12424556.001]
  • [Cites] Biol Psychiatry. 2002 Nov 15;52(10):958-75 [12437937.001]
  • [Cites] Psychopharmacology (Berl). 2003 Jan;165(3):238-44 [12451436.001]
  • [Cites] J Neurochem. 2003 Feb;84(4):698-704 [12562514.001]
  • [Cites] Neuropsychopharmacology. 2003 Apr;28(4):654-63 [12655310.001]
  • [Cites] Neuron. 2003 Jun 19;38(6):863-9 [12818173.001]
  • [Cites] Learn Behav. 2003 Aug;31(3):273-80 [14577550.001]
  • [Cites] Br J Psychiatry. 2004 Aug;185:116-26 [15286062.001]
  • [Cites] Acta Biol Exp (Warsz). 1967;27(2):147-61 [6080678.001]
  • [Cites] Arch Gen Psychiatry. 1981 Aug;38(8):869-71 [7259423.001]
  • [Cites] Arch Gen Psychiatry. 1985 Apr;42(4):367-72 [3977554.001]
  • [Cites] Pharmacol Biochem Behav. 1987 Jul;27(3):517-9 [3659074.001]
  • [Cites] Pharmacol Biochem Behav. 1988 Mar;29(3):601-7 [3362955.001]
  • [Cites] Am J Psychiatry. 1990 Jun;147(6):685-95 [2188513.001]
  • [Cites] Pharmacol Ther. 1990;47(2):147-65 [2203068.001]
  • [Cites] Psychopharmacology (Berl). 1992;107(2-3):453-6 [1615143.001]
  • [Cites] Pharmacol Biochem Behav. 1992 Sep;43(1):97-102 [1409822.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 1993;243(3-4):205-11 [8117765.001]
  • [Cites] Eur J Pharmacol. 1994 Nov 15;269(3):365-74 [7895775.001]
  • [Cites] Psychopharmacology (Berl). 1995 Mar;118(2):150-4 [7617801.001]
  • [Cites] Arch Gen Psychiatry. 1995 Dec;52(12):1048-60 [7492257.001]
  • [Cites] Am J Orthopsychiatry. 1996 Jan;66(1):17-31 [8720638.001]
  • [Cites] Arch Gen Psychiatry. 1997 Jan;54(1):81-7 [9006404.001]
  • [Cites] Behav Brain Res. 1997 Mar;84(1-2):241-6 [9079788.001]
  • [Cites] Arch Gen Psychiatry. 1997 Apr;54(4):313-21 [9107147.001]
  • [Cites] Alcohol Clin Exp Res. 1997 Sep;21(6):1083-91 [9309321.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Apr;22(2):468-73 [9581655.001]
  • [Cites] Psychol Med. 1998 Jul;28(4):773-88 [9723135.001]
  • [Cites] Eur J Pharmacol. 1999 Apr 16;370(3):233-40 [10334497.001]
  • [Cites] J Occup Environ Med. 1999 May;41(5):384-92 [10337608.001]
  • [Cites] Behav Genet. 1999 Jan;29(1):47-57 [10371758.001]
  • [Cites] Ann N Y Acad Sci. 2004 Oct;1025:515-27 [15542757.001]
  • [Cites] Neuropsychopharmacology. 2005 Feb;30(2):339-49 [15383833.001]
  • [Cites] Neuropsychopharmacology. 2005 Mar;30(3):516-24 [15637635.001]
  • [Cites] Behav Neurosci. 2005 Feb;119(1):213-23 [15727526.001]
  • [Cites] Eur J Neurosci. 2005 Apr;21(8):2243-51 [15869521.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):331-42 [15927244.001]
  • [Cites] Behav Brain Res. 2005 Nov 7;164(2):206-13 [16140402.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17852-7 [16314570.001]
  • [Cites] Learn Mem. 2006 Jan-Feb;13(1):1-3 [16452648.001]
  • [Cites] Am J Drug Alcohol Abuse. 2006;32(2):203-24 [16595324.001]
  • [Cites] J Am Chem Soc. 2006 Aug 2;128(30):9699-704 [16866524.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):389-462 [16968947.001]
  • [Cites] Am Psychol. 2006 Nov;61(8):741-56 [17115806.001]
  • [Cites] Neuropsychopharmacology. 2007 Jan;32(1):117-26 [16482090.001]
  • [Cites] Neurobiol Learn Mem. 2007 Feb;87(2):167-73 [17079171.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(2):223-31 [17211653.001]
  • [Cites] Neuropsychopharmacology. 2007 Jul;32(7):1570-82 [17164820.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Jul;31(7):1081-8 [17451404.001]
  • [Cites] Eur J Neurosci. 2007 Jul;26(2):476-86 [17650118.001]
  • [Cites] Mol Neurobiol. 2007 Aug;36(1):92-101 [17952654.001]
  • [Cites] Mol Neurobiol. 2007 Aug;36(1):102-12 [17952655.001]
  • [Cites] Br J Pharmacol. 2007 Nov;152(5):576-82 [17704824.001]
  • [Cites] Pharmacol Res. 2007 Nov;56(5):367-81 [17951068.001]
  • [Cites] J Neurochem. 2008 Jan;104(1):233-43 [17944864.001]
  • [Cites] J Neurosci. 2008 Jan 30;28(5):1076-84 [18234886.001]
  • [Cites] Alcohol. 2008 Feb;42(1):1-11 [18164576.001]
  • [Cites] Eur J Pharmacol. 2008 May 13;585(2-3):453-7 [18410917.001]
  • [Cites] Addict Biol. 2008 Jun;13(2):160-87 [18422831.001]
  • (PMID = 20838777.001).
  • [ISSN] 1432-2072
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA016843; United States / NIAAA NIH HHS / AA / R01 AA016843-04; United States / NIAAA NIH HHS / AA / AA019529-02; United States / NIAAA NIH HHS / AA / R21 AA019529; United States / NIAAA NIH HHS / AA / AA016843; United States / NIAAA NIH HHS / AA / R21 AA019529-02; United States / NIAAA NIH HHS / AA / AA016843-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Cannabinoid Receptor Modulators; 0 / Endocannabinoids; 0 / Heterocyclic Compounds, 1-Ring; 0 / LY2183240; 3K9958V90M / Ethanol; 8W8T17847W / Urea
  • [Other-IDs] NLM/ NIHMS233448; NLM/ PMC2982902
  •  go-up   go-down


31. Suge T, Ishikawa K, Kawasaki A, Suzuki K, Matsuo T, Noiri Y, Imazato S, Ebisu S: Calcium phosphate precipitation method for the treatment of dentin hypersensitivity. Am J Dent; 2002 Aug;15(4):220-6
Hazardous Substances Data Bank. CALCIUM HYDROGEN PHOSPHATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium phosphate precipitation method for the treatment of dentin hypersensitivity.
  • PURPOSE: To evaluate the feasibility of the calcium phosphate precipitation (CPP) method as a treatment for dentin hypersensitivity using vital teeth of beagle dogs.
  • Also, gingival tissue response to two types of CPP methods was examined histologically.
  • MATERIALS AND METHODS: Dentin tubules of the dogs' vital teeth were exposed by shallow cavity preparation followed by etching with 50% citric acid to simulate the condition of hypersensitive dentin.
  • After CPP treatment was applied to the vital tooth, the dentin surface and longitudinal sections were observed by SEM to evaluate the occluding ability of the CPP method.
  • The gingival tissue before and after CPP method was examined histologically with light microscopy.
  • RESULTS: Dentin tubules were occluded homogeneously and completely with an apatitic mineral after application of the CPP treatment in vital teeth.
  • However, the depth of the precipitate in dentin tubules from the dentin surface was approximately half that seen in extracted teeth.
  • No histological change was observed in gingival tissues when NaHCO3 was used as a post-treatment solution of the CPP method, whereas another CPP method using NaOH solution resulted in atrophy and degeneration of the epithelium of gingival tissue.
  • [MeSH-major] Calcium Phosphates / administration & dosage. Dentin Permeability / drug effects. Dentin Sensitivity / drug therapy
  • [MeSH-minor] Analysis of Variance. Animals. Chemical Precipitation. Dentin / ultrastructure. Dogs. Electron Probe Microanalysis. Feasibility Studies. Gingiva / drug effects. Microscopy, Electron, Scanning

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12572638.001).
  • [ISSN] 0894-8275
  • [Journal-full-title] American journal of dentistry
  • [ISO-abbreviation] Am J Dent
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / alpha-tricalcium phosphate; 0 / tetracalcium phosphate; 701EKV9RMN / calcium phosphate, monobasic, anhydrous; 97Z1WI3NDX / calcium phosphate; L11K75P92J / calcium phosphate, dibasic, anhydrous
  •  go-up   go-down


32. Municchi G, Marconcini S, D'Ambrosio A, Berardi R, Acquaviva A: Central precocious puberty in multisystem Langerhans cell histiocytosis: a case report. Pediatr Hematol Oncol; 2002 Jun;19(4):273-8
MedlinePlus Health Information. consumer health - Diabetes Insipidus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors describe a girl with multisystem Langerhans cell histiocytosis (LCH) who developed central precocious puberty (CPP).
  • She subsequently developed diabetes insipidus with a documented lesion of the pituitary stalk; she received chemotherapy and began therapy with l-desamino-8-D-argininevasopressin.
  • Growth hormone deficiency was diagnosed at the age of 4.4 years and GH replacement therapy started.
  • The patient has been off therapy for LCH since the age of 6.
  • Signs of pubertal development appeared at 7.5 years (bone age 8 years) and gonadotropin-releasing hormone analog (GnRHa) treatment was started.
  • During the observation period she developed central hypothyroidism.
  • Development of CPP during LCH is extremely rare; to the authors 'knowledge, no patient has been described so far.
  • The authors believe that CPP was secondary to LCH and did not represent a casual finding, even in the absence of hypothalamic-pituitary axis involvement.
  • The possibility of CPP development should be considered during the follow-up of these patients.


33. Utaisincharoen P, Tangthawornchaikul N, Ubol S, Chaisuriya P, Sirisinha S: TNF-alpha induces caspase 3 (CPP 32) dependent apoptosis in human cholangiocarcinoma cell line. Southeast Asian J Trop Med Public Health; 2000;31 Suppl 1:167-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-alpha induces caspase 3 (CPP 32) dependent apoptosis in human cholangiocarcinoma cell line.
  • Cholangiocarcinoma (CCA), a malignant tumor derived from bile duct epithelium, occurs with a higher incidence in tropical countires especially in some areas of Southeast Asian countries such as Thailand.
  • This tumor is relatively resistant to chemotherapy.
  • In this study, molecular mechanism of killing of this tumor by TNF-alpha was investigated.
  • Human cholangiocarcinoma cell line (HuCCA-1) was developed and used as a model for treatment.
  • Activation of HuCCA-1 with TNF-alpha in the present of actinomycin D (1 microg/ml) caused death of the tumor cells.
  • Western blotting analysis of the cells extracted demonstrated the cleavage of poly (ADP-ribose) polymerase (PARP) within 6-8 hours following TNF-alpha treatment indicating apoptotic death.
  • These results indicate that apoptosis of human cholangiocarcinoma cell line as induced by TNF-alpha treatment is mediated through caspase 3.
  • [MeSH-major] Apoptosis / drug effects. Bile Duct Neoplasms / drug therapy. Caspases / drug effects. Cholangiocarcinoma / drug therapy. Tumor Cells, Cultured / drug effects. Tumor Necrosis Factor-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11414450.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


34. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA: Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol; 2009 Dec;95(3):383-392
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study.
  • Atypical choroid plexus papilloma (APP) represents a novel intermediate-grade subtype of choroid plexus tumor (CPT), the clinical outcome of which has not been described yet.
  • We present the first analysis of a group of APP patients enrolled in the ongoing CPT-SIOP-2000 study of CPTs.
  • A worldwide registration and a randomized trial for those patients who require chemotherapy started in 2000.
  • After surgery, patients who had undergone complete resection were observed, whereas patients with incompletely resected or metastasized APP were treated with six chemotherapy courses (etoposide and vincristine, combined with either carboplatin or cyclophosphamide).
  • Of the 106 patients with a centrally confirmed CPT histology, 30 had APP, 42 CPP and 34 CPC.
  • APP patients were significantly younger (median = 0.7 years) than patients with CPP or CPC (both medians = 2.3 years).
  • Complete resection was achieved in 68 (64%) patients (79% in CPP, 63% in APP, and 47% in CPC).
  • Metastases were present at diagnosis in 17% of APP patients, 5% of CPP patients, and 21% of CPC patients.
  • All nine APP patients who received postoperative chemotherapy showed an early response after two cycles: two had complete remission, four had partial response, and three had stable disease.
  • In the treatment group, one patient with a metastasized tumor and incompletely resected APP died.
  • While APP was defined histologically, median percentages of both the Ki-67/MIB-1 proliferation marker and the p53 tumor suppressor protein increased across the three histological subtypes (from CPP to APP and then CPC), suggesting that the subtypes comprise an ordinal categorization of increasingly severe CPT tumors.
  • This ordering was reiterated by clinical outcome in the 92 patients treated per the study protocol, with 5-year EFS rates of 92% in 39 CPP patients, 83% in 24 APP patients, and 28% in 29 CPC patients.
  • APP responded favorably to chemotherapy.
  • The intermediate position of APP between CPP and CPC was supported by the clinical data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / mortality. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / mortality
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Gadolinium. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Registries. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]
  • [Cites] J Neurooncol. 2000 Sep;49(3):263-8 [11212906.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):345-51 [17576522.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3 Suppl):199-202 [17918524.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] J Neurooncol. 2002 Feb;56(3):241-6 [12061730.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):69-74 [16955222.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]
  • [Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]
  • [Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]
  • [Cites] Neuropathology. 2008 Apr;28(2):160-4 [18366349.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Microsc Res Tech. 2001 Jan 1;52(1):104-11 [11135453.001]
  • [Cites] Neuropathology. 2009 Jun;29(3):293-8 [18627486.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):1-10 [11837741.001]
  • [Cites] J Neurosurg Spine. 2006 Jun;4(6):494-6 [16776361.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1076-8 [15200124.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):192-9 [10940770.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):304-7 [15175083.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Acta Neurochir (Wien). 2007 Dec;149(12):1229-36; discussion 1236-7 [17924056.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] Childs Nerv Syst. 1989 Oct;5(5):288-98 [2804999.001]
  • (PMID = 19543851.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00500890
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA083932
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; AU0V1LM3JT / Gadolinium; BG3F62OND5 / Carboplatin
  •  go-up   go-down


35. Gong F, Li F, Zhang L, Li J, Zhang Z, Wang G: Hypoglycemic effects of crude polysaccharide from Purslane. Int J Mol Sci; 2009 Mar;10(3):880-8
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of crude polysaccharide from Purslane (CPP) on body weight (bw), blood glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), triglyceride (TG) and serum insulin levels were studied in diabetes mellitus mice.
  • CPP treatment (200, 400 mg/kg bw) for 28 days resulted in a significant decrease in the concentrations of fasting blood glucose (FBG), TC and TG.
  • Furthermore, CPP significantly increased the concentration of HDL-c, body weight and serum insulin level in the mice.
  • In addition, according to acute toxicity studies and single cell gel electrophoresis analysis, CPP did not produce any physical or behavioral signs of toxicity.
  • More significantly, our data demonstrated CPP exhibited the best effects at the dose of 400 mg/kg bw.
  • The above results suggest that CPP can control blood glucose and modulate the metabolism of glucose and blood lipids in diabetes mellitus mice, so we conclude that CPP should be evaluated as a candidate for future studies on diabetes mellitus.
  • [MeSH-major] Diabetes Mellitus, Experimental / drug therapy. Hypoglycemic Agents / therapeutic use. Plant Extracts / therapeutic use. Portulaca / metabolism
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Blood Glucose / analysis. Body Weight. Cholesterol / blood. Cholesterol, HDL / blood. Insulin / blood. Mice. Single-Cell Analysis. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fitoterapia. 2008 Jan;79(1):21-3 [17855019.001]
  • [Cites] J Ethnopharmacol. 2003 Apr;85(2-3):201-6 [12639741.001]
  • [Cites] J Herb Pharmacother. 2004;4(1):35-40 [15273075.001]
  • [Cites] J Clin Invest. 1969 Nov;48(11):2129-39 [4241908.001]
  • [Cites] Life Sci. 1984 Feb 6;34(6):591-5 [6363864.001]
  • [Cites] J Ethnopharmacol. 2007 Jun 13;112(2):305-11 [17467937.001]
  • [Cites] Diabetes Res Clin Pract. 1995 May;28(2):103-17 [7587918.001]
  • [Cites] J Ethnopharmacol. 2005 Apr 26;98(3):245-50 [15814255.001]
  • [Cites] J Ethnopharmacol. 2006 Sep 19;107(2):285-90 [16644162.001]
  • [Cites] J Trace Elem Med Biol. 2006;20(3):191-6 [16959596.001]
  • [Cites] Diabetes Care. 1995 Aug;18(8):1113-23 [7587846.001]
  • (PMID = 19399226.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Cholesterol, HDL; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Plant Extracts; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC2672007
  • [Keywords] NOTNLM ; Diabetes / Purslane / hypoglycemia / polysaccharide
  • [General-notes] NLM/ Original DateCompleted: 20100624
  •  go-up   go-down


36. Baviera M, Invernizzi RW, Carli M: Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. Psychopharmacology (Berl); 2008 Feb;196(2):269-80
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to compare the effects of conventional and atypical antipsychotics in a model of attentional performance deficit of schizophrenia induced by blockade of N-methyl-D: -aspartate (NMDA) receptors in the medial prefrontal cortex.
  • MATERIALS AND METHODS: Attentional performance was assessed using the five-choice serial reaction time task.
  • The task provides indices of attentional functioning (% correct responses), executive control (measured by anticipatory and perseverative responding), decision time (measured by correct response latency), and omissions.
  • Haloperidol and clozapine were given intraperitoneally (IP) to animals that had received vehicle or a competitive NMDA receptor antagonist, 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP), directly into the medial prefrontal cortex.
  • RESULTS: Fifty nanograms/side of CPP reduced accuracy (% correct responses) and increased anticipatory and perseverative responding.
  • Haloperidol (0.03 mg/kg IP) reduced the CPP-induced anticipatory and perseverative overresponding but not the impairment in accuracy.
  • CPP increased decision time and omissions, but these effects were not affected by either haloperidol or clozapine.
  • [MeSH-major] Attention / drug effects. Clozapine / pharmacology. Haloperidol / pharmacology. Prefrontal Cortex / drug effects. Schizophrenia / physiopathology
  • [MeSH-minor] Analysis of Variance. Animals. Antipsychotic Agents / administration & dosage. Antipsychotic Agents / pharmacology. Behavior, Animal / drug effects. Dopamine Antagonists / administration & dosage. Dopamine Antagonists / pharmacology. Dose-Response Relationship, Drug. Injections, Intraperitoneal. Male. Microinjections. Piperazines / administration & dosage. Piperazines / toxicity. Rats. Reaction Time / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Serial Learning / drug effects. Serotonin Antagonists / administration & dosage. Serotonin Antagonists / pharmacology

  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2006 Feb 16;49(4):603-15 [16476668.001]
  • [Cites] Neuropharmacology. 1999 Aug;38(8):1185-94 [10462131.001]
  • [Cites] Behav Neurosci. 2001 Aug;115(4):812-25 [11508720.001]
  • [Cites] J Neurosci. 1997 Dec 1;17(23):9285-97 [9364074.001]
  • [Cites] Psychopharmacology (Berl). 2006 Jul;187(1):73-85 [16767417.001]
  • [Cites] Synapse. 2005 Apr;56(1):12-20 [15700289.001]
  • [Cites] Schizophr Bull. 1999;25(2):201-22 [10416727.001]
  • [Cites] Neuropsychopharmacology. 2001 Oct;25(4):476-88 [11557161.001]
  • [Cites] Behav Brain Res. 1999 Apr;100(1-2):99-112 [10212057.001]
  • [Cites] Eur J Pharmacol. 2005 Sep 5;519(1-2):114-7 [16099452.001]
  • [Cites] Behav Neurosci. 2001 Aug;115(4):799-811 [11508719.001]
  • [Cites] Psychopharmacology (Berl). 1998 May;137(1):33-42 [9631954.001]
  • [Cites] Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80 [12373437.001]
  • [Cites] Behav Brain Res. 1983 Sep;9(3):361-80 [6639741.001]
  • [Cites] Psychopharmacology (Berl). 1999 Oct;146(4):348-61 [10550486.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Nov;283(2):666-74 [9353384.001]
  • [Cites] Psychopharmacology (Berl). 1992;106(2):228-34 [1532259.001]
  • [Cites] Psychopharmacology (Berl). 2003 May;167(3):304-14 [12677356.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1854-63 [16319908.001]
  • [Cites] Neuron. 2004 May 27;42(4):653-63 [15157425.001]
  • [Cites] Neuropsychopharmacology. 2002 Jun;26(6):716-28 [12007742.001]
  • [Cites] Am J Psychiatry. 1996 Mar;153(3):321-30 [8610818.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Dec;287(3):839-46 [9864262.001]
  • [Cites] Neuroscience. 1993 Feb;52(3):595-604 [8450961.001]
  • [Cites] Behav Brain Res. 1997 Dec;89(1-2):135-49 [9475622.001]
  • [Cites] Brain Res. 1995 Jan 23;670(1):165-8 [7719718.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Oct;283(1):226-34 [9336328.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Sep;266(3):1374-84 [8103793.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1900-9 [16421514.001]
  • [Cites] Psychopharmacology (Berl). 1987;91(4):458-66 [3108926.001]
  • [Cites] J Neurosci. 2000 Feb 1;20(3):1208-15 [10648725.001]
  • [Cites] Neuropsychopharmacology. 1998 Feb;18(2):63-101 [9430133.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72 [14642974.001]
  • [Cites] Psychopharmacology (Berl). 1999 Jul;145(2):193-204 [10463321.001]
  • [Cites] Am J Psychiatry. 2004 Jun;161(6):985-95 [15169686.001]
  • [Cites] J Neurosci. 1999 Jun 1;19(11):4585-94 [10341256.001]
  • [Cites] Psychopharmacology (Berl). 1998 Jan;135(2):194-200 [9497025.001]
  • [Cites] Neuropsychopharmacology. 2006 Apr;31(4):757-67 [16192987.001]
  • [Cites] Cereb Cortex. 1996 May-Jun;6(3):470-81 [8670672.001]
  • [Cites] J Clin Psychiatry. 1994 Sep;55 Suppl B:8-14 [7961581.001]
  • [Cites] J Comp Neurol. 2002 Jan 21;442(4):392-404 [11793342.001]
  • [Cites] Behav Brain Res. 2003 Jan 6;138(1):59-69 [12493630.001]
  • [Cites] J Neural Transm Gen Sect. 1995;101(1-3):127-48 [8695043.001]
  • [Cites] J Neurochem. 2001 Mar;76(5):1521-31 [11238736.001]
  • [Cites] Psychopharmacology (Berl). 1993;111(3):339-44 [7870972.001]
  • [Cites] Psychopharmacology (Berl). 2003 Nov;170(3):309-19 [12904968.001]
  • [Cites] Psychopharmacology (Berl). 2004 Nov;176(3-4):376-85 [15232674.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Nov;271(2):787-94 [7965797.001]
  • [Cites] Neuropsychopharmacology. 2007 Feb;32(2):273-83 [16641946.001]
  • [Cites] Eur Neuropsychopharmacol. 1996 Nov;6(4):305-10 [8985714.001]
  • [Cites] J Neurosci. 1996 Jan;16(1):373-9 [8613804.001]
  • [Cites] Am J Psychiatry. 1991 Oct;148(10):1301-8 [1654746.001]
  • [Cites] Neuropsychopharmacology. 2004 Sep;29(9):1637-47 [15127084.001]
  • [Cites] Neuropsychopharmacology. 1996 Feb;14 (2):87-96 [8822531.001]
  • [Cites] Schizophr Bull. 1999;25(2):233-55 [10416729.001]
  • [Cites] Brain Res. 2002 Aug 30;947(2):157-65 [12176156.001]
  • [Cites] Br J Psychiatry. 1993 Oct;163:451-5 [7902766.001]
  • [Cites] Biol Psychiatry. 2001 Nov 15;50(10 ):750-7 [11720693.001]
  • [Cites] Neuroscience. 1998 Mar;83(2):489-99 [9460757.001]
  • [Cites] Neuropsychopharmacology. 1995 Feb;12(1):57-64 [7766287.001]
  • [Cites] Psychopharmacology (Berl). 2005 Apr;179(1):99-107 [15678364.001]
  • [Cites] Neuropsychopharmacology. 1994 Nov;11(3):167-77 [7865098.001]
  • [Cites] Neurosci Lett. 1993 Apr 2;152(1-2):61-4 [8100055.001]
  • [Cites] Cereb Cortex. 2003 Apr;13(4):400-8 [12631569.001]
  • [Cites] Eur J Pharmacol. 1996 Aug 1;309(1):1-11 [8864686.001]
  • [Cites] Am J Psychiatry. 2001 Feb;158(2):176-84 [11156796.001]
  • [Cites] Psychopharmacology (Berl). 2003 Sep;169(3-4):404-11 [12590356.001]
  • [Cites] Biol Psychiatry. 2002 Jun 15;51(12):972-8 [12062881.001]
  • [Cites] J Neurophysiol. 2001 Feb;85(2):659-70 [11160501.001]
  • [Cites] Schizophr Bull. 2000;26(1):119-36 [10755673.001]
  • [Cites] J Neurosci. 2004 Jan 28;24(4):773-80 [14749421.001]
  • [Cites] Arch Gen Psychiatry. 2000 Mar;57(3):249-58 [10711911.001]
  • [Cites] Brain. 1993 Oct;116 ( Pt 5):1159-75 [8221053.001]
  • (PMID = 17940750.001).
  • [ISSN] 0033-3158
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dopamine Antagonists; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Serotonin Antagonists; 98Y1I8ZD4M / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol
  •  go-up   go-down


37. Iwasaki K, Mishima K, Egashira N, Al-Khatib IH, Ishibashi D, Irie K, Kobayashi H, Egawa T, Fujiwara M: Effect of nilvadipine on the cerebral ischemia-induced impairment of spatial memory and hippocampal apoptosis in rats. J Pharmacol Sci; 2003 Oct;93(2):188-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, mRNA expression of the apoptosis-related early oncogene bax and CPP 32 (caspase-3) was observed after 24 h.
  • In these rats, nilvadipine, but not amlodipine, significantly improved memory, concomitantly decreased hippocampal apoptosis, and suppressed both bax and CPP 32 expression.
  • These results suggest that nilvadipine improved the memory impairment in repeated ischemia by reducing bax and CPP 32 expression and suppressing the induction of apoptosis in the hippocampus.
  • Nilvadipine may have a neuroprotective effect and could be a useful pharmacotherapeutic agent for cerebrovascular dementia.
  • [MeSH-major] Brain Ischemia / psychology. Calcium Channel Blockers / pharmacology. Hippocampus / cytology. Memory Disorders / drug therapy. Memory Disorders / psychology. Nifedipine / pharmacology. Space Perception / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Calibration. Genes, bcl-2 / genetics. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Male. Maze Learning / drug effects. RNA, Messenger / biosynthesis. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Memory.
  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14578587.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / RNA, Messenger; 0214FUT37J / nilvadipine; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; I9ZF7L6G2L / Nifedipine
  •  go-up   go-down


38. Nejat F, Kazmi SS, Ardakani SB: Congenital brain tumors in a series of seven patients. Pediatr Neurosurg; 2008;44(1):1-8
MedlinePlus Health Information. consumer health - Prenatal Testing.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital brain tumors in a series of seven patients.
  • BACKGROUND: Congenital brain tumors are very rare.
  • METHODS: Seven congenital brain tumors were diagnosed during 5 years.
  • All patients presented with intracranial hypertension.
  • All neuroimaging studies revealed nonhomogenous tumors with cystic and solid components, except for the case with choroid plexus papilloma (CPP).
  • There were three teratomas, one primitive neuroectodermal tumor, one ependymoblastoma and one CPP.
  • One patient died due to complications of chemotherapy and another one due to tumor recurrence 1 year after surgery.
  • Only the patient with CPP is alive after 2 years.
  • CONCLUSIONS: Today, the availability of noninvasive imaging procedures such as computerized tomography scan and magnetic resonance imaging has improved the diagnosis of congenital brain tumors.
  • In spite of development in prenatal diagnosis, appropriate pre- and postoperative management, the mortality associated with these tumors still remains high.
  • CPP is accompanied by the best prognosis, whereas teratoma and primitive neuroectodermal tumors have the worst prognosis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fetal Diseases / diagnosis. Prenatal Diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18097184.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Mul D, Hughes IA: The use of GnRH agonists in precocious puberty. Eur J Endocrinol; 2008 Dec;159 Suppl 1:S3-8
Genetic Alliance. consumer health - Precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review several aspects of gonadotrophin releasing hormone agonists (GnRHa) treatment in central precocious puberty (CPP) are highlighted.
  • These include issues of the definition of precocity, assessment of CPP and thelarche variants.
  • Indications for treatment with GnRH agonists are discussed, not only in CPP but also in children with other reasons to suppress central activation, e.g. adopted or developmental retardation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064674.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 39
  •  go-up   go-down


40. Green IC, Cohen SL, Finkenzeller D, Christo PJ: Interventional therapies for controlling pelvic pain: what is the evidence? Curr Pain Headache Rep; 2010 Feb;14(1):22-32
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional therapies for controlling pelvic pain: what is the evidence?
  • Chronic pelvic pain (CPP) has many potential causes and is often a complex disorder with multiple contributing etiologies.
  • The evaluation and treatment of women with CPP often requires a multidimensional approach.
  • The treatment of CPP consists of two approaches:.
  • 1) treatment of pain itself or global treatment, and 2) treatment of disease-specific etiologies.
  • Most often, treatment requires a combination of both approaches.
  • This article reviews recent literature in the global treatment of CPP, including pharmacologic, psychotherapy, and neuroablative, as well as specific interventions for endometriosis, interstitial cystitis, pelvic adhesive disease, adenomyosis, and pelvic venous congestion.
  • [MeSH-major] Analgesics / therapeutic use. Cystitis, Interstitial / complications. Endometriosis / complications. Evidence-Based Medicine. Pelvic Pain / drug therapy
  • [MeSH-minor] Chronic Disease. Female. Humans

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Interstitial Cystitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pain Pract. 2005 Jun;5(2):103-10 [17177756.001]
  • [Cites] Chirurgia (Bucur). 2008 May-Jun;103(3):265-74 [18717274.001]
  • [Cites] Rev Urol. 2002;4 Suppl 1:S3-8 [16986032.001]
  • [Cites] Gen Hosp Psychiatry. 2009 May-Jun;31(3):206-19 [19410099.001]
  • [Cites] Pain. 2004 Jul;110(1-2):400-8 [15275792.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202 [18616415.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):60-7 [17900797.001]
  • [Cites] Fertil Steril. 2008 Nov;90(5):2018.e13-5 [18692791.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):884-7 [19134323.001]
  • [Cites] J Urol. 2003 Sep;170(3):810-5 [12913705.001]
  • [Cites] J Urol. 2003 Apr;169(4):1369-73 [12629364.001]
  • [Cites] Radiology. 1995 Jul;196(1):103-6 [7784552.001]
  • [Cites] Pain Physician. 2009 Sep-Oct;12(5):893-900 [19787016.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2007 Jul;34(1):112-7 [17336555.001]
  • [Cites] J Reprod Med. 2008 Mar;53(3):191-5 [18441724.001]
  • [Cites] Reg Anesth. 1997 Nov-Dec;22(6):562-8 [9425974.001]
  • [Cites] J Urol. 2005 Mar;173(3):841-3; discussion 843 [15711286.001]
  • [Cites] Am J Obstet Gynecol. 2001 May;184(6):1149-55 [11349181.001]
  • [Cites] Hum Reprod. 1998 Apr;13(4):880-3 [9619541.001]
  • [Cites] Urology. 2005 Oct;66(4):707-11 [16230121.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jul;19(7):987-90 [18227956.001]
  • [Cites] Clin Obstet Gynecol. 2009 Sep;52(3):351-61 [19661751.001]
  • [Cites] Drugs. 2009;69(6):649-75 [19405548.001]
  • [Cites] J Reprod Med. 2007 Mar;52(3):177-93 [17465285.001]
  • [Cites] Urology. 2005 Sep;66(3):494-9 [16140064.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Oct;96(10):1153-62 [2531611.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2003 Nov;14(5):305-8; discussion 308-9 [14618305.001]
  • [Cites] Curr Opin Urol. 2006 Jul;16(4):268-72 [16770126.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2006 Oct;41(10):660-3 [17199918.001]
  • [Cites] Cochrane Database Syst Rev. 2009 Oct 07;(4):CD001300 [19821276.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004992 [18425908.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):437-43 [19190927.001]
  • [Cites] J Urol. 2009 Oct;182(4):1393-400 [19683290.001]
  • [Cites] Am J Obstet Gynecol. 2009 Feb;200(2):136.e1-4 [18468569.001]
  • [Cites] Cochrane Database Syst Rev. 2009 Oct 07;(4):CD007115 [19821395.001]
  • [Cites] Br J Obstet Gynaecol. 1999 Nov;106(11):1149-55 [10549959.001]
  • [Cites] J Pain Symptom Manage. 2006 May;31(5):465-76 [16716877.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jul;19(7):943-7 [18338095.001]
  • [Cites] Urology. 2007 Oct;70(4):638-42 [17991529.001]
  • [Cites] J Pain Symptom Manage. 2003 Nov;26(5):1026-48 [14585554.001]
  • [Cites] Obstet Gynecol. 1996 Mar;87(3):321-7 [8598948.001]
  • [Cites] J Urol. 2001 Nov;166(5):1742-5 [11586214.001]
  • [Cites] J Urol. 2008 Mar;179(3):1031-4 [18206941.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):617-36 [16934530.001]
  • [Cites] Clin J Pain. 2005 Nov-Dec;21(6):553-6 [16215342.001]
  • [Cites] Hum Reprod. 2003 Mar;18(3):588-92 [12615830.001]
  • [Cites] Curr Opin Anaesthesiol. 2007 Oct;20(5):485-9 [17873602.001]
  • [Cites] Arch Intern Med. 2007 Oct 8;167(18):1922-9 [17923590.001]
  • [Cites] Hum Reprod. 2001 May;16(5):931-9 [11331640.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005452 [16034978.001]
  • [Cites] J Pediatr Adolesc Gynecol. 2008 Oct;21(5):247-57 [18794019.001]
  • [Cites] Phlebology. 2007;22(3):100-4 [18268860.001]
  • [Cites] Am J Obstet Gynecol. 2008 Dec;199(6):615.e1-8 [18845283.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD000387 [10796713.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Nov;4(11):1844-57 [19808225.001]
  • [Cites] Fertil Steril. 2003 Dec;80(6):1488-94 [14667888.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(3):CD003678 [15266496.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(1):9-14 [11294536.001]
  • [Cites] Obstet Gynecol. 2003 Mar;101(3):594-611 [12636968.001]
  • [Cites] Fertil Steril. 2008 Nov;90(5 Suppl):S260-9 [19007642.001]
  • [Cites] Obstet Gynecol. 2002 Feb;99(2):229-34 [11814502.001]
  • [Cites] Obstet Gynecol. 2008 Jun;111(6):1285-92 [18515510.001]
  • [Cites] J Urol. 2007 Jul;178(1):145-52 [17499305.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):603-16 [16563872.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2008 Oct;19(10):1379-84 [18496634.001]
  • [Cites] Curr Opin Urol. 2008 Jul;18(4):353-8 [18520754.001]
  • [Cites] Cardiovasc Intervent Radiol. 2007 Nov-Dec;30(6):1105-11 [17805925.001]
  • [Cites] Tech Vasc Interv Radiol. 2006 Mar;9(1):19-23 [17145481.001]
  • [Cites] J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):289-97 [16517774.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):428-31 [12016374.001]
  • [Cites] Wien Klin Wochenschr. 2005 Nov;117(21-22):761-8 [16416358.001]
  • [Cites] Pain Med. 2006 Sep-Oct;7(5):440-3 [17014604.001]
  • [Cites] Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003968 [19370592.001]
  • [Cites] Obstet Gynecol Surv. 2001 Feb;56(2):99-104 [11219593.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2138-41 [15126772.001]
  • [Cites] Clin Psychol Rev. 2006 Jan;26(1):17-31 [16199119.001]
  • [Cites] J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):571-9 [18657480.001]
  • [Cites] J Urol. 2005 Nov;174(5):1837-40 [16217303.001]
  • [Cites] JSLS. 2006 Oct-Dec;10(4):443-6 [17575754.001]
  • [Cites] Curr Opin Psychiatry. 2009 Mar;22(2):200-4 [19553876.001]
  • [Cites] J Fam Pract. 1999 Dec;48(12):980-90 [10628579.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Oct 17;(4):CD006113 [17943887.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2003 Sep;17(3):407-28 [14529011.001]
  • [Cites] Fertil Steril. 2002 Feb;77(2):303-8 [11821087.001]
  • [Cites] Neurourol Urodyn. 2008;27(1):28-33 [17563110.001]
  • [Cites] Aust N Z J Public Health. 2004 Aug;28(4):369-75 [15704703.001]
  • [Cites] Anesthesiology. 1990 Aug;73(2):236-9 [2382849.001]
  • [Cites] BMJ. 2007 Feb 3;334(7587):249-53 [17272567.001]
  • [Cites] Can J Psychiatry. 2008 Apr;53(4):213-23 [18478824.001]
  • [Cites] Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006568 [19588398.001]
  • (PMID = 20425211.001).
  • [ISSN] 1534-3081
  • [Journal-full-title] Current pain and headache reports
  • [ISO-abbreviation] Curr Pain Headache Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  • [Number-of-references] 97
  •  go-up   go-down


41. Wang B, Luo F, Xia YQ, Han JS: Peripheral electric stimulation inhibits morphine-induced place preference in rats. Neuroreport; 2000 Apr 7;11(5):1017-20
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conditioned place preference (CPP) is a commonly used model to detect rewarding effect of drugs.
  • To observe the effect of peripheral electric stimulation (PES) on morphine-induced CPP, we trained the rats with morphine in a CPP paradigm.
  • PES of 2 and 2/100 Hz significantly decreased CPP in morphine-trained animals in a naloxone reversible manner, while PES of 100 Hz, foot shock, needle insertion, or plain restraining, showed no effect.
  • Thus, PES with a low-frequency component (2 Hz) could specifically inhibit the expression of morphine-induced CPP, presumably via activation of opioid receptors.
  • [MeSH-major] Acupuncture Therapy / methods. Analgesics, Opioid / pharmacology. Conditioning (Psychology) / drug effects. Morphine / pharmacology. Morphine Dependence / therapy. Peripheral Nerves / physiology
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Male. Rats. Rats, Sprague-Dawley. Time Factors. Transcutaneous Electric Nerve Stimulation

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10790875.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


42. Sun Y, Perry GN, Yu J, Chen B, Tian Z: Effect of nourishing "Yin"-removing "Fire" Chinese herbal mixture on hypothalamic kisspeptin expression in female precocious rats. J Ethnopharmacol; 2010 Feb 3;127(2):274-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The female Sprague-Dawley rats were divided into intact normal (N), central precocious puberty (CPP) model (M), vehicle without CPP (V), CPP model exposed to herbal mixture (HM) and CPP model exposed to saline (S) groups.
  • At postnatal day 5, a single subcutaneous injection of 300 microg of danazol was administered to induce CPP model rats.
  • RESULTS: The day of vaginal opening and establishment of two regular estrous cycles were delayed in the HM group compared with M and S groups (P<0.05, respectively).
  • CONCLUSION: These results indicate that the kisspeptin signaling pathway might be involved in the effect of herbal mixture treatment on CPP.
  • [MeSH-major] Disease Models, Animal. Drugs, Chinese Herbal / therapeutic use. Hypothalamus / drug effects. Hypothalamus / metabolism. Proteins / metabolism. Puberty, Precocious / drug therapy
  • [MeSH-minor] Animals. Down-Regulation / drug effects. Down-Regulation / physiology. Female. Kisspeptins. Ovary / drug effects. Ovary / physiology. Rats. Rats, Sprague-Dawley. Up-Regulation / drug effects. Up-Regulation / physiology. Uterus / drug effects. Uterus / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19931369.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Kiss1 protein, rat; 0 / Kisspeptins; 0 / Proteins; 0 / nourishing Yin-removing Fire
  •  go-up   go-down


43. Houchi H, Warnault V, Barbier E, Dubois C, Pierrefiche O, Ledent C, Daoust M, Naassila M: Involvement of A2A receptors in anxiolytic, locomotor and motivational properties of ethanol in mice. Genes Brain Behav; 2008 Nov;7(8):887-98
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to investigate if the increased propensity of A2A(-/-) mice to consume ethanol is associated with an altered sensitivity in the motivational properties of ethanol in the conditioned place preference (CPP) and conditioned taste aversion (CTA) paradigms and with an altered development of sensitization to the locomotor effects of ethanol.
  • Our results show that A2A(-/-) mice produced on a CD1 background displayed a reduced ethanol-induced CPP and an increased sensitivity to the anxiolytic and locomotorstimulant effects of ethanol, but they did not show alteration in ethanol-induced CTA and locomotor sensitization.
  • Ethanol-induced CPP, ethanol consumption and the locomotor effects of ethanol were also tested in A2A(-/-) mice produced on a C57BL/6J background.
  • Our results emphasized the importance of the genetic background because alteration in ethanol consumption and preference, ethanol-induced CPP and locomotor-stimulant effects were not found in knockout mice produced on the alcohol-preferring C57BL/6J genetic background.
  • In conclusion, A2AR deficiency in mice generated on a CD1 background leads to high ethanol consumption that is associated with an increased sensitivity to the locomotor-stimulant/anxiolytic effects of ethanol and a decrease in ethanol-induced CPP.
  • [MeSH-major] Adenosine / metabolism. Alcohol-Induced Disorders, Nervous System / genetics. Brain / drug effects. Ethanol / pharmacology. Receptor, Adenosine A2A / drug effects
  • [MeSH-minor] Animals. Anti-Anxiety Agents / pharmacology. Anxiety / drug therapy. Anxiety / genetics. Anxiety / metabolism. Behavior, Animal / drug effects. Behavior, Animal / physiology. Central Nervous System Depressants / pharmacology. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Disease Models, Animal. Drug Resistance / drug effects. Drug Resistance / genetics. Genotype. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Motivation. Motor Activity / drug effects. Motor Activity / physiology. Species Specificity

  • Hazardous Substances Data Bank. Adenosine .
  • Hazardous Substances Data Bank. ETHANOL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097273.001).
  • [ISSN] 1601-183X
  • [Journal-full-title] Genes, brain, and behavior
  • [ISO-abbreviation] Genes Brain Behav.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Central Nervous System Depressants; 0 / Receptor, Adenosine A2A; 3K9958V90M / Ethanol; K72T3FS567 / Adenosine
  •  go-up   go-down


44. Elf K, Nilsson P, Ronne-Engström E, Howells T, Enblad P: Temperature disturbances in traumatic brain injury: relationship to secondary insults, barbiturate treatment and outcome. Neurol Res; 2008 Dec;30(10):1097-105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temperature disturbances in traumatic brain injury: relationship to secondary insults, barbiturate treatment and outcome.
  • OBJECTIVES: To describe the occurrence of spontaneous hyper- and hypothermia in patients with traumatic brain injury using a computerized data collecting system, to show how temperature correlates with other secondary insults, to describe how temperature affects outcome and to show how barbiturate treatment influences those analyses.
  • METHODS: Patients with > or = 54 hours of valid monitoring within the first 120 hours after trauma (one value/min) for temperature, intracranial pressure, cerebral perfusion pressure, systolic blood pressure, mean blood pressure and heart rate were included.
  • Hyperthermia correlated with occurrence of high blood pressure and high CPP.
  • Barbiturate treatment also confounded analyses regarding temperature and other secondary insults.
  • DISCUSSION: Patients with hyperthermia, hypertension, high CPP and tachycardia may suffer from a hyperdynamic state.
  • Barbiturate treatment confounds several analyses which have not been shown before.
  • [MeSH-major] Anesthetics, Intravenous / therapeutic use. Barbiturates / therapeutic use. Body Temperature / physiology. Brain Injuries / drug therapy. Brain Injuries / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Pressure / drug effects. Blood Pressure / physiology. Female. Glasgow Outcome Scale. Heart Rate / drug effects. Heart Rate / physiology. Humans. Intracranial Pressure / drug effects. Intracranial Pressure / physiology. Male. Middle Aged. Retrospective Studies. Severity of Illness Index. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19079982.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Barbiturates; WQ92Y2793G / barbituric acid
  •  go-up   go-down


45. Roma PG, Huntsberry ME, Riley AL: Separation stress, litter size, and the rewarding effects of low-dose morphine in the dams of maternally separated rats. Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar 30;31(2):429-33
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One week after weaning, the dams (n=7 per group) underwent a fully unbiased conditioned place preference (CPP) procedure to 1 mg/kg subcutaneous morphine.
  • CPP responses after each conditioning cycle were recorded.
  • Rates of acquisition and asymptotic levels of CPP were comparable in all groups; however, an inverse relationship between litter size and magnitude of morphine CPP was revealed.
  • Although these initial data indicate no differential sensitivity to the rewarding effects of low-dose morphine produced by the stress of litter separation, this assessment of litter size and drug-induced place conditioning in post-weaning litter-separated dams is the first of its kind.
  • Potential effects of other doses, drugs of abuse and post-partum manipulations remain to be evaluated within this emerging etiological model.
  • [MeSH-major] Body Size / drug effects. Maternal Deprivation. Morphine / administration & dosage. Narcotics / administration & dosage. Reward. Stress, Psychological / drug therapy
  • [MeSH-minor] Analysis of Variance. Animals. Animals, Newborn. Behavior, Animal / drug effects. Conditioning, Operant / drug effects. Female. In Vitro Techniques. Pregnancy. Rats

  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17182163.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Narcotics; 76I7G6D29C / Morphine
  •  go-up   go-down


46. Hashemi N, Mohammadirad A, Bayrami Z, Khorasani R, Vosough S, Aliahmadi A, Nikfar S, Sharifzadeh M, Kebriaeezadeh A, Abdollahi M: Restoration of morphine-induced alterations in rat submandibular gland function by N-methyl-D-aspartate agonist. Acta Biol Hung; 2006 Sep;57(3):283-94
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of morphine, 1-aminocyclobutane-cis-1,3-dicarboxylic (ACBD; NMDA agonist) and 3-((R)2-carboxypiperazin-4-yl)-propyl-l-phosphoric acid (CPP; NMDA antagonist) and their concurrent therapy on rat submandibular secretory function were studied.
  • Administration of ACBD (10 mg/kg) and CPP (10 mg/kg) alone did not influence secretion of submandibular glands.
  • In combination therapy, coadministration of CPP with morphine did not influence morphine-induced changes in salivary function while ABCD could restore all morphine-induced changes.
  • In combination treatment, ACBD prevented morphine-induced reduction of flow rate, total protein, calcium, and TGF-beta1 and reached control levels.
  • [MeSH-major] Morphine / adverse effects. N-Methylaspartate / agonists. Submandibular Gland / drug effects

  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048692.001).
  • [ISSN] 0236-5383
  • [Journal-full-title] Acta biologica Hungarica
  • [ISO-abbreviation] Acta. Biol. Hung.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Excitatory Amino Acid Antagonists; 0 / Glutamates; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 117488-23-0 / 2,4-methanoglutamate; 6384-92-5 / N-Methylaspartate; 76I7G6D29C / Morphine; 9NEZ333N27 / Sodium; RWP5GA015D / Potassium; SY7Q814VUP / Calcium
  •  go-up   go-down


47. Meybohm P, Cavus E, Bein B, Steinfath M, Brand PA, Scholz J, Dörges V: Cerebral metabolism assessed with microdialysis in uncontrolled hemorrhagic shock after penetrating liver trauma. Anesth Analg; 2006 Oct;103(4):948-54
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a porcine model of uncontrolled hemorrhagic shock, we evaluated the effects of fluid resuscitation versus arginine vasopressin (AVP) combined with hypertonic-hyperoncotic hydroxyethyl starch solution (HHS) on cerebral perfusion pressure (CPP) and on cerebral metabolism using intracerebral microdialysis.
  • Thirty minutes after drug administration, bleeding was controlled by manual compression, and colloid and crystalloid solutions were administered in both groups.
  • After hemodynamic decompensation, fluid resuscitation resulted in a smaller increase of CPP than did AVP/HHS (mean +/- sem; 24 +/- 5 vs 45 +/- 7 mm Hg; P < 0.01).
  • In conclusion, AVP/HHS proved to be superior to fluid in the initial phase of therapy with respect to CPP and cerebral oxygenation, but was comparable to fluid regarding cerebral metabolism and secondary cell damage in surviving animals.
  • [MeSH-major] Cerebral Cortex / metabolism. Cerebrovascular Circulation / physiology. Shock, Hemorrhagic / metabolism. Shock, Hemorrhagic / therapy
  • [MeSH-minor] Animals. Arginine Vasopressin / pharmacology. Carbon Dioxide / blood. Disease Models, Animal. Female. Fluid Therapy / methods. Hemodynamics. Intracranial Pressure. Liver / injuries. Male. Microdialysis. Oxygen / blood. Partial Pressure. Swine. Wounds and Injuries / blood. Wounds and Injuries / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000810.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 113-79-1 / Arginine Vasopressin; 142M471B3J / Carbon Dioxide; S88TT14065 / Oxygen
  •  go-up   go-down


48. McCall T, Binning M, Blumenthal DT, Jensen RL: Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature. Surg Neurol; 2006 Jul;66(1):62-7; discussion 67-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature.
  • BACKGROUND: Choroid plexus papillomas are typically considered benign lesions, but histology is not always predictive of their behavior.
  • We present 2 cases that illustrate the wide diversity with which choroid plexus papillomas can disseminate.
  • CASE DESCRIPTIONS: The patient described in case 1 had a primary fourth ventricular choroid plexus papilloma that produced diffuse cystic subarachnoid and leptomeningeal lesions.
  • Patient 2 also had a primary fourth ventricular tumor but with subsequent suprasellar and spinal drop metastases.
  • Patient 2 has been treated with several modalities, including radiation therapy and chemotherapy, with slowing of symptom progression.
  • CONCLUSIONS: Variations of choroid plexus papilloma dissemination include intraventricular, subarachnoid, and leptomeningeal nodules or cystic lesions, and intraparenchymal locations.
  • There is no consensus on the most effective treatment for choroid plexus papilloma metastases; surgical resection, chemotherapy, and radiation therapy may all yield benefits.
  • The prognosis for patients with disseminated choroid plexus papilloma can range from prolonged stable disease and symptoms to death within months.
  • [MeSH-major] Choroid Plexus / pathology. Choroid Plexus / surgery. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Papilloma, Choroid Plexus / diagnosis. Papilloma, Choroid Plexus / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arachnoid / pathology. Arachnoid / physiopathology. Arachnoid / surgery. Disease Progression. Female. Humans. Pia Mater / pathology. Pia Mater / physiopathology. Pia Mater / surgery. Subarachnoid Space / pathology. Subarachnoid Space / physiopathology. Subarachnoid Space / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793445.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 34
  •  go-up   go-down


49. Stiefel MF, Heuer GG, Abrahams JM, Bloom S, Smith MJ, Maloney-Wilensky E, Grady MS, LeRoux PD: The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage. J Neurosurg; 2004 Oct;101(4):594-9
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors investigated the effect of nimodipine on brain tissue PO2.
  • METHODS: Patients in whom Hunt and Hess Grade IV or V SAH had occurred who underwent aneurysm occlusion and had stable blood pressure were prospectively evaluated using continuous brain tissue PO2 monitoring.
  • Data were obtained from 11 patients and measurements of brain tissue PO2, intracranial pressure (ICP), mean arterial blood pressure (MABP), and cerebral perfusion pressure (CPP) were recorded every 15 minutes.
  • Nimodipine resulted in a significant reduction in brain tissue PO2 in seven (64%) of 11 patients.
  • The baseline MABP and CPP were 90+/-20 and 84+/-19 mm Hg, respectively.
  • The greatest reduction in brain tissue PO2 occurred 15 minutes after administration, when the mean pressure was 26.9+/-7.7 mm Hg (p < 0.05).
  • In the seven patients in whom brain tissue PO2 decreased, other physiological variables such as arterial saturation, end-tidal CO2, heart rate, MABP, ICP, and CPP did not demonstrate any association with the nimodipine-induced reduction in PO2.
  • In four patients PO2 remained stable and none of these patients had a significant increase in brain tissue PO2.
  • CONCLUSIONS: Although nimodipine use is associated with improved outcome following SAH, in some patients it can temporarily reduce brain tissue PO2.
  • [MeSH-major] Calcium Channel Blockers / pharmacology. Intracranial Aneurysm / complications. Intracranial Aneurysm / surgery. Nimodipine / pharmacology. Oxygen / analysis. Subarachnoid Hemorrhage / drug therapy
  • [MeSH-minor] Aged. Brain / blood supply. Female. Humans. Intracranial Pressure. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15481712.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 57WA9QZ5WH / Nimodipine; S88TT14065 / Oxygen
  •  go-up   go-down


50. Glantz L, Godovic G, Lekar M, Kramer M, Eidelman LA: Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial. J Pain Symptom Manage; 2004 Mar;27(3):277-81
Hazardous Substances Data Bank. NITROGLYCERIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial.
  • Chronic post-thoracotomy pain (CPP) is associated with surgical intercostal nerve injury.
  • Like other forms of neuropathic pain, there is no ideal treatment.
  • The present study investigated the efficacy of NTG combined with the nonsteroidal anti-inflammatory drug etodolac for the treatment of CPP.
  • NTG, 5 mg/day, was added to the treatment.
  • A significant reduction in VAS was observed on day 14 of treatment (from 66.7 +/- 11 to 42.1 +/- 5, P< 0.05).
  • We conclude that NTG added to etodolac appears to be effective for the treatment of CPP, with minimal side effects.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Etodolac / administration & dosage. Nitroglycerin / administration & dosage. Pain, Postoperative / drug therapy. Thoracotomy / adverse effects. Vasodilator Agents / administration & dosage
  • [MeSH-minor] Administration, Cutaneous. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15038339.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Vasodilator Agents; 2M36281008 / Etodolac; G59M7S0WS3 / Nitroglycerin
  •  go-up   go-down


51. Fishbain DA, Cutler RB, Cole B, Lewis J, Rosomoff RS, Rosomoff HL: Medico-legal rounds: medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: a case report. Pain Med; 2003 Jun;4(2):195-201
Hazardous Substances Data Bank. METHADONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) To present an example of a medico-legal problem that developed as a result of a decision to rotate a chronic pain patient (CPP) to methadone in order to taper the CPP from oxycodone;.
  • METHODS: This is a case report of a CPP treated at a regional hospital pain clinic.
  • Methadone rotation was used in order to taper the CPP from oxycodone because of addictive disease.
  • RESULTS: During the rotation process, the CPP expired.
  • [MeSH-major] Analgesics, Opioid / adverse effects. Medication Errors / legislation & jurisprudence. Methadone / adverse effects. Opioid-Related Disorders. Pain / drug therapy. Pain Clinics / standards. Quality of Health Care / legislation & jurisprudence. Quality of Health Care / standards
  • [MeSH-minor] Adult. Autopsy. Chronic Disease. Decision Making. Expert Testimony. Florida. Humans. Male. Malpractice / legislation & jurisprudence. Oxycodone / adverse effects. Oxycodone / therapeutic use. Psychiatry

  • MedlinePlus Health Information. consumer health - Medication Errors.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYCODONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pain Med. 2004 Mar;5(1):109-10 [14996244.001]
  • [CommentIn] Pain Med. 2003 Jun;4(2):202-5 [12873270.001]
  • (PMID = 12873269.001).
  • [ISSN] 1526-2375
  • [Journal-full-title] Pain medicine (Malden, Mass.)
  • [ISO-abbreviation] Pain Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Legal Cases
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; CD35PMG570 / Oxycodone; UC6VBE7V1Z / Methadone
  •  go-up   go-down


52. Arellanes-García L, Navarro-López L, Recillas-Gispert C: Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome. Ocul Immunol Inflamm; 2003 Mar;11(1):53-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome.
  • PURPOSE: To describe the clinical manifestations of classic pars planitis (CPP) in Mexican patients.
  • We report here the most frequent complications, medical and surgical treatment, and visual prognosis.
  • MATERIAL AND METHODS: A retrospective, descriptive case series examined the clinical features, complications, and treatment (medical and surgical) of CPP patients seen at the Inflammatory Eye Disease Clinic from January 1990 to September 1999.
  • Periocular corticosteroids were used in 97.5% of cases, systemic corticosteroids in 68.1%, and other immunosuppressive drugs in 21.3%.
  • CONCLUSIONS: CPP in the Mexican population is more frequent in males and usually presents in patients less than 14 years of age.
  • Treatment comprises periocular and systemic corticosteroids or other immunosuppressive drugs.
  • [MeSH-major] Pars Planitis / complications. Pars Planitis / drug therapy. Visual Acuity
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Anti-Inflammatory Agents / therapeutic use. Cataract / etiology. Child. Child, Preschool. Eye Diseases / etiology. Female. Glucocorticoids. Humans. Immunosuppressive Agents / therapeutic use. Macular Edema / etiology. Male. Mexico / epidemiology. Retinal Vasculitis / etiology. Retrospective Studies. Vision Disorders / etiology. Vitreous Body / pathology

  • Genetic Alliance. consumer health - Pars planitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854027.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 0 / Immunosuppressive Agents
  •  go-up   go-down


53. Ciccocioppo R, Economidou D, Fedeli A, Massi M: The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol Behav; 2003 Jun;79(1):121-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats.
  • Studies aimed at the pharmacological characterization of the receptor, which mediates the effect, have shown that the C-terminal 13 amino acid sequence is crucial for activity and that the selective NOP receptor antagonist [Nphe(1)]N/OFQ(1-13)NH(2) blocks the effect of N/OFQ on ethanol drinking.
  • In place conditioning studies, N/OFQ abolishes the conditioned place preference (CPP) induced by ethanol in msP rats, or by morphine in nonselected Wistar rats; these findings suggest that N/OFQ is able to abolish the rewarding properties of ethanol and morphine.
  • Together, these findings suggest that N/OFQ and its receptor may represent an interesting target for pharmacological treatment of alcohol abuse.
  • [MeSH-minor] Animals. Association Learning / drug effects. Association Learning / physiology. Conditioning, Classical / drug effects. Conditioning, Classical / physiology. Ethanol / pharmacology. Humans. Injections, Intraventricular. Mice. Morphine / pharmacology. Morphine Dependence / physiopathology. Motivation. Rats. Social Environment. Stress, Psychological / complications. Ventral Tegmental Area / drug effects. Ventral Tegmental Area / physiopathology

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12818717.001).
  • [ISSN] 0031-9384
  • [Journal-full-title] Physiology & behavior
  • [ISO-abbreviation] Physiol. Behav.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alcohol Deterrents; 0 / Opioid Peptides; 0 / Peptide Fragments; 0 / Receptors, Opioid; 0 / nociceptin orphanin FQ(1-17)OH; 0 / nociceptin receptor; 3K9958V90M / Ethanol; 76I7G6D29C / Morphine
  •  go-up   go-down


54. Berrada M, Yang Z, Lehnert S: Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments. Int J Radiat Oncol Biol Phys; 2002 Dec 1;54(5):1550-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments.
  • PURPOSE: To evaluate an intratumoral polymer implant for sustained delivery of 5-fluorouracil (5-FU) in a mouse tumor model.
  • METHODS AND MATERIALS: 5-FU was incorporated into a polyanhydride-based polymer, bis(p-carboxyphenoxy)propane sebacic acid (CPP:SA) and implanted in RIF-1 mouse fibrosarcoma growing s.c.
  • The effectiveness of treatment was evaluated by tumor growth delay.
  • A second drug, cis-diamminedichloroplatinum (cis-DDP), was administered by intraperitoneal injection or by osmotic pump.
  • RESULTS: For drug/polymer implant alone, the tumor growth delay was proportional to the amount of drug in the implant.
  • The 5-FU polymer implant was most effective when combined with cis-DDP or with acute or fractionated radiation, and in some cases, the effects of combined treatments were greater than additive.
  • CONCLUSION: Results indicate that 5-FU can be effectively delivered by polymer implant and that this mode of delivery is particularly appropriate for combined treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Cobalt Radioisotopes. Combined Modality Therapy. Iodine Radioisotopes / therapeutic use. Mice. Neoplasm Transplantation. Organoplatinum Compounds. Polymers / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Radiometry. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459384.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobalt Radioisotopes; 0 / Iodine Radioisotopes; 0 / Organoplatinum Compounds; 0 / Polymers; 0 / Radiation-Sensitizing Agents; 78022-86-3 / diammine platinum(II) dilactate; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Stergiou GS, Efstathiou SP, Argyraki CK, Gantzarou AP, Roussias LG, Mountokalakis TD: Clinic, home and ambulatory pulse pressure: comparison and reproducibility. J Hypertens; 2002 Oct;20(10):1987-93
MedlinePlus Health Information. consumer health - Home Care Services.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to compare mean values and reproducibility of PP obtained in the clinic (CPP), at home (HPP) and with ambulatory monitoring (APP) and to evaluate potential implications for trials aiming to assess drug effects on PP.
  • METHODS: A total of 393 hypertensive subjects [mean age 51.5 +/- 11.5 (SD) years, 59% men, 35% treated] measured CPP (two visits), HPP (6 days) and APP (24 h).
  • The reproducibility of PP was assessed using the SD of differences (SDD) between measurements in 133 untreated subjects who had repeated CPP (five visits), HPP (6 days) and APP measurements (two occasions).
  • RESULTS: There was no difference between mean CPP (51.0 +/- 13.3 mmHg) and HPP (50.2 +/- 11.0) whereas APP (48.8 +/- 8.4) was lower than both CPP [mean difference 2.3 +/- 10.3 mmHg; 95% confidence interval (CI), 1.2, 3.3; P < 0.01] and HPP (1.5 +/- 7.8; 95% CI, 0.7, 2.3; P < 0.01).
  • The SDD between repeated measurements was about 10 mmHg for CPP (one visit), 5.2 mmHg for HPP (2 days) and 4 mmHg for APP (24-h).
  • For a parallel comparative trial aiming to detect a difference of 3 mmHg PP in the effect of two drugs, 415 subjects would be required when using CPP, compared to 127 using HPP and 63 using APP.
  • CONCLUSIONS: These data suggest that although differences among mean values of CPP, HPP and APP are small, differences in their reproducibility are important and should be taken into account in the design of trials assessing drug effects on PP.
  • [MeSH-minor] Adult. Age Factors. Aged. Antihypertensive Agents / therapeutic use. Circadian Rhythm / drug effects. Circadian Rhythm / physiology. Female. Humans. Hypertension / diagnosis. Hypertension / drug therapy. Hypertension / physiopathology. Male. Middle Aged. Pulse. Reproducibility of Results. Statistics as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12359977.001).
  • [ISSN] 0263-6352
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  •  go-up   go-down


56. Decker P, Muller S: Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol; 2002 Sep;3(3):275-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
  • PARP is activated at an intermediate stage of apoptosis and is then cleaved and inactivated at a late stage by apoptotic proteases, namely caspase-3/CPP-32/Yama/apopain and caspase-7.
  • With regard to the increasing interest towards PARP, the aim of this review is to explain the cellular role of PARP and the advantages of modulating its activity in diverse preventive or therapeutic strategies.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / physiology. Enzyme Inhibitors / pharmacology. Humans. Poly Adenosine Diphosphate Ribose / biosynthesis. Poly(ADP-ribose) Polymerase Inhibitors. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12164482.001).
  • [ISSN] 1389-2010
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 26656-46-2 / Poly Adenosine Diphosphate Ribose; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 100
  •  go-up   go-down


57. Steiner T, Pilz J, Schellinger P, Wirtz R, Friederichs V, Aschoff A, Hacke W: Multimodal online monitoring in middle cerebral artery territory stroke. Stroke; 2001 Nov;32(11):2500-6
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Patients with large middle cerebral artery infarction and elevated intracranial pressure (ICP) who are undergoing invasive intensive care therapy require technical monitoring.
  • Furthermore, the effects of what is considered to be standard antiedema medical treatment are not fully understood.
  • METHODS: ICP, cerebral perfusion pressure (CPP), and partial brain tissue oxygen pressure (PbrO(2)) were continuously measured within the white matter of the frontal lobe unilaterally or bilaterally.
  • We analyzed the effects of antiedema drugs and looked for pattern changes in the PbrO(2) before transtentorial herniation in patients in whom this could not be prevented.
  • A total of 297 antiedema drug administrations were analyzed in 11 patients.
  • Hyper-HAES and mannitol were most often associated with an increase in CPP and PbrO(2), whereas the use of thiopental and tromethamine led to negative or contrary effects, although ICP was decreased in every case.
  • CONCLUSIONS: Multimodal monitoring can be used to monitor antiedema drug effects.
  • Furthermore, this method might help to optimize the timing of invasive therapy in space-occupying infarction.
  • [MeSH-major] Infarction, Middle Cerebral Artery / drug therapy. Monitoring, Physiologic / methods. Online Systems
  • [MeSH-minor] Brain Edema / drug therapy. Feasibility Studies. Frontal Lobe / chemistry. Frontal Lobe / physiopathology. Humans. Intracranial Hypertension. Intracranial Pressure / drug effects. Oxygen / analysis. Partial Pressure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692007.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


58. Himmelseher S, Pfenninger E: [Neuroprotection in neuroanesthesia: current practices in Germany]. Anaesthesist; 2000 May;49(5):412-9
MedlinePlus Health Information. consumer health - Anesthesia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the questions concerning "neuroprotective therapy" were linked to a general survey on clinical neuroanesthesia performed by the scientific neuroanesthesia working group of the DGAI, the only departments that were assessed were those which had participated in an earlier study on neuroanesthesia in 1991.
  • Therapy varied considerably between departments.
  • Following head trauma 69% of injured patients were managed with enhanced cerebral perfusion pressure (CPP) within the range of 70-90 mmHg.
  • If necessary, CPP increase was induced by vasopressors (exogenous supply of catecholamines in 100% of instances) and the administration of fluids (97% of instances).
  • The most commonly used therapeutic approaches to treat intracranial hypertension were mannitol (95% of instances), hyperventilation (91% of instances), cerebrospinal fluid drainage (89% of instances), and barbiturates (86% of instances).
  • Tris (hydroxymethyl)-aminomethane was administered in almost 49%, mild hypothermia in 37%, and hypertonic-hyperoncotic solutions in 28% of patients treated for an increase in intracranial pressure.
  • Following intracranial aneurysm surgery "triple-H" therapy was used in 74% of patients, applied as hemodilution in 94% and as hypervolemia and hypertension in 87% of instances.
  • It was used in 83% of patients during perioperative care and in 52% of patients during intensive care therapy.
  • Specific neuroprotective drugs were applied in 68% of departments, with barbiturates (38% of instances), nimodipine (23% of instances), and corticosteroids (10% of instances) as the main agents named.
  • These brain-protective medications were administered especially in intracranial hypertension in 30%, in intracranial aneurysms in 21%, and in subarachnoid hemorrhages subsequent to head trauma in 18% of instances described.
  • CONCLUSION: These findings demonstrate that the neuroprotective therapy administered in anesthesiological departments in Germany is not yet standardized, i.e., there is a wide variation.
  • [MeSH-minor] Blood Pressure / physiology. Cerebrovascular Circulation / drug effects. Cerebrovascular Circulation / physiology. Craniocerebral Trauma / surgery. Data Collection. Germany. Humans. Hypothermia, Induced. Intracranial Aneurysm / surgery. Intracranial Hypertension / prevention & control. Intracranial Hypertension / therapy. Neuroprotective Agents / therapeutic use. Respiration, Artificial. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10883355.001).
  • [ISSN] 0003-2417
  • [Journal-full-title] Der Anaesthesist
  • [ISO-abbreviation] Anaesthesist
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Neuroprotective Agents
  •  go-up   go-down


59. Krstevska-Konstantinova M, Jancevska A, Gucev Z: Autoimmune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence? J Pediatr Endocrinol Metab; 2010 Apr;23(4):403-6
MedlinePlus Health Information. consumer health - Diabetes Type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence?
  • Very few abnormalities in endocrine function have been reported during long term gonadotropin-releasing hormone agonist (GnRHa) treatment in girls.
  • Most authors agree that this therapy is safe and effective.
  • We present an unusual outcome of long term GnRHa therapy in two girls with central precocious puberty(CPP) of idiopathic or organic origin.
  • They have received monthly depot injections of triptorelin acetate for a time period of 8 years.
  • Another girl with a hypothalamic hamartoma developed diabetes mellitus at the age of 9 years.
  • Both of these girls were early diagnosed for CPP, at 6 months and 8 months respectively, and given GnRHa treatment.
  • So far, it is not known whether these autoimmune diseases are related to the GnRHa treatment or are simply a coincidence.
  • However, we suggest a closer monitoring of girls with CPP who have had a long period of treatment.
  • [MeSH-major] Diabetes Mellitus, Type 1 / etiology. Puberty, Precocious / drug therapy. Thyroiditis, Autoimmune / etiology. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Child. Female. Hamartoma / complications. Hamartoma / drug therapy. Humans. Luteolytic Agents / therapeutic use. Pituitary Diseases / complications. Pituitary Diseases / drug therapy


60. Yang H, Liu S, Cai H, Wan L, Li S, Li Y, Cheng J, Lu X: Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J Biol Chem; 2010 Aug 13;285(33):25666-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.
  • The use of cell-penetrating peptides (CPPs) as drug carriers for targeted therapy is limited by the unrestricted cellular translocation of CPPs.
  • The preferential induction of tumor cell death by penetratin (Antp)-directed peptides (PNC27 and PNC28), however, suggests that the CPP Antp may contribute to the preferential cytotoxicity of these peptides.
  • The IC(50) values of PNC27 in tumor cells were 2-3 times lower than in normal cells.
  • However, all three engineered peptides demonstrated similar cytotoxic effects in tumor and normal cells.
  • Another three chimeric peptides containing the leader peptide Antp with different mitochondria-disrupting peptides (KLA-Antp (KGA), B27-Antp (BA27), and B28-Antp (BA28)), preferentially induced apoptosis in tumor cells.
  • The IC(50) values of these peptides (3-10 microM) were 3-6 times lower in tumor cells than in normal cells.
  • In contrast, TAT-directed peptides (TAT-KLA (TK), TAT-B27 (TB27), and TAT-B28 (TB28)), were cytotoxic to both tumor and normal cells.
  • Furthermore, Antp-directed peptides bind chondroitin sulfate (CS), and the removal of endogenous CS reduces the cytotoxic effects of Antp-directed peptides in tumor cells.
  • The overexpression of CS in tumor cells is positively correlated to the cell entry and cytotoxicity of Antp- directed peptides.
  • These results suggest that CS overexpression in tumor cells is an important molecular portal that mediates the preferential cytotoxicity of Antp-directed peptides.
  • [MeSH-major] Apoptosis / drug effects. Carrier Proteins / pharmacology. Chondroitin Sulfates / pharmacology. Mitochondria / drug effects. Mitochondria / metabolism. Peptides / pharmacology
  • [MeSH-minor] Animals. Biological Transport / drug effects. Cell Line. Cell Line, Tumor. Cell Survival / drug effects. Female. Glycosaminoglycans / metabolism. Glycosaminoglycans / pharmacology. HeLa Cells. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Tumor Suppressor Protein p53 / pharmacology. Tumor Suppressor Protein p53 / therapeutic use. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] AAPS J. 2006;8(3):E532-51 [17025272.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1460-6 [17446061.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6368-75 [17616696.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):788-93 [17635149.001]
  • [Cites] J Pharm Sci. 2008 Jan;97(1):144-62 [17763452.001]
  • [Cites] Acc Chem Res. 2008 Jan;41(1):98-107 [17705444.001]
  • [Cites] Bioconjug Chem. 2008 Jan;19(1):70-5 [18001077.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):580-97 [18045730.001]
  • [Cites] Org Biomol Chem. 2008 Jul 7;6(13):2242-55 [18563254.001]
  • [Cites] In Vivo. 2008 May-Jun;22(3):385-9 [18610752.001]
  • [Cites] J Biol Chem. 2008 Aug 29;283(35):24274-84 [18603532.001]
  • [Cites] Biochim Biophys Acta. 2008 Dec;1786(2):126-38 [18440319.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3588-600 [18931881.001]
  • [Cites] Curr Drug Discov Technol. 2008 Dec;5(4):289-301 [19075609.001]
  • [Cites] Bioconjug Chem. 2008 Dec;19(12):2363-74 [19053306.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):233-45 [19160015.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34924-31 [10574967.001]
  • [Cites] Curr Opin Cell Biol. 2000 Aug;12(4):400-6 [10873818.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12438-43 [11606716.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1926-35 [11865069.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4282-8 [12154030.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Nov 1;298(3):439-49 [12413961.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1431-44 [12629507.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1307-15 [12738679.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35109-14 [12837762.001]
  • [Cites] Cell Mol Life Sci. 2004 Jul;61(14):1785-94 [15241554.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28375-81 [8910461.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Biochemistry. 1997 Feb 25;36(8):2104-11 [9047309.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6079-84 [9600920.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1032-8 [10470080.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):55-64 [15645452.001]
  • [Cites] Biochem J. 2005 Sep 1;390(Pt 2):407-18 [15859953.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7840-6 [16140953.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10646-50 [16322205.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):20-8 [16432159.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3764-72 [16585203.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1577-85 [16688716.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):1944-9 [16928814.001]
  • [Cites] J Am Chem Soc. 2007 Apr 25;129(16):4961-72 [17397150.001]
  • (PMID = 20484051.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycosaminoglycans; 0 / PNC-27; 0 / Peptides; 0 / Tumor Suppressor Protein p53; 0 / penetratin; 9007-28-7 / Chondroitin Sulfates
  • [Other-IDs] NLM/ PMC2919130
  •  go-up   go-down


61. Armstead WM, Kiessling JW, Kofke WA, Vavilala MS: SNP improves cerebral hemodynamics during normotension but fails to prevent sex dependent impaired cerebral autoregulation during hypotension after brain injury. Brain Res; 2010 May 12;1330:142-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SNP improves cerebral hemodynamics during normotension but fails to prevent sex dependent impaired cerebral autoregulation during hypotension after brain injury.
  • Traumatic brain injury (TBI) is a leading cause of morbidity in children and boys are disproportionately represented.
  • Previous studies show that adrenomedullin, a cerebrovasodilator, prevented sex dependent impairment of autoregulation during hypotension after piglet fluid percussion brain injury (FPI).
  • Reductions in pial artery diameter, cortical CBF, and cerebral perfusion pressure (CPP) concomitant with elevated intracranial pressure (ICP) after FPI were greater in male compared to female piglets during normotension which was blunted by SNP.
  • SNP did not prevent reductions in CBF, CPP or autoregulatory index during combined hypotension and FPI in either sex.
  • These data suggest that therapies directed at a purely hemodynamic increase in CPP will fail to improve outcome during combined TBI and hypotension.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12866-9 [10536014.001]
  • [Cites] J Neurotrauma. 2010 Feb;27(2):391-402 [20170313.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Aug;21(8):887-906 [11487724.001]
  • [Cites] J Neurosurg. 2002 Jan;96(1):103-8 [11794590.001]
  • [Cites] Anesthesiology. 2003 Feb;98(2):412-9 [12552201.001]
  • [Cites] Curr Opin Crit Care. 2004 Apr;10(2):120-5 [15075722.001]
  • [Cites] Pediatr Crit Care Med. 2004 May;5(3):257-63 [15115564.001]
  • [Cites] Pediatrics. 2004 Jul;114(1):79-85 [15231911.001]
  • [Cites] Circ Res. 1980 Jan;46(1):37-47 [7349916.001]
  • [Cites] J Neurosurg. 1981 Feb;54(2):170-8 [7452330.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):145-52 [7876842.001]
  • [Cites] Pediatr Neurosurg. 1997 Apr;26(4):200-7 [9436831.001]
  • [Cites] J Head Trauma Rehabil. 2005 May-Jun;20(3):229-38 [15908823.001]
  • [Cites] Crit Care Med. 2005 Nov;33(11):2645-50 [16276192.001]
  • [Cites] Dev Neurosci. 2006;28(4-5):348-53 [16943658.001]
  • [Cites] Intensive Care Med. 2006 Oct;32(10):1475-84 [16896859.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Oct;27(10):1702-9 [17377515.001]
  • [Cites] Anesthesiology. 2008 Apr;108(4):588-95 [18362589.001]
  • [Cites] J Cereb Blood Flow Metab. 2009 Mar;29(3):524-33 [19050721.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Jul;21(7):779-81 [11435789.001]
  • (PMID = 20298682.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD057355-03; United States / NICHD NIH HHS / HD / R01 HD057355; United States / NICHD NIH HHS / HD / HD57355; United States / NICHD NIH HHS / HD / R01 HD057355-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 169D1260KM / Nitroprusside; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS189580; NLM/ PMC2860054
  •  go-up   go-down


62. Velázquez-Sánchez C, Ferragud A, Hernández-Rabaza V, Nácher A, Merino V, Cardá M, Murga J, Canales JJ: The dopamine uptake inhibitor 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward. Neuropsychopharmacology; 2009 Nov;34(12):2497-507
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benztropine (BZT) analogs, a family of high-affinity dopamine transporter ligands, are molecules that exhibit pharmacological and behavioral characteristics predictive of significant therapeutic potential in cocaine addiction.
  • Here, we examined in mice the effects of 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane (AHN-1055) on motor activity, conditioned place preference (CPP) and c-Fos expression in the striatum.
  • Interaction assays showed that cocaine's ability to stimulate locomotor activity was decreased by AHN-1055 treatment, but not by treatment with D-amphetamine.
  • Remarkably, the BZT analog dose-dependently blocked cocaine-induced CPP without producing CPP when given alone, and blocked in conditioned mice cocaine-stimulated early-gene activation in the nucleus accumbens and dorsomedial striatum.
  • These observations provide evidence that AHN-1055 does not behave as a classical psychomotor stimulant and that some of its properties, including attenuation of cocaine-induced striatal c-Fos expression, locomotor stimulation, and CPP, support its candidacy, and that of structurally related molecules, as possible pharmacotherapies in cocaine addiction.
  • [MeSH-major] Benztropine / analogs & derivatives. Cocaine-Related Disorders / drug therapy. Conditioning, Classical / drug effects. Dopamine Uptake Inhibitors / pharmacology. Gene Expression / drug effects. Motor Activity / drug effects
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Cocaine / pharmacology. Dose-Response Relationship, Drug. Male. Mice. Nomifensine / pharmacology. Proto-Oncogene Proteins c-fos / metabolism. Reward. Space Perception / drug effects. Stereotyped Behavior / drug effects

  • MedlinePlus Health Information. consumer health - Cocaine.
  • Hazardous Substances Data Bank. NOMIFENSINE .
  • Hazardous Substances Data Bank. COCAINE .
  • Hazardous Substances Data Bank. BENZTROPINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606084.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Uptake Inhibitors; 0 / N-methyl-3-(bis(4'-fluorophenyl)methoxy)tropane; 0 / Proto-Oncogene Proteins c-fos; 1LGS5JRP31 / Nomifensine; 1NHL2J4X8K / Benztropine; I5Y540LHVR / Cocaine
  •  go-up   go-down


63. Toussaint M, Delair B, Foulon C, Lempereur N, Vaccher C, Maurice T, Melnyk P: Tic hydantoin sigma-1 agonist: pharmacological characterization on cocaine-induced stimulant and appetitive effects. Eur Neuropsychopharmacol; 2009 Jul;19(7):504-15
Hazardous Substances Data Bank. COCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tic hydantoin sigma-1 agonist: pharmacological characterization on cocaine-induced stimulant and appetitive effects.
  • The most active enantiomer 4, facilitated CPP acquisition but failed to substitute for cocaine.
  • When CPP was acquired with cocaine and then extinguished, 4 provoked reactivation of CPP.
  • Preliminary ADME properties are in favour of an optimal therapeutic development.
  • Such Tic-hydantoin compound may serve as a new effective agonist therapy in cocaine addiction.
  • [MeSH-major] Appetitive Behavior / drug effects. Cocaine / pharmacology. Dopamine Uptake Inhibitors / pharmacology. Hydantoins / pharmacology. Hyperkinesis / chemically induced. Receptors, sigma / agonists
  • [MeSH-minor] Analysis of Variance. Animals. Behavior, Animal / drug effects. Cellulose, Oxidized / pharmacology. Chromatography, High Pressure Liquid / methods. Conditioning, Operant / drug effects. Enzyme Inhibitors / pharmacology. Ethylenediamines / pharmacology. Extinction, Psychological / drug effects. Locomotion / drug effects. Male. Mice. Protein Binding / drug effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249191.001).
  • [ISSN] 1873-7862
  • [Journal-full-title] European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
  • [ISO-abbreviation] Eur Neuropsychopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Dopamine Uptake Inhibitors; 0 / Enzyme Inhibitors; 0 / Ethylenediamines; 0 / Hydantoins; 0 / INTERCEED; 0 / Receptors, sigma; 138356-20-4 / BD 1047; I5Y540LHVR / Cocaine
  •  go-up   go-down


64. Benturquia N, Le Marec T, Scherrmann JM, Noble F: Effects of nitrous oxide on dopamine release in the rat nucleus accumbens and expectation of reward. Neuroscience; 2008 Aug 13;155(2):341-4
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently we have shown that nitrous oxide (N2O) was able to block the expression of morphine-induced conditioned place preference (CPP) in mice.
  • Because dopamine (DA) has also been associated with the positive place conditioning we hypothesize that exposure to N2O would be significantly associated with a modification of extracellular level of DA.
  • Levels of DA, in the nucleus accumbens (Nac), in awake and freely moving rats during positive place conditioning after morphine chronic treatment has been measured by microdialysis.
  • Expression of morphine-induced CPP was totally abolished in mice and rats exposed to N2O.
  • In conclusion we showed the capacity of N2O to block the expression of morphine-induced CPP in mice and in rats.
  • [MeSH-major] Dopamine / metabolism. Morphine Dependence / drug therapy. Nitrous Oxide / pharmacology. Nucleus Accumbens / drug effects. Reward
  • [MeSH-minor] Analgesics, Opioid / pharmacology. Animals. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Drug Interactions. Male. Mice. Mice, Inbred Strains. Microdialysis. Morphine / pharmacology. Rats. Rats, Sprague-Dawley. Spatial Behavior / drug effects

  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. Nitrous oxide .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571333.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine; K50XQU1029 / Nitrous Oxide; VTD58H1Z2X / Dopamine
  •  go-up   go-down


65. Esmaeili B, Basseda Z, Dehpour AR: Antagonism of muscarinic M1 receptors by dicyclomine inhibits the consolidation of morphine-associated contextual memory. Brain Res Bull; 2008 Jul 1;76(4):380-7
Hazardous Substances Data Bank. DICYCLOMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • M1 muscarinic receptor has been shown to be involved in cognitive functions of the brain.
  • Conditioned place preference (CPP) paradigm involves memory for the association between environmental stimuli and the rewarding properties produced by a treatment.
  • Using a balanced CPP design, we studied the possible involvement of M1 muscarinic receptors on the acquisition, expression and consolidation of morphine place conditioning in male mice.
  • Subcutaneous administration of morphine sulphate-induced CPP in a dose-dependent manner.
  • Using a 6-day schedule of conditioning, it was found that dicyclomine, an M1 muscarinic antagonist, significantly reduced the time spent by mice in the morphine compartment when given immediately, but not 6h, after each conditioning session (consolidation).
  • It had no effect when administered 30 min before each conditioning session during CPP training period (acquisition) or 30 min before testing for place preference in the absence of morphine (expression).
  • It is concluded that M1 muscarinic receptors may play a time-dependent role in the consolidation of reward-related memory of morphine.
  • [MeSH-major] Dicyclomine / pharmacology. Learning / drug effects. Memory / drug effects. Morphine / pharmacology. Receptor, Muscarinic M1 / antagonists & inhibitors
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Dose-Response Relationship, Drug. Drug Interactions / physiology. Male. Mice. Morphine Dependence / drug therapy. Morphine Dependence / metabolism. Muscarinic Antagonists / pharmacology. Narcotics / pharmacology. Reward. Time Factors

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502314.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Narcotics; 0 / Receptor, Muscarinic M1; 4KV4X8IF6V / Dicyclomine; 76I7G6D29C / Morphine
  •  go-up   go-down


66. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK: A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol; 2008 May 2;378(3):565-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The capsid domain of the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein is a critical determinant of virus assembly, and is therefore a potential target for developing drugs for AIDS therapy.
  • Using this structural information, we have utilized a structure-based rational design approach to stabilize the alpha-helical structure of CAI and convert it to a cell-penetrating peptide (CPP).
  • This proof-of-concept cell-penetrating peptide may aid validation of capsid as an anti-HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to this protein.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Sep 21;407(6802):409-13 [11014200.001]
  • [Cites] Biophys J. 2001 Jul;81(1):586-94 [11423440.001]
  • [Cites] AIDS. 2001;15 Suppl 5:S13-20 [11816161.001]
  • [Cites] J Virol. 2002 Mar;76(6):2641-7 [11861830.001]
  • [Cites] J Virol. 2002 Jul;76(14):6900-8 [12072491.001]
  • [Cites] Virology. 2006 Apr 25;348(1):84-95 [16442581.001]
  • [Cites] J Virol. 2006 Jun;80(12):5716-22 [16731910.001]
  • [Cites] J Virol. 2006 Aug;80(16):7939-51 [16873251.001]
  • [Cites] PLoS Biol. 2006 Dec;4(12):e435 [17147474.001]
  • [Cites] J Virol. 2007 Jul;81(14):7476-90 [17507489.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Nov;46(11):3597-605 [12384371.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]
  • [Cites] J Mol Biol. 2003 Jan 24;325(4):759-72 [12507478.001]
  • [Cites] J Mol Biol. 2003 Apr 11;327(5):1013-20 [12662926.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11273-8 [13679575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60 [14573704.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Oct 14;44(40):6525-9 [16172999.001]
  • [Cites] J Virol. 2004 Jan;78(2):922-9 [14694123.001]
  • [Cites] J Virol. 2004 Feb;78(3):1375-83 [14722292.001]
  • [Cites] J Virol. 2004 Mar;78(5):2545-52 [14963157.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Mar 22;14(6):1403-6 [15006371.001]
  • [Cites] J Virol. 2004 Jun;78(11):5670-8 [15140964.001]
  • [Cites] Protein Sci. 2004 Jun;13(6):1512-23 [15152086.001]
  • [Cites] Biochemistry. 2004 Aug 17;43(32):10435-41 [15301542.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1466-70 [15353804.001]
  • [Cites] J Gen Virol. 2004 Oct;85(Pt 10):2903-13 [15448352.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Nov;48(11):4349-59 [15504864.001]
  • [Cites] J Virol. 1986 Aug;59(2):284-91 [3016298.001]
  • [Cites] J Exp Med. 1991 Dec 1;174(6):1557-63 [1836013.001]
  • [Cites] J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74 [8207412.001]
  • [Cites] J Virol. 1996 Aug;70(8):5106-14 [8764018.001]
  • [Cites] Science. 1997 Oct 31;278(5339):849-53 [9346481.001]
  • [Cites] Eur J Biochem. 1997 Oct 15;249(2):592-600 [9370371.001]
  • [Cites] Virology. 1998 Nov 10;251(1):1-15 [9813197.001]
  • [Cites] Biochemistry. 2004 Nov 9;43(44):13926-31 [15518540.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17664-70 [15734744.001]
  • [Cites] Nat Struct Mol Biol. 2005 Aug;12(8):678-82 [16041386.001]
  • [Cites] Nat Struct Mol Biol. 2005 Aug;12(8):671-7 [16041387.001]
  • [Cites] Biochemistry. 2000 Sep 26;39(38):11657-66 [10995233.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3503-8 [10725407.001]
  • [Cites] J Virol. 2000 Apr;74(8):3859-70 [10729160.001]
  • [Cites] J Virol. 2004 Jan;78(2):724-32 [14694104.001]
  • (PMID = 18374356.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010778-01; United States / NIGMS NIH HHS / GM / P41 GM066354-05; United States / NIGMS NIH HHS / GM / GM-66354; United States / NIGMS NIH HHS / GM / P41 GM066354; United States / NIGMS NIH HHS / GM / P41 GM066354-01; United States / NIGMS NIH HHS / GM / GM066354-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Gene Products, gag; 0 / NYAD-1 peptide; 0 / Peptides; 0 / Peptides, Cyclic
  • [Other-IDs] NLM/ NIHMS76587; NLM/ PMC2695608
  •  go-up   go-down


67. Xiao HP, Gu MN, Xiao JF, Xu X, Zhao ZL: [Effects of hypertonic sodium chloride hydroxyethyl starch 40 injection in treatment of acute intracranial hypertension complicated by hemorrhagic shock in dogs]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar;28(3):385-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of hypertonic sodium chloride hydroxyethyl starch 40 injection in treatment of acute intracranial hypertension complicated by hemorrhagic shock in dogs].
  • OBJECTIVE: To observe the effect of hypertonic sodium chloride hydroxyethyl starch 40 injection (HSH) in treatment of acute intracranial hypertension complicated by hemorrhagic shock in dogs, and explore the mechanism of the effects of HSH.
  • Canine models of acute intracranial hypertension complicated by hemorrhagic shock were established by epidural balloon inflation with saline and rapid discharge of the arterial blood.
  • During the shock and resuscitationperiod, the intracranial pressure (ICP), mean arterial pressure (MAP) and cerebral perfusion pressure (CPP) of the dogs were monitored, and the serum sodium level and plasma osmolality were measured at 30 min, 1 h and 4 h after the resuscitation.
  • RESULTS: All dogs had similar MAP, CPP, and ICP before resuscitation (P>0.05).
  • The CPP was also significantly increased after resuscitation (P<0.01), and in HS group, CPP decreased significantly after 2 h (P<0.01), and HSH group maintained the high CPP after 4 h.
  • CONCLUSION: In dogs with acute intracranial hypertension and hemorrhagic shock, HSH can effectively resuscitate hemorrhagic shock and decrease ICP, and the effect is longer-lasting than that of HS.
  • [MeSH-major] Hydroxyethyl Starch Derivatives / therapeutic use. Intracranial Hypertension / drug therapy. Saline Solution, Hypertonic / therapeutic use. Shock, Hemorrhagic / drug therapy
  • [MeSH-minor] Acute Disease. Animals. Dogs. Female. Male. Plasma Substitutes / administration & dosage. Plasma Substitutes / therapeutic use. Random Allocation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359696.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes; 0 / Saline Solution, Hypertonic
  •  go-up   go-down


68. Sadler R, Herzig V, Schmidt WJ: Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference. Behav Pharmacol; 2007 Nov;18(7):699-703
Hazardous Substances Data Bank. DIZOCILPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference.
  • Long-lasting drug-associated memories can contribute to relapse; therefore these memories must be inactivated to enable sustainable success in addiction therapy.
  • As drug associations are usually acquired over several conditioning events, we assume that an effective treatment should be repeatedly applied to achieve persistent effects.
  • In this study, we examine whether 10 repeated memory reactivation tests followed by systemic N-methyl-D-aspartate receptor antagonist MK-801 (0.1 mg/kg) administrations can disrupt memory reconsolidation in rats, leading to a reduction of well-established amphetamine-conditioned place preference (CPP).
  • We found that immediate (but not 60-min delayed) administration of MK-801 after the tests reduced amphetamine-CPP expression after at least four treatments.
  • These effects were specific to CPP expression as no MK-801-induced change in locomotion was observed during all tests.
  • We discuss these results as being caused by MK-801 disrupting memory reconsolidation and we propose the applied repeated-treatment regimen as a new therapeutic research strategy to persistently disrupt drug-associated memories.
  • [MeSH-major] Amphetamine / pharmacology. Central Nervous System Stimulants / pharmacology. Conditioning, Operant / drug effects. Dizocilpine Maleate / pharmacology. Memory / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Male. Motor Activity / drug effects. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Memory.
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912055.001).
  • [ISSN] 0955-8810
  • [Journal-full-title] Behavioural pharmacology
  • [ISO-abbreviation] Behav Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Receptors, N-Methyl-D-Aspartate; 6LR8C1B66Q / Dizocilpine Maleate; CK833KGX7E / Amphetamine
  •  go-up   go-down


69. Toumba M, Bacopoulou I, Savva SC, Skordis N: Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height. Indian Pediatr; 2007 Jul;44(7):497-502
MedlinePlus Health Information. consumer health - Growth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height.
  • OBJECTIVE: This study was conducted to study the role of combination therapy of growth hormone and Gonadotropin-releasing hormone (GnRH) analogues in girls with idiopathic central precocious puberty (CPP) or idiopathic short stature (ISS).
  • METHODS: Five girls with CPP (median age 9.1 y, pubertal stage 2-3) (3 of them previously treated with GnRH analogue (GnRHa) for 16.2 +/- 0.3 months) and 8 girls with ISS (median age 11.4 y, pubertal stage 2-3) (previously treated with GH for 10.95 +/- 1.42 months), were treated with recombinant human GH (0.33 mg/kg/week) and GnRHa (3.75 mg/28 days) for 22 months.
  • RESULTS: Height of girls with CPP improved from - 1.3 to - 0.2 SDS and height for BA from - 2.1 to - 0.6 SDS (P = 0.042).
  • CONCLUSION: Combined treatment improves height and PAH in CPP.
  • [MeSH-major] Body Height / drug effects. Gonadotropin-Releasing Hormone / analogs & derivatives. Growth Disorders / drug therapy. Growth Hormone / therapeutic use. Puberty, Precocious / drug therapy
  • [MeSH-minor] Algorithms. Bone Development / drug effects. Child. Drug Therapy, Combination. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684302.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


70. Meybohm P, Cavus E, Bein B, Steinfath M, Weber B, Hamann C, Scholz J, Dörges V: Small volume resuscitation: a randomized controlled trial with either norepinephrine or vasopressin during severe hemorrhage. J Trauma; 2007 Mar;62(3):640-6
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was designed to evaluate the effects of hypertonic-hyperoncotic hydroxyethyl starch solution (HHS) combined with either norepinephrine (NE) or arginine vasopressin (AVP) on cerebral perfusion pressure (CPP) and brain metabolism after hemorrhagic shock.
  • After 30 minutes of therapy, bleeding was controlled by manual compression and all surviving animals were observed for 1 hour.
  • RESULTS: After hemodynamic decompensation, AVP resulted in a significantly higher increase of CPP (mean +/- SD; 47 +/- 19 versus 28 +/- 9 mm Hg; p < 0.01) and cerebral venous partial pressure of oxygen (66 +/- 8 versus 49 +/- 9 mm Hg; p < 0.05) compared with NE after 10 minutes of therapy.
  • Brain metabolism was found comparable in both groups at any time.
  • CONCLUSIONS: AVP was comparable to NE with respect to hemodynamics and blood gases, as well as brain metabolism in surviving animals throughout the study period.
  • [MeSH-major] Hydroxyethyl Starch Derivatives / therapeutic use. Norepinephrine / therapeutic use. Plasma Substitutes / therapeutic use. Resuscitation / methods. Shock, Hemorrhagic / therapy. Vasoconstrictor Agents / therapeutic use. Vasopressins / therapeutic use
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Brain / metabolism. Cardiac Output / drug effects. Cerebrovascular Circulation / drug effects. Microdialysis. Oxygen / blood. Sus scrofa

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414341.001).
  • [ISSN] 0022-5282
  • [Journal-full-title] The Journal of trauma
  • [ISO-abbreviation] J Trauma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes; 0 / Vasoconstrictor Agents; 11000-17-2 / Vasopressins; S88TT14065 / Oxygen; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


71. Gonc EN, Kandemir N: Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency. Clin Endocrinol (Oxf); 2007 May;66(5):672-7
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study was designed to assess the long-term effects of growth hormone (GH) replacement therapy on bone mass and bone turnover markers in children with isolated GH deficiency (IGHD) and multiple pituitary hormone deficiency (MPHD).
  • MATERIALS AND METHODS: Fifty children (35 IGHD, 15 MPHD) receiving GH replacement therapy were enrolled in the study.
  • Bone mineral density (BMD) of the lumbar region and bone turnover markers [PTH, osteocalcin, bone-specific alkaline phosphatase (boneALP), and the carboxyterminal propeptide of type-1 collagen (CPP-I)] were assessed annually.
  • RESULTS: The height standard deviation score (SDS) of patients with IGHD and MPHD at diagnosis was statistically significant (P = 0.012), and the change in height SDS during 3 years (Deltaheight SDS(3 years)) was statistically similar between these two groups (P = 0.651).
  • The BMD z-scores of the two groups were comparable at the start of GH therapy (P = 0.083), and then increased in both groups similarly during 5 years of GH replacement therapy (F = 0.349, P = 0.567).
  • When the BMD z-scores during 5 years of GH therapy were analysed in the IGHD and MPHD groups separately, it was found that the BMD z-score increased significantly in IGHD (P < 0.001) but the increase was not significant in MPHD (P = 0.140).
  • Multiple regression analysis showed that the change in BMD z-score during 3 years of GH therapy (DeltaBMD z-score(3 years)) was predicted by the BMD z-score and height SDS at the start of GH therapy and by Deltaheight SDS(3 years) in the IGHD group (t = -2.582, P = 0.02; t = 2.322, P = 0.034 and t = 2.908, P = 0.01, respectively).
  • Age and BMD z-score and height SDS at diagnosis were found to have predictive values for the DeltaBMD z-score(3 years) (t = -3.652, P = 0.022; t = -4.073, P = 0.015 and t = 3.389, P = 0.028, respectively) in the MPHD group.
  • The changes in boneALP, osteocalcin, CPP-1 and PTH levels during the therapy were statistically similar between the IGHD and MPHD groups.
  • CONCLUSION: BMD increased during GH therapy in the IGHD and MPHD groups.
  • Early diagnosis and treatment could improve peak bone mass in patients with MPHD.
  • The time and dose of sex steroids for pubertal induction and progression, which mimics physiological secretion, might also contribute to bone accretion in patients with MPHD.
  • [MeSH-major] Bone Density / drug effects. Bone Remodeling / drug effects. Hormone Replacement Therapy. Human Growth Hormone / administration & dosage. Pituitary Diseases / drug therapy. Pituitary Hormones / deficiency

  • Genetic Alliance. consumer health - Growth Hormone Deficiency.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381489.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Pituitary Hormones; 0 / Procollagen; 0 / procollagen type I carboxy terminal peptide; 104982-03-8 / Osteocalcin; 12629-01-5 / Human Growth Hormone; 9002-72-6 / Growth Hormone; EC 3.1.3.1 / Alkaline Phosphatase; SY7Q814VUP / Calcium
  •  go-up   go-down


72. Hummel M, Schroeder J, Liu-Chen LY, Cowan A, Unterwald EM: An antisense oligodeoxynucleotide to the mu opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice. Neuroscience; 2006 Oct 13;142(2):481-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the conditioned place preference (CPP) study, mice received five i.c.v. infusions of mismatch ODN or MOR AS ODN (days 1-5).
  • An unbiased counterbalanced conditioning procedure was used where mice were conditioned with saline (4 ml/kg, i.p.) and cocaine (15 mg/kg, i.p.) on alternate days for four sessions (days 3-6).
  • Mice were tested on day 7 for CPP.
  • Immediately following testing, [3H]DAMGO (D-Ala2, N-Me-Phe4, Gly-ol5-enkephalin) receptor binding to brain homogenates was conducted.
  • [MeSH-major] Cocaine-Related Disorders / drug therapy. Cocaine-Related Disorders / physiopathology. Oligodeoxyribonucleotides, Antisense / therapeutic use. Receptors, Opioid, mu / physiology. Reward
  • [MeSH-minor] Analysis of Variance. Animals. Behavior, Animal. Conditioning, Operant / drug effects. Drug Administration Routes. Drug Interactions. Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / pharmacokinetics. Male. Mice. Mice, Inbred C57BL. Morphine / pharmacology. Narcotics / pharmacology. Protein Binding / drug effects. Radiography / methods. Time Factors. Tritium / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Cocaine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. MORPHINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893609.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 09580; United States / NIDA NIH HHS / DA / P30 DA 13429; United States / PHS HHS / / T32 07237
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Narcotics; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Receptors, Opioid, mu; 10028-17-8 / Tritium; 100929-53-1 / Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; 76I7G6D29C / Morphine
  •  go-up   go-down


73. Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, Gelber H, Spitz IM: The histrelin implant: a novel treatment for central precocious puberty. Pediatrics; 2005 Dec;116(6):e798-802
Hazardous Substances Data Bank. HISTRELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histrelin implant: a novel treatment for central precocious puberty.
  • OBJECTIVE: Standard treatment of central precocious puberty (CPP) consists of intramuscular or subcutaneous administration of a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) at 3- to 4-week intervals.
  • Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 microg/day.
  • The aims of this study were to determine if a histrelin implant would suppress gonadotropin and estradiol (E2) in girls with CPP for 1 year and to compare the suppression to standard treatment.
  • METHODS: We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression.
  • Mean age at diagnosis was 6 years (range: 2-9 years).
  • Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued.
  • GnRH-STs were performed before depot GnRHa treatment, immediately before implant insertion, at the 6- and 9-month visits for each patient and the 12- and 15-month visit for those girls followed for 15 months.
  • CONCLUSIONS: The histrelin implant consistently suppresses clinical and laboratory parameters of puberty for 1 year and is a promising new technique for treating CPP without the pain and inconvenience of monthly injections.
  • [MeSH-major] Drug Implants. Gonadotropin-Releasing Hormone / analogs & derivatives. Puberty, Precocious / drug therapy

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322137.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Gonadotropins, Pituitary; 33515-09-2 / Gonadotropin-Releasing Hormone; H50H3S3W74 / histrelin
  •  go-up   go-down


74. Russo SJ, Festa ED, Fabian SJ, Gazi FM, Kraish M, Jenab S, Quiñones-Jenab V: Gonadal hormones differentially modulate cocaine-induced conditioned place preference in male and female rats. Neuroscience; 2003;120(2):523-33
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, conditioned place preference (CPP), a measure of non-contingent reward, was used to determine the effects of endogenous gonadal hormones and of estrogen and progesterone replacement on cocaine reward.
  • Although both intact and gonadectomized male and female rats showed a significant CPP for cocaine, ovariectomy attenuated the magnitude of CPP.
  • These alterations coincided with a decrease in serum levels of corticosterone.
  • In ovariectomized rats, pretreatment with progesterone inhibited cocaine CPP while estrogen plus progesterone potentiated the magnitude of CPP.
  • [MeSH-major] Cocaine / pharmacology. Conditioning (Psychology) / drug effects. Estrogens / pharmacology. Progesterone / pharmacology. Sex Characteristics
  • [MeSH-minor] Analysis of Variance. Anesthetics, Local / pharmacology. Animals. Behavior, Animal. Biogenic Monoamines / metabolism. Cesarean Section / methods. Chromatography, High Pressure Liquid / instrumentation. Chromatography, High Pressure Liquid / methods. Corticosterone / blood. Drug Interactions. Exploratory Behavior / drug effects. Exploratory Behavior / physiology. Female. Hormone Replacement Therapy / methods. Male. Motor Activity / drug effects. Motor Activity / physiology. Nucleus Accumbens / drug effects. Nucleus Accumbens / metabolism. Radioimmunoassay / methods. Rats. Rats, Inbred F344. Reaction Time. Reward. Time Factors. Ventral Tegmental Area / drug effects. Ventral Tegmental Area / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12890521.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA12136; United States / NIGMS NIH HHS / GM / GM60654; United States / NINDS NIH HHS / NS / NS-41073; United States / NCRR NIH HHS / RR / RR-03037
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Biogenic Monoamines; 0 / Estrogens; 4G7DS2Q64Y / Progesterone; I5Y540LHVR / Cocaine; W980KJ009P / Corticosterone
  •  go-up   go-down


75. Stocchetti N, Rossi S, Zanier ER, Colombo A, Beretta L, Citerio G: Pyrexia in head-injured patients admitted to intensive care. Intensive Care Med; 2002 Nov;28(11):1555-62
MedlinePlus Health Information. consumer health - Pain Relievers.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (b) to elucidate the relationships between pyrexia and neurological severity, length of stay in the ICU, intracranial hypertension, and cerebral perfusion pressure (CPP); and (c) to describe the effects of antipyretic therapy on temperature, intracranial pressure (ICP) and CPP.
  • PATIENTS: 110 patients with traumatic brain injury.
  • Various antipyretic therapies were used in 66 patients.
  • Pharmacological treatment was slightly effective (mean temperature reduction 0.58+/-0.7 degrees C) but caused a significant drop in CPP (6.5+/-12.5 mmHg).
  • Its incidence is higher in more severe cases and is correlated with a longer ICU stay.
  • It may affect ICP, but its contribution is difficult to assess when other major causes of increased intracranial volume are present.
  • Antipyretic therapy is poorly effective for controlling body temperature and may be deleterious for CPP.
  • [MeSH-major] Analgesics, Non-Narcotic / therapeutic use. Craniocerebral Trauma / complications. Fever / drug therapy. Fever / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Intensive Care Units / statistics & numerical data. Intracranial Pressure. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Retrospective Studies. Risk Factors. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Head Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12415441.001).
  • [ISSN] 0342-4642
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic
  •  go-up   go-down


76. Omboni S, Fogari R, Mancia G: A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives. Blood Press; 2001;10(3):170-5
MedlinePlus Health Information. consumer health - High Blood Pressure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND METHODS: After 2 weeks of placebo 50 mild to moderate essential hypertensives (age 54+/-5 years) were subjected to 8 weeks of treatment with delapril 30 mg once daily.
  • Twenty-four-hour means, trough-to-peak ratio (T/P) and smoothness index (SI, the ratio between the average of the 24-h BP changes after T and its standard deviation) were calculated for systolic (S) and diastolic (D) BP.
  • RESULTS: CBP and ABP were significantly reduced by treatment.
  • Pulse pressure (PP, the SBP-DBP difference) was also significantly (p < 0.01) reduced by delapril (5.7+/-6.2 and 3.3+/-3.8 mmHg, CPP and APP).
  • CONCLUSIONS: Delapril effectively and smoothly reduces BP over 24 h, this effect being evident also on PP, a parameter with a relevant prognostic value.
  • [MeSH-major] Angiotensin-Converting Enzyme Inhibitors / administration & dosage. Antihypertensive Agents / administration & dosage. Blood Pressure / drug effects. Hypertension / drug therapy. Indans / administration & dosage

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11688765.001).
  • [ISSN] 0803-7051
  • [Journal-full-title] Blood pressure
  • [ISO-abbreviation] Blood Press.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antihypertensive Agents; 0 / Indans; W77UAL9THI / delapril
  •  go-up   go-down


77. Pollack AE, Haisley EC: NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats. Brain Res; 2001 Apr 6;897(1-2):213-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment with NMDA glutamate antagonists MK-801 or CPP dose-dependently attenuates these quinpirole-mediated responses.
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Brain Chemistry / drug effects. Denervation. Dizocilpine Maleate / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Male. Oxidopamine. Parkinson Disease / drug therapy. Parkinson Disease / metabolism. Piperazines / pharmacology. Proto-Oncogene Proteins c-fos / metabolism. Rats. Rats, Sprague-Dawley. Sympatholytics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. APOMORPHINE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11282380.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-fos; 0 / Receptors, Dopamine D2; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Sympatholytics; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 6LR8C1B66Q / Dizocilpine Maleate; 8HW4YBZ748 / Oxidopamine; N21FAR7B4S / Apomorphine
  •  go-up   go-down


78. Wang R, Zhang Y, Qing H, Liu M, Yang P: The extinction of morphine-induced conditioned place preference by histone deacetylase inhibition. Neurosci Lett; 2010 Oct 11;483(2):137-42
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we will examine the effect of histone deacetylase (HDAC) inhibitors on extinction of morphine-induced conditioned place preference (CPP).
  • To exclude the effect of repeated NaBut injections themselves on morphine-CPP in the absence of extinction session, rats received injection of either NaBut or vehicle for 8 days.
  • We found that HDAC inhibition during nonconfined extinction or confined extinction consolidation can facilitate extinction of morphine-induced CPP.
  • We also showed that the extinction of drug seeking via HDAC inhibition modulates extinction learning such that reinstatement behavior is significantly attenuated.
  • There is no effect of repeated NaBut injections themselves on morphine-CPP in the absence of extinction session.
  • In conclusion, our results extend earlier reports on the ability of HDACi to modify the behavioral effects of drugs of abuse.
  • Our increasing understanding of these epigenetic mechanisms will provide key answers to basic processes in drug addiction and hopefully provide insight into designing improved treatments for drug addiction.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Enzyme Inhibitors / pharmacology. Extinction, Psychological / drug effects. Histone Deacetylase 1 / antagonists & inhibitors. Morphine Dependence / drug therapy. Protein Processing, Post-Translational / genetics
  • [MeSH-minor] Analgesics, Opioid / pharmacology. Animals. Behavior, Animal / drug effects. Behavior, Animal / physiology. Disease Models, Animal. Male. Morphine / pharmacology. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20691756.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Enzyme Inhibitors; 76I7G6D29C / Morphine; EC 3.5.1.98 / Hdac1 protein, rat; EC 3.5.1.98 / Histone Deacetylase 1
  •  go-up   go-down


79. Hirsch HJ, Lahlou N, Gillis D, Strich D, Rosenberg-Hagen B, Chertin B, Farkas A, Hartman H, Spitz IM: Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. J Clin Endocrinol Metab; 2010 Jun;95(6):2841-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
  • BACKGROUND: Gonadotropin free alpha-subunit (FAS) levels paradoxically increase during GnRH agonist (GnRHa) treatment of central precocious puberty (CPP).
  • OBJECTIVES: We aimed to determine whether FAS levels remain elevated during treatment with the implant, to assess the dynamics of FAS after removal, and to ascertain the reliability of FAS for monitoring gonadotropin secretion.
  • METHODS: Ten girls with CPP were studied.
  • Duration of implant treatment ranged from 18-63 months with repeated implant removals and insertions of new implants.
  • LH, FSH, E(2), and FAS were measured before implant insertion in the two naive patients and during treatment, and in all girls before and after implant removal.
  • RESULTS: FAS levels were 0.2 and 0.4 ng/ml (normal, <0.6 ng/ml) in the two naive girls and increased to 2.4 and 5.1 ng/ml within 2-5 d of insertion.
  • FAS level (mean +/- SD) in all 10 girls during histrelin implant treatment was 1.19 +/- 0.49 ng/ml and rapidly decreased to 0.31 +/- 0.12 ng/ml within 1 wk of implant removal (P < 0.03).
  • CONCLUSIONS: Compared to LH, FSH, and E(2), FAS responds more rapidly to implant removal and represents the most sensitive indicator of gonadotropin recovery after histrelin implant treatment.
  • [MeSH-major] Glycoprotein Hormones, alpha Subunit / metabolism. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropins / metabolism. Puberty, Precocious / drug therapy. Puberty, Precocious / metabolism
  • [MeSH-minor] Child. Delayed-Action Preparations. Drug Implants. Estradiol / blood. Female. Follicle Stimulating Hormone. Follicle Stimulating Hormone, Human / blood. Humans. Hydrogels. Luteinizing Hormone / blood. Recovery of Function

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. HISTRELIN .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339028.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Drug Implants; 0 / Follicle Stimulating Hormone, Human; 0 / Glycoprotein Hormones, alpha Subunit; 0 / Gonadotropins; 0 / Hydrogels; 33515-09-2 / Gonadotropin-Releasing Hormone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; H50H3S3W74 / histrelin
  •  go-up   go-down


80. Fishbain DA, Lewis JE, Gao J, Cole B, Rosomoff RS: Alleged medical abandonment in chronic opioid analgesic therapy: case report. Pain Med; 2009 May-Jun;10(4):722-9
Hazardous Substances Data Bank. OXYCODONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleged medical abandonment in chronic opioid analgesic therapy: case report.
  • 1) present details of a chronic pain patient (CPP) on chronic opioid analgesic therapy (COAT), who diverted her opioids and was terminated from treatment, and subsequently committed suicide;.
  • METHODS: This is a case report of a CPP treated by a pain physician who demonstrated aberrant drug-related behaviors and required large doses of controlled-release oxycodone.
  • [MeSH-major] Analgesics, Opioid / adverse effects. Malpractice / legislation & jurisprudence. Pain, Intractable / drug therapy. Physician-Patient Relations. Refusal to Treat / legislation & jurisprudence. Suicide / legislation & jurisprudence
  • [MeSH-minor] Abdominal Pain / drug therapy. Abdominal Pain / etiology. Abdominal Pain / physiopathology. Adult. Alcoholism / complications. Alprazolam / administration & dosage. Crime. Drug Administration Schedule. Fatal Outcome. Female. Humans. Hypnotics and Sedatives / administration & dosage. Opioid-Related Disorders / etiology. Opioid-Related Disorders / psychology. Oxycodone / administration & dosage. Oxycodone / adverse effects. Pancreatitis, Chronic / complications. Pancreatitis, Chronic / physiopathology. Patient Compliance. Self Medication / psychology


81. Llena C, Forner L, Baca P: Anticariogenicity of casein phosphopeptide-amorphous calcium phosphate: a review of the literature. J Contemp Dent Pract; 2009;10(3):1-9
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: This review of the literature examines the role of the natural components of saliva in maintaining tooth mineralization and the role of different casein phosphopeptide amorphous calcium phosphate-based (CPP-ACP) compounds in controlling demineralization/remineralization and their clinical applications.
  • BACKGROUND: A group of peptides, known as CPP, have been shown to stabilize calcium and phosphate preserving them in an amorphous or soluble form known as amorphous calcium phosphate (ACP).
  • Calcium and phosphate are essential components of enamel and dentine and form highly insoluble complexes, but in the presence of CPP they remain soluble and biologically available.
  • This CPP-ACP complex applied to teeth by means of chewing-gum, toothpaste, lozenges, mouth rinses, or sprays is able to adhere to the dental biofilm and enamel hydroxyapatite providing bioavailable calcium and phosphate ions.
  • REVIEW RESULTS: Significantly high levels of calcium and phosphate have been found in both biofilm and subsurface incipient caries lesions and in lower level demineralization of enamel or dentine surfaces previously treated with CPP-ACP based compounds.
  • When placed on the surface of a tooth with early carious lesions, pastes with CPP-ACP complexes can prevent tooth demineralization and improve enamel remineralization and enhance fluoride activity.
  • CLINICAL SIGNIFICANCE: Use of CPP-ACP based compounds offers a potential for use in the prevention of dental caries.
  • [MeSH-major] Cariostatic Agents / therapeutic use. Caseins / therapeutic use. Dental Caries / prevention & control
  • [MeSH-minor] Biofilms. Calcium / pharmacokinetics. Dental Enamel / metabolism. Dental Plaque / chemistry. Dentin / metabolism. Humans. Phosphates / pharmacokinetics. Saliva / physiology. Tooth Erosion / prevention & control. Tooth Remineralization / methods. Xerostomia / drug therapy

  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430620.001).
  • [ISSN] 1526-3711
  • [Journal-full-title] The journal of contemporary dental practice
  • [ISO-abbreviation] J Contemp Dent Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cariostatic Agents; 0 / Caseins; 0 / Phosphates; 0 / casein phosphopeptide-amorphous calcium phosphate nanocomplex; SY7Q814VUP / Calcium
  • [Number-of-references] 31
  •  go-up   go-down


82. Kang L, Wang D, Li B, Hu M, Zhang P, Li J: Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats. Am J Drug Alcohol Abuse; 2008;34(5):541-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of mirtazapine, a noradrenergic and specific serotonergic antidepressant, on morphine withdrawal and morphine conditioned place preference (CPP) were investigated in rats.
  • The expression of morphine-induced CPP was significantly blocked by mirtazapine (10 or 30 mg/kg, i.p.
  • ), while chronic treatment with mirtazapine (1 or 10 mg/kg, i.p. once, daily, for six consecutive days) significantly attenuated the acquisition of morphine CPP.
  • Our results demonstrated that mirtazapine attenuates morphine withdrawal and morphine-induced CPP in rats and suggest that mirtazapine may have therapeutic potential in the treatment of opiate dependence.
  • [MeSH-major] Antidepressive Agents, Tricyclic / pharmacology. Mianserin / analogs & derivatives. Morphine Dependence / drug therapy. Substance Withdrawal Syndrome / drug therapy
  • [MeSH-minor] Animals. Conditioning, Operant / drug effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Male. Morphine / adverse effects. Rats. Rats, Sprague-Dawley. Serotonin Receptor Agonists / administration & dosage. Serotonin Receptor Agonists / pharmacology

  • Hazardous Substances Data Bank. MIANSERIN .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618337.001).
  • [ISSN] 1097-9891
  • [Journal-full-title] The American journal of drug and alcohol abuse
  • [ISO-abbreviation] Am J Drug Alcohol Abuse
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 0 / Serotonin Receptor Agonists; 250PJI13LM / Mianserin; 76I7G6D29C / Morphine; A051Q2099Q / mirtazapine
  •  go-up   go-down


83. Isaac H, Patel L, Meyer S, Hall CM, Cusick C, Price DA, Clayton PE: Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res; 2007;68(4):157-63
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty.
  • AIMS: To compare the efficacy of goserelin 10.8 mg (Zoladex LA-ZLA) administered 9-12 weekly with 3.6 mg (Zoladex-Z) given monthly in suppressing pubertal development, and effect on body mass index (BMI).
  • METHODS: Children with central precocious puberty (CPP) treated with Z (n = 34) or ZLA (n = 28) were studied retrospectively.
  • Pubertal scores and BMI SDS during 24 months' treatment were compared.
  • RESULTS: To attain adequate pubertal suppression, more patients on ZLA than Z required increase in injection frequency (p = 0.02) and this was so for 7/8 patients with a structural aetiology for CPP on ZLA and 2/8 on Z.
  • Children with CPP had an elevated BMI at the onset of therapy and ZLA had a transient positive influence on BMI.
  • [MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Goserelin / administration & dosage. Puberty, Precocious / drug therapy
  • [MeSH-minor] Body Height / drug effects. Body Mass Index. Child. Delayed-Action Preparations. Drug Administration Schedule. Female. Growth and Development / drug effects. Humans. Male. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17356292.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


84. Bordman R, Jackson B: Below the belt: approach to chronic pelvic pain. Can Fam Physician; 2006 Dec;52(12):1556-62
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a practical approach to the symptom complex called chronic pelvic pain (CPP).
  • Chronic pelvic pain is defined as nonmenstrual pain lasting 6 months or more that is severe enough to cause functional disability or require medical or surgical treatment.
  • MAIN MESSAGE: While the source of pain in CPP can be gynecologic, urologic, gastrointestinal, musculoskeletal, or psychoneurologic, 4 conditions account for most CPP: endometriosis, adhesions, interstitial cystitis, and irritable bowel syndrome.
  • Nonnarcotic analgesics are first-line therapy for pain relief; hormonal therapies are beneficial if the pain has a cyclical component.
  • CONCLUSION: Although caring for patients with CPP can be challenging and frustrating, family physicians are in an ideal position to manage and coordinate their care.
  • [MeSH-major] Pelvic Pain / diagnosis. Pelvic Pain / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Chronic Disease. Cystitis, Interstitial / complications. Cystitis, Interstitial / diagnosis. Cystitis, Interstitial / drug therapy. Endometriosis / complications. Endometriosis / diagnosis. Endometriosis / drug therapy. Female. Humans. Irritable Bowel Syndrome / complications. Irritable Bowel Syndrome / diagnosis. Irritable Bowel Syndrome / therapy. Physical Examination

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med Bull. 2004;72:15-29 [15767561.001]
  • [Cites] Clin Obstet Gynecol. 1998 Jun;41(2):422-35 [9646974.001]
  • [Cites] Am Fam Physician. 1999 Oct 15;60(6):1753-62, 1767-8 [10537390.001]
  • [Cites] Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Jun;14(3):467-94 [10962637.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(4):CD000387 [11034686.001]
  • [Cites] J Am Board Fam Pract. 2001 Mar-Apr;14(2):95-106 [11314930.001]
  • [Cites] Int J Gynaecol Obstet. 2001 Sep;74 Suppl 1:S15-20 [11549395.001]
  • [Cites] Obstet Gynecol Surv. 2001 Dec;56(12):757-64 [11753178.001]
  • [Cites] J Obstet Gynaecol Can. 2002 Jan;24(1):37-61; quiz 74-6 [12196887.001]
  • [Cites] Fertil Steril. 2002 Nov;78(5):961-72 [12413979.001]
  • [Cites] Obstet Gynecol. 2003 Mar;101(3):594-611 [12636968.001]
  • [Cites] Obstet Gynecol Clin North Am. 2003 Mar;30(1):133-50 [12699262.001]
  • [Cites] J Urol. 2003 Sep;170(3):807-9 [12913704.001]
  • [Cites] Obstet Gynecol Surv. 2003 Sep;58(9):615-23 [12972837.001]
  • [Cites] J Fam Pract. 2003 Dec;52(12):942-50 [14653980.001]
  • [Cites] Obstet Gynecol. 2004 Mar;103(3):589-605 [14990428.001]
  • [Cites] J Reprod Med. 2004 Mar;49(3 Suppl):230-4 [15088861.001]
  • [Cites] Obstet Gynecol. 1991 May;77(5):740-4 [1826544.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Jan;99(1):59-62 [1547175.001]
  • [Cites] Urology. 1997 May;49(5A Suppl):58-63 [9146003.001]
  • [Cites] J Gen Intern Med. 1997 Jul;12(7):439-45 [9229283.001]
  • [Cites] Clin Obstet Gynecol. 1997 Sep;40(3):554-63 [9328736.001]
  • [Cites] Obstet Gynecol. 2003 Aug;102(2):397-408 [12907119.001]
  • (PMID = 17279236.001).
  • [ISSN] 1715-5258
  • [Journal-full-title] Canadian family physician Médecin de famille canadien
  • [ISO-abbreviation] Can Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1783755
  •  go-up   go-down


85. Abes S, Moulton H, Turner J, Clair P, Richard JP, Iversen P, Gait MJ, Lebleu B: Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem Soc Trans; 2007 Feb;35(Pt 1):53-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, splicing correction by CPP-conjugated steric-block ON analogues is inefficient in the absence of endosomolytic agents.
  • They offer promising leads for the development of efficient cellular delivery vectors for therapeutic steric-block ON analogues.
  • [MeSH-minor] Alternative Splicing. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Drug Delivery Systems. Gene Transfer Techniques. Genetic Therapy / methods. Genomics / methods. Humans. Models, Biological

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233600.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105178803
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nucleic Acids; 0 / Oligonucleotides; 0 / Peptides
  • [Number-of-references] 22
  •  go-up   go-down


86. Zhou J, Fan J, Hsieh JT: Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle. Cancer Res; 2006 Sep 15;66(18):8954-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle.
  • Differentially expressed in ovarian cancer-2/disabled 2 (DOC-2/DAB2) protein, often lost in prostate cancer and other cancer types, is a part of homeostatic machinery in normal prostate epithelium.
  • In this study, we further synthesized peptide based on the functional proline-rich domain and examined its biological function in prostate cancer using cell-permeable peptide (CPP) as a delivery system.
  • Taken together, we conclude that a functional peptide derived from proline-rich domain in DOC-2/DAB2 has growth-inhibitory activity as its native protein, and CPP seems to be an efficient delivery system in prostate cancer cells.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / pharmacology. MAP Kinase Signaling System / drug effects. Oligopeptides / pharmacology. Peptide Fragments / pharmacology. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Amino Acid Sequence. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Membrane Permeability / drug effects. Cell Membrane Permeability / physiology. Drug Design. Humans. Male. Molecular Sequence Data. Protein Structure, Tertiary. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982733.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DAB2 protein, human; 0 / Oligopeptides; 0 / Peptide Fragments; 0 / R11 peptide; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


87. Leung MC, Meredith IT, Cameron JD: Aortic stiffness affects the coronary blood flow response to percutaneous coronary intervention. Am J Physiol Heart Circ Physiol; 2006 Feb;290(2):H624-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aortic mechanical indexes measured included central pulse-wave velocity (cPWV) and central pulse pressure (cPP).
  • With the adjustment for age and gender, resting and hyperemic CBF were inversely related to cPWV irrespective of the presence of stenosis (resting: before PCI, r2 = 0.452, P < 0.01; after PCI, r2 = 0.261, P = 0.043; hyperemic: before PCI r2 = 0.503, P = 0.005; after PCI r2 = 0.500, P = 0.002), whereas they were related to cPP in absence of stenosis (resting: r2 = 0.368, P = 0.022; hyperemic: r2 = 0.370, P = 0.016).
  • A stiff aorta is associated with a reduction in CBF, a lower hyperemic CBF response, and may reduce the improvement in hyperemic CBF after successful PCI.
  • [MeSH-major] Angina Pectoris / physiopathology. Angina Pectoris / therapy. Angioplasty, Balloon, Coronary. Aorta / physiopathology. Coronary Circulation
  • [MeSH-minor] Adenosine / pharmacology. Aged. Blood Flow Velocity. Blood Pressure. Blood Volume / drug effects. Coronary Stenosis / complications. Elasticity. Female. Humans. Male. Middle Aged. Pulse. Vasodilator Agents / pharmacology

  • MedlinePlus Health Information. consumer health - Angina.
  • Hazardous Substances Data Bank. Adenosine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1311 [16467460.001]
  • (PMID = 16143654.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; K72T3FS567 / Adenosine
  •  go-up   go-down


88. Herzig V, Schmidt WJ: Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats. Neurosci Lett; 2005 Feb 10;374(2):119-23
Hazardous Substances Data Bank. ACAMPROSATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats.
  • Relapse prevention in clean addicts is a great challenge for addiction-therapy.
  • As strong cravings often precede relapse, anti-craving drugs seem to be a promising way for addicts to stay clean.
  • Naloxone and acamprosate are two candidates for anti-craving drugs that are already used for relapse prevention in alcoholic patients.
  • However, it has to be figured out if both drugs are also effective in opiate-addicts.
  • In order to evaluate their effectiveness, a conditioned place preference (CPP) paradigm was used in rats conditioned to 10 mg/kg, i.p., morphine.
  • As acamprosate and naloxone have been suggested to selectively affect different types of craving (withdrawal-craving versus reward-craving), we have tried to modulate craving-behaviour by maintaining two groups of rats under different conditions (isolated versus group-housed).
  • Thereafter, the effectiveness of acamprosate (200 mg/kg, i.p.) and naloxone (2 mg/kg, i.p.) in reducing morphine-CPP expression was evaluated.
  • As a result, isolation produced a weak reduction in morphine-CPP development.
  • Furthermore, acamprosate and naloxone had no effect on morphine-CPP expression.
  • Based on the present results, we assume that the anti-craving drugs acamprosate and naloxone may not be effective for relapse prevention in opiate-addicts.
  • [MeSH-major] Alcohol Deterrents / pharmacology. Conditioning, Operant / drug effects. Morphine / pharmacology. Naloxone / pharmacology. Narcotic Antagonists / pharmacology. Narcotics / pharmacology. Taurine / analogs & derivatives. Taurine / pharmacology
  • [MeSH-minor] Analysis of Variance. Animals. Behavior, Animal. Drug Interactions. Locomotion / drug effects. Male. Rats. Rats, Sprague-Dawley. Social Isolation. Spatial Behavior / drug effects

  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. NALOXONE .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644276.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Alcohol Deterrents; 0 / Narcotic Antagonists; 0 / Narcotics; 1EQV5MLY3D / Taurine; 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine; N4K14YGM3J / acamprosate
  •  go-up   go-down


89. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A: Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation; 2004 Sep 7;110(10):1231-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide.
  • BACKGROUND: Ischemia/reperfusion (I/R) injury complicates myocardial infarction and stroke by exacerbating tissue damage and increasing risk of mortality.
  • We have recently identified C-type natriuretic peptide (CNP) as an endothelium-derived hyperpolarizing factor in the mesenteric resistance vasculature and described a novel signaling pathway involving activation of natriuretic peptide receptor C (NPR-C), which plays a pivotal role in the regulation of local blood flow.
  • METHODS AND RESULTS: CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elicited dose-dependent decreases in coronary perfusion pressure (CPP) that were blocked by Ba(2+) and ouabain in the isolated Langendorff rat heart.
  • CNP and cANF(4-23) reduced infarct size after 25 minutes of global ischemia and 120 minutes of reperfusion, maintaining CPP and left ventricular pressure at preischemic values.
  • Moreover, this newly defined pathway represents a protective mechanism against I/R injury and a novel target for therapeutic intervention in ischemic cardiovascular disorders.
  • [MeSH-major] Coronary Circulation / drug effects. Natriuretic Peptide, C-Type / physiology. Receptors, Atrial Natriuretic Factor / physiology
  • [MeSH-minor] Acetylcholine / pharmacology. Animals. Atrial Natriuretic Factor / pharmacology. Atrial Natriuretic Factor / therapeutic use. Barium / pharmacology. Drug Evaluation, Preclinical. Endothelium, Vascular / drug effects. Endothelium, Vascular / secretion. Male. Myocardial Infarction / drug therapy. Myocardial Infarction / pathology. Myocardial Reperfusion Injury / prevention & control. NG-Nitroarginine Methyl Ester / pharmacology. Nitric Oxide / physiology. Ouabain / pharmacology. Peptide Fragments / pharmacology. Peptide Fragments / therapeutic use. Rats. Rats, Wistar. Signal Transduction. Vasodilation / drug effects. Vasodilator Agents / pharmacology. Vasodilator Agents / therapeutic use


90. Wolff JE, Sajedi M, Brant R, Coppes MJ, Egeler RM: Choroid plexus tumours. Br J Cancer; 2002 Nov 4;87(10):1086-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumours.
  • Choroid plexus tumours are rare epithelial brain tumours and limited information is available regarding their biology and the best treatment.
  • A meta-analysis was done to determine prognostic factors and the influence of various treatment modalities.
  • A thorough review of the medical literature (1966-1998) revealed 566 well-documented choroid plexus tumours.
  • These were entered into a database, which was analysed to determine prognostic factors and treatment modalities.
  • Most patients with a supratentorial tumour were children, while the most common sites in adults were the fourth ventricle and the cerebellar pontine angle.
  • Cerebellar pontine angle tumours were more frequently benign.
  • Histology was the most important prognostic factor, as one, five, and 10-year projected survival rates were 90, 81, and 77% in choroid plexus-papilloma (n=353) compared to only 71, 41, and 35% in choroid plexus-carcinoma respectively (P<0.0005).
  • Surgery was prognostically relevant for both choroid plexus-papilloma (P=0.0005) and choroid plexus-carcinoma (P=0.0001).
  • Radiotherapy was associated with significantly better survival in choroid plexus-carcinomas.
  • Eight of 22 documented choroid plexus-carcinomas responded to chemotherapy.
  • Relapse after primary treatment was a poor prognostic factor in choroid plexus-carcinoma patients but not in choroid plexus-papilloma patients.
  • Treatment of choroid plexus tumours should start with radical surgical resection.
  • This should be followed by adjuvant treatment in case of choroid plexus-carcinoma, and a "wait and see" approach in choroid plexus-papilloma.
  • [MeSH-major] Choroid Plexus Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Cancer Research UK
  • [Cites] Zentralbl Allg Pathol. 1989;135(3):235-40 [2773602.001]
  • [Cites] Childs Nerv Syst. 1997 May;13(5):244-9 [9224912.001]
  • [Cites] Acta Oncol. 1990;29(2):241-3 [2185805.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jul-Aug;11(4):793-9 [2114770.001]
  • [Cites] Childs Nerv Syst. 1990 Sep;6(6):331-4 [2257546.001]
  • [Cites] Acta Neuropathol. 1990;80(6):635-41 [1703384.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):323-5 [11452945.001]
  • [Cites] Childs Brain. 1975;1(2-3):81-115 [1081032.001]
  • [Cites] Childs Brain. 1977;3(1):12-24 [844343.001]
  • [Cites] Int J Cancer. 1978 Jan 15;21(1):12-7 [203540.001]
  • [Cites] Acta Neurochir (Wien). 1978;43(3-4):239-49 [212932.001]
  • [Cites] No Shinkei Geka. 1979 Aug;7(8):815-8 [492463.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1981 Feb;54(2):245-7 [6969788.001]
  • [Cites] Acta Neuropathol. 1981;53(1):29-33 [7010876.001]
  • [Cites] Neurosurg Rev. 1981;4(3):129-37 [7301142.001]
  • [Cites] Neurochirurgie. 1986;32(3):258-61 [3762840.001]
  • [Cites] Acta Cytol. 1988 Mar-Apr;32(2):263-6 [2450440.001]
  • [Cites] Arch Geschwulstforsch. 1988;58(1):51-5 [3369921.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Pediatr Neurosci. 1988;14(1):23-30 [3217283.001]
  • [Cites] Neurosurgery. 1988 Sep;23(3):384-9 [3226520.001]
  • [Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):564-5 [2058519.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] J Neurooncol. 1992 Jan;12(1):69-74 [1541980.001]
  • [Cites] N Engl J Med. 1992 Apr 9;326(15):988-93 [1312224.001]
  • [Cites] Brain Dev. 1991 Nov;13(6):438-41 [1667249.001]
  • [Cites] Neurosurgery. 1992 Sep;31(3):563-6 [1383866.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):855-8 [8431869.001]
  • [Cites] Hum Genet. 1993 Feb;90(6):611-3 [8444466.001]
  • [Cites] Hum Genet. 1994 Feb;93(2):227 [8112757.001]
  • [Cites] Neurosurgery. 1994 May;34(5):910-2; discussion 912 [8052392.001]
  • [Cites] Br J Neurosurg. 1994;8(2):169-77 [7917088.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] Brain Dev. 1995 Jul-Aug;17(4):283-5 [7503393.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):293-5 [9251736.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] Virology. 1995 Oct 1;212(2):710-7 [7571441.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 May;17(5):939-42 [8733971.001]
  • [Cites] Neuropediatrics. 1996 Jun;27(3):143-8 [8837074.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4820-5 [8841004.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] Pathol Res Pract. 1996 Aug;192(8):840-4 [8897520.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] J Korean Med Sci. 1997 Apr;12(2):162-7 [9170025.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1279-82 [9179902.001]
  • [Cites] Eur J Hum Genet. 1997 Mar-Apr;5(2):61-8 [9195154.001]
  • [Cites] Tumori. 1989 Oct 31;75(5):463-9 [2690434.001]
  • (PMID = 12402146.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Scotland
  • [Other-IDs] NLM/ PMC2376189
  •  go-up   go-down


91. Gibson JB, Maxwell RA, Schweitzer JB, Fabian TC, Proctor KG: Resuscitation from severe hemorrhagic shock after traumatic brain injury using saline, shed blood, or a blood substitute. Shock; 2002 Mar;17(3):234-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resuscitation from severe hemorrhagic shock after traumatic brain injury using saline, shed blood, or a blood substitute.
  • The original purpose of this study was to compare initial resuscitation of hemorrhagic hypotension after traumatic brain injury (TBI) with saline and shed blood.
  • At constant arterial O2 saturation (SaO2), mixed venous O2 saturation (SvO2), cerebral perfusion pressure (CPP), and cerebral venous O2 saturation (ScvO2) were all higher, intracranial pressure (ICP) was lower, and CO2 reactivity was preserved with blood vs. saline (all P < 0.05).
  • In Series 2, SAP, ICP, CPP, and lactate were higher with DCLHb vs. saline (all P< 0.05).
  • These experimental results are comparable to those in a recent multicenter trial using DCLHb for the treatment of severe traumatic shock.
  • [MeSH-major] Aspirin / analogs & derivatives. Brain Injuries / complications. Resuscitation / methods. Shock, Hemorrhagic / therapy
  • [MeSH-minor] Animals. Blood Substitutes / therapeutic use. Blood Transfusion / methods. Brain / metabolism. Brain Ischemia / etiology. Brain Ischemia / prevention & control. Carbon Dioxide / metabolism. Female. Hemoglobins / therapeutic use. Intracranial Pressure / drug effects. Male. Oxygen / metabolism. Sodium Chloride / therapeutic use. Survival Rate. Swine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11900344.001).
  • [ISSN] 1073-2322
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Substitutes; 0 / Hemoglobins; 0 / diaspirin-cross-linked hemoglobin; 142M471B3J / Carbon Dioxide; 451W47IQ8X / Sodium Chloride; R16CO5Y76E / Aspirin; S88TT14065 / Oxygen
  •  go-up   go-down


92. Lampit M, Golander A, Guttmann H, Hochberg Z: Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study. J Clin Endocrinol Metab; 2002 Feb;87(2):687-90
Genetic Alliance. consumer health - Central precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study.
  • During GnRH agonist therapy of patients with central precocious puberty (CPP), growth is sometimes suppressed to subnormal velocity.
  • The working hypotheses were that estrogen levels are suppressed by GnRH agonist therapy below normal prepubertal levels, that such suppression is responsible for the slow growth of girls with CPP during GnRH agonist therapy, and that a mini-dose of estrogen replacement will normalize growth.
  • The present pilot study examined growth and bone maturation over 2 yr in 13 patients with CPP and compared therapy with a combination of GnRH agonist and 8 microg conjugated equine estrogen (group 1) to therapy with GnRH agonist alone (group 2).
  • Both groups had adequate suppression of gonadotropins, and E2 levels were below detection levels of our assay throughout the study period.
  • In group 1 patients the ratio of the change in bone age/change in chronological age decreased from 1.2 +/- 0.7 to 0.75 +/- 0.3, and in group 2 patients it decreased to 0.6 +/- 0.3 and 0.4 +/- 0.2 (P < 0.05) during the first and second years of therapy, respectively.
  • It is concluded on a pilot basis that estrogen suppression is responsible for the slow growth of girls with CPP during GnRH agonist therapy and that a mini-dose of estrogen replacement is safe and effective for at least 24 months in maintaining normal prepubertal growth without acceleration of bone maturation or pubertal development.
  • The current pilot results do not suggest an indication or provide a justification for such therapy.
  • [MeSH-major] Estrogen Replacement Therapy. Estrogens, Conjugated (USP) / administration & dosage. Gonadotropin-Releasing Hormone / agonists. Puberty, Precocious / drug therapy
  • [MeSH-minor] Age Determination by Skeleton. Aging / physiology. Animals. Body Height / drug effects. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Growth. Horses. Humans. Pilot Projects

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11836305.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Conjugated (USP); 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


93. Brackett RL, Pouw B, Blyden JF, Nour M, Matsumoto RR: Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology; 2000 Jan 28;39(3):407-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mice were pre-treated (i.p.) with vehicle or an antagonist from one of the following classes: NMDA/glycine site antagonist (7-chlorokynurenic acid, ACEA-1021, ACEA-1031, ACEA-1328, DCQX, R(+)-HA-966), competitive antagonist (CPP, D-AP7), channel blocker (MK-801, memantine), or allosteric modulator (ifenprodil, CP-101,606, Co 101022, haloperidol).
  • After a 15 min pre-treatment period, the mice were administered a convulsive (60 mg/kg, i.p.) or lethal (125 mg/kg, i.p.) dose of cocaine, equivalent to the calculated ED/LD97 values.
  • Pre-treatment with competitive or NMDA/glycine site antagonists dose-dependently attenuated cocaine-induced convulsions and lethality (P<0.05).
  • Pre-treatment with channel blockers or allosteric modulators of the NMDA receptor protected against cocaine-induced convulsions (P<0.05), but were ineffective or less effective than the competitive and glycine site antagonists in preventing death.
  • Significantly, post-treatment with NMDA/glycine site antagonists (ACEA-1021, ACEA-1031, ACEA-1328) after a cocaine overdose prevented death in a significant number of animals.
  • The data suggest that NMDA receptors are involved in the pathophysiology of a cocaine overdose.
  • [MeSH-major] Calcium Channel Blockers / therapeutic use. Cocaine. Dopamine Uptake Inhibitors. Excitatory Amino Acid Antagonists / therapeutic use. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Seizures / drug therapy

  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10698007.001).
  • [ISSN] 0028-3908
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Dopamine Uptake Inhibitors; 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, N-Methyl-D-Aspartate; I5Y540LHVR / Cocaine
  •  go-up   go-down


94. Miller BS, Shukla AR: Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists. Clin Ther; 2010 Sep;32(10):1749-51
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Long-acting forms of gonadotropin-releasing hormone (GnRH) receptor agonists are commonly used for the treatment of central precocious puberty (CPP).
  • OBJECTIVE: The aim of this study was to report an adverse drug reaction in a child with sterile abscess formation following treatment with 2 different branded long-acting forms of GnRH agonists.
  • CASE SUMMARY: An otherwise healthy 8-year-old white female (weight, 40.7 kg; height, 140.1 cm) with documented CPP and no known drug allergies developed a sterile abscess at the site of the monthly intramuscular injection of 15 mg of leuprolide acetate.
  • At the time of the removal of the second insert, Gram stain and swab culture of the purulent wound discharge were negative.
  • The Naranjo Adverse Drug Reaction Causality Score was 10 (definite, ≥9).
  • CONCLUSION: This report describes a case of sterile abscess formation definitely associated with 2 different forms of long-acting GnRH agonist treatment in a child.
  • [MeSH-minor] Child. Delayed-Action Preparations. Drug Implants. Female. Humans. Injections, Intramuscular. Nafarelin / administration & dosage. Nafarelin / therapeutic use. Puberty, Precocious / drug therapy

  • MedlinePlus Health Information. consumer health - Abscess.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Excerpta Medica Inc. All rights reserved.
  • (PMID = 21194598.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Drug Implants; 0 / Receptors, LHRH; 1X0094V6JV / Nafarelin; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


95. Bidwell GL 3rd, Raucher D: Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv Drug Deliv Rev; 2010 Dec 30;62(15):1486-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell penetrating elastin-like polypeptides for therapeutic peptide delivery.
  • Current treatment of solid tumors is limited by side effects that result from the non-specific delivery of drugs to the tumor site.
  • Alternative targeted therapeutic approaches for localized tumors would significantly reduce systemic toxicity.
  • Peptide therapeutics are a promising new strategy for targeted cancer therapy because of the ease of peptide design and the specificity of peptides for their intracellular molecular targets.
  • However, the utility of peptides is limited by their poor pharmacokinetic parameters and poor tissue and cellular membrane permeability in vivo.
  • This review article summarizes the development of elastin-like polypeptide (ELP) as a potential carrier for thermally targeted delivery of therapeutic peptides (TP), and the use of cell penetrating peptides (CPP) to enhance the intracellular delivery of the ELP-fused TPs.
  • CPP-fused ELPs have been used to deliver a peptide inhibitor of c-Myc function and a peptide mimetic of p21 in several cancer models in vitro, and both polypeptides are currently yielding promising results in in vivo models of breast and brain cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [Cites] Cancer Res. 1987 Dec 15;47(24 Pt 1):6437-43 [2824033.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] J Cell Biol. 1989 Feb;108(2):389-400 [2563728.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 19;81(8):570-6 [2649688.001]
  • [Cites] Prog Biophys Mol Biol. 1992;57(1):23-57 [1549698.001]
  • [Cites] J Biol Chem. 1994 Jan 21;269(3):1785-93 [8294427.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10444-50 [8144628.001]
  • [Cites] Recent Results Cancer Res. 1995;138:81-90 [7899701.001]
  • [Cites] Curr Biol. 1995 Mar 1;5(3):275-82 [7780738.001]
  • [Cites] Molecules. 2009;14(6):1999-2015 [19513001.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 2009;26(2):119-55 [19673689.001]
  • [Cites] Expert Opin Drug Deliv. 2009 Oct;6(10):1033-47 [19637980.001]
  • [Cites] Expert Opin Drug Deliv. 2009 Oct;6(10):1079-90 [19645633.001]
  • [Cites] Expert Opin Drug Deliv. 2009 Oct;6(10):1049-64 [19743895.001]
  • [Cites] Nat Mater. 2009 Dec;8(12):993-9 [19898461.001]
  • [Cites] Int J Cancer. 2010 Jan 15;126(2):533-44 [19588502.001]
  • [Cites] Adv Drug Deliv Rev. 2010 Feb 17;62(2):231-9 [20004693.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 1;73(5):620-31 [17161827.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4418-24 [17483356.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):313-26 [17483874.001]
  • [Cites] J Drug Target. 2007 Aug-Sep;15(7-8):457-64 [17671892.001]
  • [Cites] Mol Pharmacol. 2000 Apr;57(4):679-86 [10727512.001]
  • [Cites] Eur J Pharm Biopharm. 2000 Jul;50(1):147-60 [10840198.001]
  • [Cites] FASEB J. 2001 Jan;15(1):31-33 [11099487.001]
  • [Cites] Int J Hyperthermia. 2001 Jan-Feb;17(1):1-18 [11212876.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1548-54 [11245464.001]
  • [Cites] Exp Cell Res. 2001 May 1;265(2):234-41 [11302688.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):185-95 [11799137.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S78-84 [11821791.001]
  • [Cites] Biomacromolecules. 2002 Mar-Apr;3(2):357-67 [11888323.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1597-602 [12352464.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Biochemistry. 2002 Dec 3;41(48):14150-7 [12450378.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]
  • [Cites] AAPS PharmSci. 2002;4(4):E26 [12645998.001]
  • [Cites] Curr Protein Pept Sci. 2003 Apr;4(2):125-32 [12678851.001]
  • [Cites] Curr Protein Pept Sci. 2003 Apr;4(2):133-40 [12678852.001]
  • [Cites] J Control Release. 2003 Aug 28;91(1-2):31-43 [12932635.001]
  • [Cites] Pharm Res. 2004 Mar;21(3):389-93 [15070086.001]
  • [Cites] Science. 1983 Jul 22;221(4608):368-70 [6408733.001]
  • [Cites] Biopolymers. 1985 Dec;24(12):2345-56 [4092092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(16):5948-52 [3461466.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14255-8 [7782278.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):22008-16 [7665622.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):595-607 [8637717.001]
  • [Cites] Curr Biol. 1997 Jan 1;7(1):71-80 [8999999.001]
  • [Cites] Br J Cancer. 1997;75(7):1028-34 [9083339.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):16010-7 [9188504.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4B):2895-7 [9329557.001]
  • [Cites] J Control Release. 1996 May;39(2-3):121-9 [11539926.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6):616-25 [9422258.001]
  • [Cites] Oncogene. 1998 Jan 22;16(3):311-20 [9467956.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):84-7 [9695814.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3654-9 [9721875.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3480-8 [10416614.001]
  • [Cites] Science. 1999 Sep 3;285(5433):1569-72 [10477521.001]
  • [Cites] Drug Discov Today. 2004 Dec 1;9(23):1012-9 [15574317.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 [15722167.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):637-51 [15722168.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1076-85 [16020665.001]
  • [Cites] J Control Release. 2005 Nov 28;108(2-3):396-408 [16157413.001]
  • [Cites] Biochem Pharmacol. 2006 Jan 12;71(3):248-56 [16316634.001]
  • [Cites] Trends Biotechnol. 2006 Jan;24(1):39-47 [16307811.001]
  • [Cites] Drug Discov Today. 2006 Sep;11(17-18):812-8 [16935749.001]
  • [Cites] J Control Release. 2006 Nov 28;116(2):170-8 [16919353.001]
  • [Cites] Chemotherapy. 2007;53(1):73-6 [17202815.001]
  • [Cites] Pharm Res. 2008 Mar;25(3):683-91 [17762916.001]
  • [Cites] Adv Drug Deliv Rev. 2008 May 22;60(8):899-914 [18406004.001]
  • [Cites] Curr Opin Oncol. 2008 Jul;20(4):438-43 [18525341.001]
  • [Cites] J Control Release. 2008 Aug 7;129(3):179-86 [18547669.001]
  • [Cites] Biochim Biophys Acta. 2008 Dec;1786(2):126-38 [18440319.001]
  • [Cites] Curr Pharm Des. 2008;14(34):3628-36 [19075739.001]
  • [Cites] Eur J Pharm Biopharm. 2009 Mar;71(3):409-19 [19070661.001]
  • [Cites] J Control Release. 2009 Apr 2;135(1):2-10 [19095020.001]
  • [Cites] Br J Pharmacol. 2009 May;157(2):195-206 [19309362.001]
  • (PMID = 20478348.001).
  • [ISSN] 1872-8294
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA113813; United States / NCI NIH HHS / CA / R43 CA135799; United States / NCI NIH HHS / CA / R43 CA135799-01A2; United States / NCI NIH HHS / CA / R21 CA113813-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell-Penetrating Peptides; 0 / Peptides; 9007-58-3 / Elastin
  • [Other-IDs] NLM/ NIHMS206184; NLM/ PMC2964383
  •  go-up   go-down


96. Han Y, Li CS: [Effects of hypertension state induced by norepinephrine on liver in a swine model of cardiopulmonary resuscitation]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Feb;22(2):89-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the same time, the animals of two groups received normal saline at the speed of 10 ml * kg(-1) * h(-1).
  • RESULTS: The heart rate (HR), MAP, cardiac output (CO) and coronary perfusion pressure (CPP) were obviously higher, while the oxygen extraction ratio was lower in the HT group than in the NP group.
  • [MeSH-major] Heart Arrest / therapy. Hypertension / chemically induced. Liver / drug effects. Norepinephrine / pharmacology
  • [MeSH-minor] Animals. Cardiopulmonary Resuscitation. Disease Models, Animal. Female. Hemodynamics / drug effects. Male. Swine. Ventricular Fibrillation / pathology. Ventricular Fibrillation / physiopathology. Ventricular Fibrillation / therapy

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20170612.001).
  • [ISSN] 1003-0603
  • [Journal-full-title] Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
  • [ISO-abbreviation] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


97. Jackson KJ, Walters CL, Miles MF, Martin BR, Damaj MI: Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice. Neuropharmacology; 2009 Sep;57(4):347-55
Hazardous Substances Data Bank. NICOTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice.
  • Approximately 50-70% of the risk for developing nicotine dependence is attributed to genetics; therefore, it is of great significance to characterize the genetic mechanisms involved in nicotine reinforcement and dependence in hopes of generating better smoking cessation therapies.
  • The overall goal of these studies was to characterize behavioral and pharmacological responses to nicotine in C57Bl/6 (B6) and DBA/2 (D2) mice, two inbred strains commonly used for genetic studies on behavioral traits.
  • B6 and D2 mice where subjected to a battery of behavioral tests to measure nicotine's acute effects, calcium-mediated antinociceptive responses, tolerance to chronic treatment with osmotic mini pumps, and following three days of nicotine withdrawal.
  • B6, but not D2 mice, developed tolerance to nicotine and nicotine conditioned place preference (CPP).
  • These results provide a thorough, simultaneous evaluation of the pharmacological and behavioral differences to experimenter-administered nicotine as measured in several behavioral tests of aspects that contribute to smoking behavior.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacology (Berl). 2007 Feb;190(3):269-319 [16896961.001]
  • [Cites] Psychopharmacology (Berl). 2006 Mar;184(3-4):456-63 [16463055.001]
  • [Cites] Eur J Pharmacol. 2005 May 23;516(1):40-5 [15922326.001]
  • [Cites] Pharmacol Biochem Behav. 1999 Oct;64(2):221-8 [10515295.001]
  • [Cites] Addiction. 1997 Oct;92(10):1277-87 [9489045.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Oct;259(1):392-402 [1920127.001]
  • [Cites] Pharmacol Biochem Behav. 1989 Jul;33(3):667-78 [2587608.001]
  • [Cites] Pharmacol Biochem Behav. 1988 May;30(1):269-78 [3174752.001]
  • [Cites] Pharmacol Biochem Behav. 1985 Aug;23(2):325-30 [4059317.001]
  • [Cites] Pharmacol Biochem Behav. 1977 Jan;6(1):25-30 [850690.001]
  • [Cites] Mol Pharmacol. 2002 Aug;62(2):334-42 [12130686.001]
  • [Cites] Eur J Pharmacol. 2000 Sep 15;404(1-2):103-10 [10980268.001]
  • [Cites] Neuropsychopharmacology. 2000 May;22(5):451-65 [10731620.001]
  • [Cites] J Pharmacol Exp Ther. 1983 Jul;226(1):291-302 [6864548.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Apr;325(1):302-12 [18184829.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jul;322(1):399-407 [17446302.001]
  • [Cites] Mol Pharmacol. 2007 Mar;71(3):826-34 [17158199.001]
  • [Cites] Eur J Pharmacol. 1980 Oct 17;67(2-3):313-6 [6893963.001]
  • (PMID = 19619563.001).
  • [ISSN] 1873-7064
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / DA012610-02; United States / NIAAA NIH HHS / AA / U01 AA016662; United States / NIDA NIH HHS / DA / R01 DA012610; United States / NIAAA NIH HHS / AA / R01 AA013678; United States / NIAAA NIH HHS / AA / U01 AA016667; United States / NIDA NIH HHS / DA / #DA/ 12610; United States / NIDA NIH HHS / DA / R01 DA012610-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Nicotinic Agonists; 6M3C89ZY6R / Nicotine; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • [Other-IDs] NLM/ NIHMS133451; NLM/ PMC2753410
  •  go-up   go-down


98. Bidwell GL 3rd, Davis AN, Raucher D: Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release; 2009 Apr 2;135(1):2-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides.
  • The therapeutic index of current anti-cancer chemotherapeutics can be improved by two major mechanisms:.
  • 1) developing drugs which are specifically toxic to the cancer cells and 2) developing methods to deliver drugs to the tumor site.
  • In an attempt to combine these approaches, we developed a thermally responsive polypeptide inhibitor of c-Myc.
  • This polypeptide is based on the thermally responsive Elastin-like polypeptide (ELP).
  • When injected systemically, ELP-fused drugs will aggregate and accumulate at the tumor site where local hyperthermia is applied.
  • This data demonstrates that ELP can be targeted to the desired cellular compartment simply by choice of the CPP used, resulting in a more potent nuclear targeted c-Myc inhibitory polypeptide which may be beneficial in cancer therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Carriers / chemistry. Peptide Fragments / chemistry. Peptides / chemistry. Proto-Oncogene Proteins c-myc / antagonists & inhibitors. Recombinant Fusion Proteins / chemistry
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Proliferation / drug effects. Cytoplasm / drug effects. Cytoplasm / metabolism. Dose-Response Relationship, Drug. Female. Humans. Hyperthermia, Induced. Microscopy, Fluorescence. Neoplasms / drug therapy. Neoplasms / metabolism. Phase Transition. Temperature. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095020.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA 113813-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / MYC protein, human; 0 / Peptide Fragments; 0 / Peptides; 0 / Proto-Oncogene Proteins c-myc; 0 / Recombinant Fusion Proteins; 81857-53-6 / elastin polypentapeptide
  •  go-up   go-down


99. Jacka MJ, Zygun D: Survey of management of severe head injury in Canada. Can J Neurol Sci; 2007 Aug;34(3):307-12
MedlinePlus Health Information. consumer health - Critical Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine: 1. the degrees of consensus and disagreement among Canadian critical care clinicians regarding the appropriateness (benefit exceeding risk) of common therapeutic manoeuvres in patients with severe closed head injury (CHI), and 2. the frequency with which clinicians employed these manoeuvres.
  • In a scenario of diffuse axonal injury (DAI), clinicians agreed strongly that fever reduction, early enteral feeding, intensive glucose control, and cerebral perfusion pressure (CPP)-directed management were appropriate.
  • The appropriateness ratings of the interventions considered in the scenario of an intracranial contusion mirrored the DAI scenario.
  • The correlation between CPP-guided therapy and the use of the EVD was weak.
  • CONCLUSIONS: This survey has described current practice with regard to treatment of patients with severe CHI.
  • Suggested priorities for evaluation include the use of osmotic diuretics, anticonvulsants, and intracranial manometry.
  • [MeSH-major] Brain Injuries / therapy. Critical Care / methods. Head Injuries, Closed / therapy. Health Care Surveys. Neurology / methods. Neurosurgery / methods. Practice Patterns, Physicians' / statistics & numerical data
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Canada / epidemiology. Diffuse Axonal Injury / drug therapy. Diffuse Axonal Injury / physiopathology. Diuretics, Osmotic / therapeutic use. Female. Hematoma, Epidural, Cranial / drug therapy. Hematoma, Epidural, Cranial / physiopathology. Hematoma, Epidural, Cranial / surgery. Humans. Hypothermia, Induced / utilization. Intensive Care Units. Intracranial Hypertension / diagnosis. Intracranial Hypertension / prevention & control. Intracranial Hypertension / therapy. Male. Malnutrition / prevention & control. Malnutrition / therapy. Middle Aged. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803027.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Diuretics, Osmotic
  •  go-up   go-down


100. Chen MH, Xie L, Liu TW, Song FQ, He T, Zeng ZY, Mo SR: Epinephrine, but not vasopressin, improves survival rates in an adult rabbit model of asphyxia cardiac arrest. Am J Emerg Med; 2007 Jun;25(5):509-14
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The coronary perfusion pressure (CPP) was calculated as the difference between the minimal diastolic aortic and simultaneously recorded right atrial pressure.
  • Restoration of spontaneous circulation was defined as an unassisted pulse with a systolic arterial pressure of 60 mm Hg or higher for 5 minutes or longer.
  • We induced arrest in 62 rabbits, 15 of whom had ROSC before drug administration and were excluded from analysis.
  • Before and after drug administration, CPP in epinephrine group increased significantly (from -4 +/- 4 to 36 +/- 9 mm Hg at peak value, P = .000), whereas CPP in vasopressin group increased only slightly (from 9 +/- 5 to 18 +/- 6 mm Hg at peak value, P = .20).
  • After drug administration, 13 of 24 epinephrine rabbit had ROSC, and only 2 of 23 vasopressin rabbit had ROSC (P < .01).
  • [MeSH-major] Cardiopulmonary Resuscitation / methods. Epinephrine / pharmacology. Heart Arrest / drug therapy. Vasopressins / pharmacology
  • [MeSH-minor] Analysis of Variance. Animals. Asphyxia. Disease Models, Animal. Electrocardiography. Rabbits

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - CPR.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Emerg Med. 2008 Mar;26(3):368-70; author reply 370 [18358954.001]
  • (PMID = 17543653.001).
  • [ISSN] 1532-8171
  • [Journal-full-title] The American journal of emergency medicine
  • [ISO-abbreviation] Am J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11000-17-2 / Vasopressins; YKH834O4BH / Epinephrine
  •  go-up   go-down






Advertisement